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The Thesis describes investigations of the interactions between opiate drugs and
oxytocin neurones in the hypothalamic supraoptic nucleus (SON) of the female albino
rat. Both acute and chronic opiate effects were examined, acting at the /i- and x-
subtypes of opiate receptor using whole animal and in vitro techniques.
The tolerance which develops to the chronic intracerebroventricular (i.c.v.)
infusion of morphine was quantified in terms of firing rate of identified oxytocin
neurones in vivo. We contrasted the attenuation of acute morphine-induced inhibition
of firing rate, presumably through the ju-type opiate receptor, with the acute effects of
die selective x-type receptor agonist, U50,488H. There was no cross-tolerance
between morphine and U50,488H. hi both cases naloxone, the broad spectrum opiate
antagonist evoked a reversal of opiate inhibition of activity with overshoot, indicating
wididrawal excitation due to dependence.
The density of x-receptors in the SON was assessed by autoradiography after
chronic i.c.v. infusion of morphine, to see if the manifestations of tolerance in terms
of neuronal activity might be reflected in a change in receptor density in die SON.
Highly selective ligands for the fx- and 5-subtypes of opiate receptor were used to
saturate binding to these two receptor subtypes, thus allowing measurement of x-
receptor density by displacement of a high affinity radio-labelled ligand widi the
equivalent unlabelled ligand. Tolerance to morphine did not produce a measurable
change in die density of x-opiate receptors in the SON.
The roles of two post-receptor systems in die cell response to opiates were
investigated. Using i.c.v. pertussis toxin (PT) to inactivate the regulatory GTP-
binding proteins (G-proteins) susceptible to it, Gi and Go, we tested the potency of
morphine to inhibit the electrical activity of identified OT neurones of the SON, in
vivo. Morphine inhibited firing rate less potently after PT but U50,488H remained as
potent as in die i.c.v. vehicle-injected group. The G-proteins Gi or Go are involved
therefore in post-receptor transduction in these cells or in cells projecting to die SON
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which might mediate the acute effects of morphine.
Adenylate cyclase (AC) activity measured in vitro as cAMP content of isolated
SON was assessed in SON taken from morphine-naive and chronic morphine-infused
rats. Whereas vasoactive intestinal peptide (VIP) was able to powerfully stimulate
AC, incubation in vitro with morphine did not affect tissue content of cAMP and
treatment of SON derived from chronic morphine-infused rats with naloxone did not
result in any change in tissue cAMP. cAMP appears to play no part in post-receptor
events following the activation of the opiate receptor in OT neurones of tire SON.
Finally we investigated the contribution of the region anterior and ventral to the
third ventricle (the AV3V region) to the full expression of the withdrawal
hyperexcitation of OT neurones and resultant massive and sustained release of OT
into the systemic circulation. In chronic morphine infused rats, we studied plasma OT
concentration, assayed before and at intervals after an electrolytic lesion of the AV3V
region which left the SON and PVN intact. The withdrawal response was diminished
but was still evident in AV3V-lesioned rats. So only part of the withdrawal response
to naloxone is mediated outside the SON itself in the AV3V region. This suggests
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Introduction
i.l. Opioids: an historical perspective
Opium occurs naturally as the exudate of the unripe seed capsules of the opium
poppy, Papaver somniferum, indigenous to Asia Minor. Opium contains over 20
alkaloids, 4 of which have been exploited medicinally - the phenanthrene derivatives
morphine and codeine and tire benzylisoquinoline derivatives, papaverine and
noscapine.
The psychological and medicinal properties of opium were known in the Ancient
world. Sumerian ideograms in 4000B.C. describe the poppy as tire 'plant of joy' with
narcotic* power (*derived from the Greek word meaning drowsiness or stupor).
Ancient Egyptian children were passified with an opiunr-containing draught. The use
of opium is detailed in tire medicinal records of tire Babylonian king Asurbanipal, c.
700 B.C.. Greek classical literature too makes frequent reference to the ingestion of
opium - Homer told of tire 'cup of Helen' taken to induce forgetfulness, which was
laced with tire drug; Hippocrates, Virgil and Plutarch wrote of its hypnotic powers.
Theophrastus recorded in his extensive botanical writings details of growing and
harvesting the opium poppy.
In the 1st century A.D. Dioscorides who wrote De Materia Medica, (tire leading
work on pharmacology for some centuries), described opiunr. During the 5th to 10th
centuries A.D. Arabic medical wisdom percolated through Europe as a result of tire
closer contact between Moslems and Christians with the advent of the Crusades.
Along with this came the promotion of opiunr as a panacea, not only for ailing men
but also for animals suffering the rigors of long treks. Opium was originally taken by
mouth either with food or in drink but was not smoked in this region until tire practice
spread from China in the 19th century where it became popular after tire discovery of
America and the advent of pipe tobacco smoking. The use of opiunr became even
more widespread it is thought with tire prohibition of alcohol by tire Prophet
7
Mohammed and opium addiction accompanied subsequent Moslem migrations and
trade routes. Arabian traders introduced opium to India and China. Chinese medical
texts as early as 1000A.D. describe it as a cure for diarrhoea. In die East, opium took
on, in addition to its role a universal medicine, an important social use, akin to that of
alcohol in die West, because of the powerful feeling of well-being induced in its users.
The Swiss physician, Paracelsus, in the early 16th century extolled die properties of
opium so wholeheartedly diat any preparation containing it was called laudanum
(derived from the Latin laudare, to praise). Thomas Sydenham, a great English
physician introduced opium to Britain (about 1680) and said of it, "...among die
remedies which it has pleased Almighty God to give to man to relieve his sufferings,
none is so universal and so efficacious as opium". As the causes of so many illnesses
were a mystery to die physicians of die day, the dirust of medicine was to alleviate
symptoms of disease and hi this respect opium was unmatched by odier available
treatments. Most doctors approved endiusiastically of opium to die extent diat a high
proportion became addicts as did dieir wives.
Towards die end of die 17di century, opium smoking became popular in China as
tobacco smoking was introduced. A mixture of tobacco and opium might be smoked
as a treatment for malaria, but diis led hi time to die smoking of opium alone, largely
for non-medical reasons. The last Emporer of the Mhig Dynasty, Ch'ung Ch'en
prohibited the smoking of tobacco and opium but bodi practices were conthiued,
especially hi die southern provhices where diey were smuggled in by British and
Portugese merchants. The East India Company monopolised die trade hi opium
through the port of Canton and despite a reinforcement of die Chinese ban on
importation of opium, trade continued to grow. The seizure and destruction of
shipments of opium hi 1839 by die Chinese hi an attempt to enforce their prohibition
led to British intervention and the First Opium War. The defeated Chinese lost
sovereignty of five Chinese ports and of Hong Kong, which were opened for trade and
settlement by foreigners. A second engagement culminated hi die Treaty of Tientsin
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and the legalisation allowing importation of opium into China. As imports continued
to grow, the Chinese government eventually decided to cultivate the poppy themselves
and it began to replace cereal crops on a large scale.
In 1906 a campaign to abolish opium use was begun, involving limiting import,
with the help of the British, and reclaiming land for cereal production. With the
establishment of the First Republic of China in 1912, the importation, production and
use of opium became illegal and by 1917 the illegal consumption of opium was almost
eradicated. With the next thirty years of political upheaval in China came the re-
establishment of the opium problem, accompanied by a new interest in morphine and
diamorphine. The turning point for the opiate problem in China came with the
creation of the Peoples's Republic of China in 1949. Dealers in opiates were
persecuted and addicts rehabilitated whilst fanners were encouraged with financial
incentives to switch to the cultivation of alternative crops. (The sources of much of
this background information were, Bowman and Rand, 1980 and Latimer and
Goldberg, 1981).
Thus far, opium had been ingested as the crude form of the drug itself, or as a
laudanum. In 1803, Durosne and in 1805, a German pharmacist, Sertumer isolated the
main alkaloid in opium and named it morphia after morpheus, the Greek God of
dreams. Robiguet extracted noscapine in 1817 and codeine in 1832; thebaine was
isolated in 1835 by Pelletier and papaverine by Merck in 1848. Soon pure alkaloids
would replace the preparations of opium in medicinal use.
Until die 20di century, opium and laudanum were widely available, not only from
apothecaries but from general stores and opium in some form was an essential
component of die well-stocked medicine chest. Aldiough the opium poppy was grown
hi Britain briefly, die climate did not support its successful cultivation and British
laudanum was not generally used (Berridge, 1977). Opium was available mostly as
the laudanum but also as the camphorated tincture (paregoric elixir) and raw opium as
pills or penny sticks. Many remedies contained opium and even so called 'cures' for
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addicts to opium almost always contained the drug of addiction. The growing
problem of misuse of opium and of morphine, the most powerful derivative of opium,
was aggravated by the development of the hypodermic syringe by Dr Alexander Wood
of Edinburgh. The subcutaneous administration of morphine was far more controlled
and immediate than the enteral route, giving maximum intensity of effect rapidly. The
parenteral route of administration was not thought to give rise to addiction as
morphine does not enter the stomach where the 'appetite' for die drug was thought to
arise. In fact, this method of morphine administration is especially liable to lead to
addiction. The wife of Dr Wood was the first individual recorded to have died from
die effects of opium addiction due to the hypodermic administration of morphine.
The misguided confidence of physicians in the safety of this mode of
administration saw the distribution of hypodermic syringes to patients, widi
instructions and die freedom to administer morphine when required. The rapidity of
effect and die much greater euphoria experienced using his method led to addicts
converting to injection of opiates. In Europe such demand was created for injection
apparatus that kits were manufactured in gold and silver, often richly decorated with
gemstones.
In 1880, H.H. Kane in, "The Hypodermic Injection of Morphia" said, "There is no
proceeding hi medicine that has become so rapidly popular; no plan of medication that
has been so carelessly used and dioroughly abused; and no therapeutic discovery diat
has been so great a blessing and so great a curse to mankind as the hypodermic
injection of morphia".
This method of administration of morphine was practiced for a further 10 or 15
years before the danger became apparent. Just as the early Arabian armies were
plagued by the use of opium, so many years later were the Eurpoean and American
armies vulnerable, but much more so, during the Franco-Prussian War and the
American Civil War. For now the much more potent morphine could be easily
injected to combat disease and to treat injury, giving rise to the "army disease" -
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widespread opiate addiction. In the USA the pharmaceutical industry produced
morphine for parenteral administration in enormous quantities and soldiers were given
syringes and a supply of morphine to administer ad libitum leading to a significant
dependence problem. A further stimulus to the emergent opiate problem in the USA
was that of a rapidly expanding population whose growth and dispersion was not
matched by a supply of qualified medical practitioners and pharmacists resulting in the
widespread use of proprietary medicines, many of which contained opiates. The
incidence of opiate dependence grew dramatically but it was not until 1890 that an
attempt at control was made by imposition of a tax and in 1909, a prohibition of
opium smoking was introduced. Legislation in tire form of tire Narcotic Act of 1914
imposed tight controls on drugs deemed to be addictive but tire drug problem was not
conquered and illegal trade in opiates continued to flourish. In tire late 1960s habitual
users of dianrorphine (heroin) were estimated at 0.1 % of the population.
In tire United Kingdom, opium was widely available from apothecaries,
pharmacists and physicians but tire spread of opium use through patent medicines was
not as prevalent as in tire USA, so dependence was not a problem of the same
magnitude. The Dangerous Drugs Act of 1920 aimed to control tire importation of
opium and tire manufacture and distribution of opium products but tire continued
dispensing of opiates to addicts by tire medical profession was not interfered with,
unlike the situation in the USA where physicians supplying opiates to addicts to
prevent the onset of withdrawal were imprisoned. Opiate dependence was not a
serious problem in Britain until tire nrid 1960s when the parenteral use of diamorphine
became the most prevalent form of opiate drug abuse. Since then there has been a
decline in the number of opiate addicts.
Chemical modification of the opium alkaloids yielded synthetic congeners often
heralded as morphine substitutes, free of serious side effects, most importantly, the
potential for addiction. In 1898, dianrorphine (heroin), acetylated at both -OH groups
of morphine was synthesised by Dreser. It shares tire euphoric, analgesic, sedative and
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resiratory depressant actions of morphine and in the body is converted to morphine. It
is thought chiefly to act through the morphine produced upon its catabolism. It was
introduced as a cough remedy and as a cure for morphine addiction. However, it
turned out to be more addictive than morphine and became the drug of choice for
many addicts. The allure of heroin lies partly in its greater lipid solubility which
enables the user to absorb the drug simply by sniffing the powder through the nostrils.
This has attracted many for whom tire use of a hypodermic syringe was a disincentive.
As well as reputedly producing a more intense eurphoria than morphine, the
accompanying vomiting and constipation are less serious than experienced with
morphine.
Pethidine, synthesised in the late 1930s was hoped to be of use as a spasmolytic, but
pharmacological screening uncovered analgesic and other morphine-like properties. It
was the first wholly synthetic analgesic which could replace morphine clinically. It is
less potent than morphine with a shorter duration of action and is still used widely in
obstetrics because of its short half-life. Like morphine it gives rise to tolerance and
dependence and rapid withdrawal leads to anxiety, depression and cramps and at
higher initial doses, confusion, hallucination and convulsion. The depression is an
effect of pethidine whilst the central nervous system stimulation occurring at higher
doses is the result of norpethidine, the demethylated metabolite of pethidine.
However, pethidine has never been significantly abused.
The synthesis of methadone grew out of examination of the structural similarities
between morphine and pethidine. Although a more powerful analgesic than morphine,
methadone also produces euphoria, tolerance and psychological and physical
dependence. The withdrawal symptoms are less severe than with morphine but are
more prolonged. It is as effective orally as parenterally and morphine and methadone
show cross-tolerance. For these reasons methadone was chosen as a morphine
substitute in die treatment of morphine and heroin addicts. However, mediadone itself
has become a popularly abused drug.
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(Much of this information was drawn from Latimer and Goldberg, 1981).
1.2. The chemistry and structure of opiates/opioids
Although originally the term 'opiates' was applied to drugs with a similar action to
morphine that are derived from the opium poppy, or their derivatives, and 'opioids'
was used to describe those morphine-like drugs produced completely synthetically, the
two terms are now used interchangeably.
The structure of morphine as given below was proposed by Gulland and Robinson
in 1925. The alkaloid morphine is a substituted phenanthrene molecule containing
importantly, a piperidine ring which is common to morphine-like molecules.
Morphine is biologically active only as tire naturally occurring /aevo-isomer. The
morphine molecule has been modified to produce other opiates, as listed in Table
1.2.2.. Some deserve to be highlighted. Most significant perhaps is diacetylmorphine,
or heroin which is formed by the acetylation of the two -OH groups of morphine (see
Figure 1.2.1.). Codeine although naturally occurring is not found in sufficient
quantities to meet its wide demand and is therefore prepared by the methylation of
morphine (see Figure 1.2.1.). Etorphine (M99; not shown in Table 1.2.2.) is a
derivative of morphine which is prepared from the naturally occurring thebaine and is
1,000-10,000 x more potent than morphine. The opiate antagonist (see later for





Figure 1.2.1. The chemical structure of morphine
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Table 1.2.2. Chemical structures of some congeners of morphine
Generic name Substitution at carbon atom number:
3 6 17
Morphine -oh -oh -ch3
Diacetylmorphine -ococh3 -ococh3 -ch3
Codeine -och3 -oh cnXu1
Naloxone -oh =0 -ch2ch=ch2
Table 1.2.2. The carbon atom number for substitutions refers to Figure 1.2.1.
depicting the morphine molecule with all carbon atoms numbered. The opiate
antagonist naloxone has a single rather than a double bond between C7 and C8 of
Figure 1.2.1. (Adapted from Jaffe and Martin, 1975).
1.3. The pharmacological profile of acute opiates
Opioids share a similar pharmacological profile which I will illustrate with that of
morphine, the principle opiate used in this study. Primarily, morphine affects the
central nervous system (CNS) and the gastrointestinal system (GI system).
1.3.1. The effects of morphine on the CNS
Morphine is a major analgesic with its site of action in the CNS. This analgesia
occurs without loss of consciousness and may be very profound or might be
incomplete but the accompanying perception of pain is often lost. Other effects
include drowsiness, changes in mood and mental clouding. Euphoria can occur but so
can dysphoria in normal pain-free subjects with nausea and occasional vomiting. It is
this euphoria which has led to the use of opiates for pleasure. After intravenous
injection of morphine, tire habitual user experiences an intense physical pleasure
followed by a feeling of relaxation and social ease. At higher doses sedation
predominates with daydreaming and fantasising. Libido and aggression are
diminished and there is disinterest in the environment and sleep.
1.3.2. The effects of morphine on the GI system
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Opium was used for relief of gastrointestinal complaints such as diarrhoea and
dysentry, centuries before its analgesic potency was recognised. Propulsive
contractions of the small intestine are markedly reduced by morphine. In the colon,
peristalsis is abolished and tone increased and finally the tone of the anal sphincter is
increased. These factors result in constipation being a common feature of morphine
administration. These effects are not subject to tolerance (see below).
1.3.3. Other effects of morphine
Morphine is a powerful depressant of respiration by its effect on the respiratory
centres in the brain stem. Death after morphine is almost always the result of this
effect.
1.4. Tolerance to and dependence upon morphine
In the preceding Introduction I outlined the very gradual growth of awareness of
the effects of exposure to chronic opiates and the attempts then made to legislate
against opiate abuse and to develop non-addictive alternatives for medicinal use. hi
the next section I will provide definitions for some terms commonly used in this
Thesis.
Tolerance: a state which can be both physiological and psychological, in which,
"...an organism is less susceptible to the effect of drug as a consequence of its prior
administration. ...Tolerance to narcotic analgesics is the alteration in response (change
in character or intensity) induced by prior administration of the drug which either
directly or indirectly contributes to or sustains drug-seeking behaviour." (Martin and
Sloan, 1977). This can be broadened to encompass tolerance exhibited to opiates at
die cellular level (see later Introduction) as follows: die state produced by prior
exposure (usually repeated) to an opiate which involves adaptation of cellular
processes initially affected (perhaps inhibited) by exposure to die opiate such that cell
function appears as normal. The responsiveness of the cell to subsequent exposure to
die same* drug however is attenuated and a higher dose of opiate is required to
achieve die same magnitude of response as was achieved widi die initial dose (*see the
15
definition of cross-tolerance).
Tolerance differs from tachyphylaxis only in the time scale over which it occurs
and there is no sharp separation of tire two phenomena. Tolerance which is termed
tachyphylaxis is that which occurs over a relatively short time span and after less
frequent exposure to the drug. The loss of effect of opiates both in vivo and in vitro is
usually thought of as tolerance and not tachyphylaxis.
Cross-tolerance describes the state in which tolerance induced by one drug has
conferred tolerance to another drug to which the organism (or cell) has not previously
been exposed. The second drug does not necessarily possess a similar molecular
structure to the first but usually has an affinity for the same type (or sub-type) of
receptor* and shares a similar pharmacology (*see later Introduction). Cross-
tolerance is often thought to indicate that a common receptor binding site exists for the
two drugs. Because morphine or diacetylmorphine (heroin) addicts are cross-tolerant
to methadone, another opiate, methadone can substitute for morphine during morphine
withdrawal (see below), alleviating the withdrawal syndrome; methadone has a much
less intense withdrawal syndrome than that of morphine.
Physical dependence upon a drug is not apparent until the drug is withdrawn when
symptoms of a withdrawal syndrome can be observed. If the drug is withdrawn by
administration of a competitive receptor antagonist, this is referred to as precipitated
withdrawal.
Tolerance to opiates in man leads to the use of increasing doses to achieve tire same
analgesic or euphoric effect as initial doses produced. Systematic study of the
phenomenon of tolerance to opiates in man was made only in 1929-1930 (Light et al,
1929-1930) even though it was clinically recognised during the 19th century. For die
morphine addict heart rate, blood pressure and respiration fell within normal bounds.
During withdrawal, a variety of symptoms were commonly observed. These included
yawning, lacrimation, mydriasis (dilatation of the pupil), chills, piloerection,
perspiration, muscle twitching, weakness, hyperdiermia and an increase in metabolic
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rate (Light and Torrance, 1929). The withdrawal syndrome is complex and varies
subtly between opiates. Himmelsbach studied the withdrawal syndromes associated
with a variety of opiates as well as morphine and found that the manifestations of
withdrawal returned to baseline levels at different rates according to the opiate used
and that full recovery might take 6 months (Himmelsbach, 1942).
Tolerance to and dependence upon opiates have been demonstrated in laboratory
animals and it is in the animal model that headway has been made in attempting to
define the mechanisms underlying the development of opiate tolerance and
dependence. Tolerance has been demonstrated in terms of neuronal function at several
different levels of the nervous system, both peripheral and central (Martin and Sloan,
1977). The diencephalon appears to be pivotal in expression of the behavioural signs
of withdrawal. The limbic system may mediate some acute psychological features of
withdrawal (Martin and Sloan, 1977). Until experiments were able to focus on in vitro
preparations including individual neurones, it proved difficult to assess the
contribution of putative cellular mechanisms underlying tolerance and dependence.
The fact that morphine is only active as the naturally occurring /aevo-isomer
suggested that it acts at stereospecific receptor sites to have its biological effect.
Indeed an opiate binding site was discovered which was saturable and for which
opiates bound competitively according to their potency (Goldstein et al, 1971; Pert
and Snyder, 1973; Simon et al, 1973; Terenius, 1973) in nervous tissue. The
discovery of opiate receptors provided a new starting point for future studies of
mechanisms of tolerance and dependence. Subtypes of opiate receptor were first
postulated by Martin in 1967 to account for the action of nalorphine in man. It
antagonised morphine whilst being analgesic itself (Martin 1967). Also, some opiates
fail to show full cross-tolerance and have different binding distributions in the same
tissue (Chang et al, 1979; Robson and Kosterlitz, 1979; Wuster et al, 1980; Zukin
and Zukin, 1981; Goodman and Snyder, 1982). Multiple opiate receptors described
as mu, delta, kappa, sigma and epsilon were proposed as a result of these findings
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(Martin et al, 1976; Lord et al, 1977; Schulz et al, 1979; Chang and Cuatrecasas,
1981; Pfeiffer and Herz, 1981; Zukin and Zukin, 1981). The race to understand tire
mechanisms of opiate tolerance and dependence was now accompanied by die hope of
finding a subtype of opiate receptor which would mediate the analgesic effects of
morphine but without the potential for dependence. Agonists at the mu- (p.), kappa-
(/c) and delta-(o) subtypes of opiate receptor however all develop tolerance and
dependence and each have their distinct withdrawal syndromes (Redmond and
Krystal, 1984). In this study it was die intention to look only at the p- and /c-subtypes
of opiate receptor hi oxytocin neurones of the supraoptic and paraventricular nuclei:
morphine was used to activate the ^-receptor and U50,488H (tra/iv-(±)-3,4-dichloro-
iV-mediyl-/7-(2-[ 1 -pyrrolidinyl]cyclohexyl)benzeneacetamide, mediane sulphonate
salt) to activate the x-receptor. Morphine is an avid ligand for die m-receptor with
little relative affinity for die k- or 5-subtype of opiate receptor (Kosterlitz, 1985).
U50,488H is a high affinity ligand for die k-receptor with a low relative affinity for
the p- or 5-subtype of opiate receptor (Kosterlitz, 1985; Lahti et al, 1985; Clarke and
Pasternak, 1988).
Suggested mechanisms of tolerance and dependence have included changes hi
opiate receptor number, conformation or function (Collier, 1965; see Chapter 5),
modulation of intracellular second messenger systems (West and Miller, 1983;
Redmond and Krystal, 1984; see Chapter 4), regulation of the availability or die state
of regulatory GTP-bindhig proteins (G-protehis; Crain et al, 1986; Nestler et al,
1989; see Chapter 3) or changes hi neuronal intracellular calcium (West and Miller,
1983; Redmond and Krystal, 1984). Some of diese putative mechanisms have been
hivestigated in this Thesis hi terms of bodi acute and chronic morphine action upon
supraoptic oxytocin neurones in die rat and full experimental details are contained
herein.
After the discovery of the opiate receptor, endogenous opioids were sought after
with the expectancy diat where there are receptors, widi a distribution hi die CNS
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which is far from random, there must be endogenous ligands to activate them. In
1975, John Hughes, Hans Kosterlitz and colleagues reported the existence of two
pentapeptides isolated from pig brain which possessed naloxone-reversible, morphine¬
like qualities in guinea-pig isolated ileum in vitro (Hughes et al, 1975). The two
opioid peptides were named [Leu]enkephalin (Tyr-Gly-Gly-Phe-Leu) and
[Met]enkephalin (Tyr-Gly-Gly-Phe-Met), distinguished only by the presence of a
terminal leucine or a methionine amino acid residue. Also in 1975, Goldstein and
coworkers discovered a peptide in bovine pituitary gland with opioid qualities (Cox et
al, 1975; Teschemacher et al, 1975). This was in fact a 31 ammo acid polypeptide
and its actions were antagonised competitively by naloxone. It was designated /3-
endorphin. /3-endorphin is derived from the carboxy terminus of another pituitary
hormone, jS-lipotropin (/3-LPH) and [met]enkephalin corresponds to the first 5 amino
acids of /3-endorphin. [met]enkephalin is a product of a longer peptide, proenkephalin
A. [leu]enkephalin may be derived from /3-LPH or form proenkephalin B. Anodrer
peptide derived from proenkepahlin B is dynorphin which exists as dynorphin A (1-
17), dynorphin A (1-8) and dynorphin B. Truncated versions of dynorphin include a-
neo endorphin and /3-neo endorphin. These peptides bind with differing affinities to
the three principle opiate receptors (Kosterlitz, 1985). None of the endogenous opioid
peptides binds with such high relative affinity to any one opiate receptor as some of
tire synthetic opiates are known to. Perhaps their selectivity in vivo is determined as
much by the presence and distribution of receptor subtypes in a tissue as by relative
affinity of tire endogenous ligand. Endogenous opioid peptides are found in tire
oxytocin neurosecretory system, both in the nragnocellular nuclei and in the posterior
pituitary gland (see Introduction below). Endogenous opioid peptides have even been
colocalised within the same neurone with oxytocin or vasopressin and have been
implicated in tire control of posterior pituitary hormone secretion, both centrally and
peripherally (Lincohr and Russell, 1986). Here are circumstances then which have
created immense interest in terms of the potential interaction between endogenous
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opioid peptides and the mechanisms which regulate posterior pituitary hormone
secretion. This hypothalamo-neurohypophyseal neurosecretory system offers a
window to investigate how opiates induce tolerance and dependence in a well defined
system.
1.1. Oxytocin: an historical perspective
Whilst the discovery of the vasopressor activity contained in the neurohypophysis
had already been made before the end of the 19th century (Oliver and Schafer, 1895)
tire oxytocic (o£vg, quick, tokvq, birth) potency of pituitary extract was not noted until
1906 by Sir Henry Dale. He was working at the Wellcome Physiological Research
Laboratories on the pharmacology of ergot, a drug widely used at the time in
obstetrics. During an experiment investigating tire reversal by ergot of the effects of
adrenaline and of sympathetic stimulation in the spinal cat, he controlled these
experiments by testing tire potency of ergot to reverse tire known pressor effect of
pituitary extract. As well as blood pressure, he was also monitoring tire tone and
rhydrnr of the uterus and so not only did he detect the usual pressor action of pituitary
extract, unaffected by pretreatnrent with ergot, but he also observed powerful
stimulation of tire uterine muscle (Dale, 1906) thanks to chance rather than design as
he later recalled (Dale, 1953). He went on however to systematically investigate the
oxytocic activity in pituitary extract (Dale, 1909) and it became clear that oxytocic
activity was present in tire posterior lobe of the pituitary together with tire pressor
activity. The promotion of contraction of the alveoli of tire lactating mammary gland
(nrilk-ejection) by extracts of posterior pituitary further stimulated interest in tire
active principle(s) contained in the neural lobe (Ott and Scott, 1910). Whether a
single agent accounted for both the pressor and the oxytocic activity of pituitary
extract became a controversial question after tire publication of Dale's observations
and remained so even after tire separation of two factors from posterior pituitary
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extract with distinct pharmacologies (Dudley, 1919) which were later shown to be
susceptible to proteolytic enzyme degradation and therefore probably to be peptidergic
in nature (Dale and Dudley, 1921). Sharpey-Schafer addressed this point of
disagreement, still current some years after the publication of tire above paper
(Sharpey-Schafer, 1926): comparative studies in birds, fish, amphibians and
mammals revealed that pressor and oxytocic activities did not always coexist in
extracts of the posterior pituitary. Herring suggested from observations in bovine
posterior pituitary that tire two autacoids were largely separated into the pars
intermedia (containing oxytocic activity) and the pars nervosa (containing pressor
activity). Herring concluded that there were two active components of posterior
pituitary extract, one acting on tire uterus and mammary gland and the other on blood
pressure and tire kidney. He drought that both were produced by dre epidreliunr of dre
pars intermedia and drat dre pressor factor was transformed as it passed to dre pars
nervosa. Sharpey-Schafer upon reviewing this and other evidence concluded, '...it
seems probable that the various physiological effects of extracts of posterior lobe must
be caused by more dran one autacoid, possibly several.' and widr informed judgement
later to be borne out, 'That it has not been possible to effect a chemical isolation is
hardly surprising seeing that such bodies would be separated out together by most
precipitation agents, for it is probable drere is not much dissimilarity in dreir chemical
constitution.'.
Upon publication of Dale's observations the potential usefulness of pituitary extract
in various branches of medicine, but particularly obstetrics was recognised, and
posterior pituitary extract was quickly adopted as a tool in controlling post-partum
haemorrhage and later in smaller doses in cases of delayed labour (see Robinson and
Amico, 1985) . Pituitary extract was recommended for intestinal stasis, particularly
that experienced after surgery and whole pituitary gland given by moudi was used for
treating habitual constipation (Sharpey-Schafer, 1926). These early commercial
extracts of pituitary suffered contamination with histamine, which in fact appears to
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have been the effective agent for intestinal complaints.
Work continued to isolate the active principles in posterior pituitary extract and in
1928 Kamm and coworkers succeeded in isolating oxytocic and pressor agents with
high activity (Kamm et al, 1928) which were later purified to yield analytically-pure
oxytocin by chromatography (Livermore and Du Vigneaud, 1949).
The amino acid sequence of oxytocin was elucidated in 1950 (Pierce and Du
Vigneaud, 1950) and the structure simultaneously by Du Vigneaud and coworkers and
by Tuppy (Du Vigneaud and Trippett, 1953; Tuppy, 1953). The structure was
proposed to be as follows:
H-Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2
and this was confirmed with die total synthesis of oxytocin by Du Vigneaud in
1953 (Du Vigneaud et al, 1953). The chemical similarity between oxytocin and
arginine vasopressin (found in man) foretold by Sharpey-Schafer was confirmed when
the structure of arginine vasopressin was established in 1954 by Du Vigneaud's group
(Du Vigneaud et al, 1954) to be the following:
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2
The elucidation of the structures of oxytocin and arginine-vasopressin finally put to
rest the dispute over die existence of one, two or more active principles contained in
the posterior pituitary.
In tandem with diese advances was die development of the concept of
neurosecretion. The idea of axons serving as conduits through which chemical
messengers were carried has its origins with Galen and Aristotle who interpreted the
function of spinal nerves hi this way. This understanding of how nerves function was
widely accepted until it was finally challenged by the findings of electrophysiologists
in the 19di century which were seemingly to die contrary. Experimental evidence to
support die concept of neurosecretion was provided in 1919 when Carl Speidel
published his observations on giant neurones hi posterior spinal cord of elasmobranch
fish which he described as possessing all the cytological requirements for secretory
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function (Speidel, 1919). A similar finding was reported by Ernst Scharrer who
identified neurones in tire minnow brain which possessed tire attributes of secretory
cells upon histological examination (Scharrer, 1928). The term 'neurosecretion' was
originally applied to tire apparent function of any neurone which was found to contain
particles similar to secretory granules normally associated with endocrine cells
(Scharrer and Scarrer, 1940) but this was to change as understanding of neuronal
structure and function improved. Posterior pituitary hormones were drought to be
secreted by dre pituicytes (Bucy, 1932) however, it was shown to be necessary to
bilaterally ablate the supraoptic nuclei or to make lesions proxinrally in the neural
stalk, causing atrophy of the posterior pituitary in order to produce diabetes insipidus
(Fisher et al, 1938). hr 1938 Rasmussen reported nerve fibres widrin dre neural lobe
and suggested drat dre neurohypophyseal hormones were released from drese nerve
terminals (Rasmussen, 1938). The full import of these observations was not
appreciated until later reports utilising bodr hormone assay and histological analysis
indicated a link between the activity of supraoptic and paraventricular nuclei and the
posterior pituitary (Bargmann, 1949; Ortman, 1951; Hild and Zetler, 1953).
Evidence continued to accumulate until Bargmann and Scharrer reported that
transsection of the pituitary stalk resulted in accumulation of the neurosecretory
substance proximal to die level of transsection and to a decline in the posterior
pituitary content of hormone distally. There followed die proposal that the
neurosecretory material was related to the neurohypophyseal hormones, was
syndiesised in the cell bodies of neurones hi the supraoptic and paraventricular nuclei
from where it was transported down the axons to the posterior pituitary where it
accumulated to be secreted into the blood stream (Bargmami and Scharrer, 1951).
This proposal revived the ancient concept of neurosecretion, at die same time
restricting the application of die term according to new understanding of die
neurosecretory process afforded most excellently by the hypodialamic
supraoptic/paraventricular nuclei-posterior pituitary axis. The definition of a
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neurosecretory system in mammals also fulfilled the promise of earlier work (Speidel,
1919; Scharrer, 1928) that neurosecretion might be demonstrated ubiquitously in a
variety of species. As the means became available to distinguish between
neurosecretory terminals, which generally contact basement membranes or glial
elements in a non-synaptic way and normal neuronal terminals, classification of
neurones as neurosecretory became less problematic (Bern and Knowles, 1966) and
although branches of neurosecretory neurones may well terminate in conventional
synapses, the quality unique to neurosecretory neurones is that of synthesising and
then secreting a hormone in the traditional way described for non-neuronal endocrine
cells.
Until the late 1950s tire concept of neurosecretion rested mainly upon histological
evidence, but the understanding of the neural control of hormone secretion was
advanced significantly by the pioneering experiments of Barry Cross which aimed to
define the neural control of oxytocin secretion from the neurohypophysis utilising the
release of oxytocin from stimulated supraoptic and paraventricular neurones (Cross,
1966; Folley, 1969). Electrical stimulation of the paraventricular nucleus, the
supraoptic nucleus or die supraoptico-hypophyseal tract resulted in effects upon die
mammary gland and uterus of die rabbit which mimicked the injection of 10-50mU
oxytocin and spinal transsection did not abolish this response (Cross, 1958a; Cross,
1958b). The possibility diat such electrical stimulation of die hypothalamus might
even initiate labour in the late-pregnant rabbit was tested and confirmed (Cross,
1958c). These experiments illustrated the striking correlation between electrical
activity of neurosecretory neurones and hormone release. The neural control of
oxytocin secretion was further defined by Cross and Green who recorded from
putative magnocellular neurones whilst applying a hyperosmotic stimulus, known to
liberate vasopressin (Cross and Green, 1959) and by a series of brain lesioning studies
which mapped the central pathways of the 'Ferguson reflex' - the stimulation of
oxytocin release in response to vaginal distension or dilation of the cervix (Cross,
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1973).
In 1964, Kandel had succeeded in antidromically activating neurones in the
preoptic nucleus of the goldfish thus enabling their identification (Kandel, 1964). hi
1966, Yagi and coworkers extended this technique to the rat, using the ventral
approach to the pituitary stalk (Yagi et al, 1966). They were followed by Richard
Dyball who was able to antidromically activate neurones projecting from the
paraventricular and supraoptic nuclei to the posterior pituitary by a transaural
approach (Dyball, 1969). The technique of antidromic activation contributed to what
was to be a major step forward hi further defining the relationship between electrical
activity hi hypothalamic oxytocin- or vasopressin-secreting neurones (referred to
henceforth as oxytocin or vasopressin neurones respectively) and has been described
as, "...the most powerful tool available..." for their identification hi vivo (Poulain and
Wakerley, 1982). The use of this tool has made the hypothalamo-neurohypophyseal
axis die best described example of a neurosecretory system.
Distinction between oxytocin and vasopressin neurones, bodi of which project to
die posterior pituitary, and can be antidromically-activated became possible
electrophysiological^ in vivo by the way in which diey responded to a variety of
systemic stimuli designed to mimic physiological stimuli, thus allowing more precise
study of die nature of the relationship between hormone release and electrical activity.
In an early electrophysiological study Cross and Green (1959) had not found any
difference between the shape of die action potential or pattern of electrical activity
between hypodialamus, including supraoptic and paraventricular nuclei and odier
brain regions under basal recordhig conditions. However, the two neurohypophyseal
hormones could be released to different degrees accordhig to the stimulus used
(Heller, 1966) suggesting die two hormones might be located hi separate populations
of neurones under differential control. More recent immunocytochemical experiments
have demonstrated the separation of oxytocin and vasopressin into two magnocellular
neuronal subgroups (Swaab et al, 1975; Vandesande and Dierickx, 1975) which are
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not located separately in the two main magnocellular nuclei but are interspersed
together. But given the difficulty in stimulating vasopressin release in isolation from
that of oxytocin, the discovery that the suckling stimulus in the lactating animal
selectively provokes the release of oxytocin was a landmark in the study of
neurosecretion with particular application in the field of neurohypophyseal
neurosecretion. Jonathon Wakerley combined antidromic activation of
paraventricular oxytocin/vasopressin neurones with the application of a hungry litter
to an anaesthetised lactating rat in order to follow both electrical activity and oxytocin
release in terms of milk let down and the resultant increase in pup weight as diey
suckled. After some time throughout which the pups suckled continuously, the litter
were observed to simultaneously stretch and suck more energetically for 10-15
seconds. This episode occurred repeatedly at 5-10min intervals. This was the first
report of the milk-ejection reflex, which was shown to be the result of the intermittent
release of a pulse of oxytocin (l-2ng) but not of vasopressin in response to a
continuous suckling stimulus and which was preceded by a characteristic high
frequency (50-80Hz) burst of activity in a proportion of antidromically-activated
neurones (Wakerley and Lincoln, 1971a; Lincoln et al, 1973; Wakerley and Lincoln,
1973; Lincoln and Wakerley, 1974). Thus the electrophysiological differentiation of
oxytocin and vasopressin neurones in vivo was possible based on dieir responses to die
suckling stimulus (Poulain et al, 1977).
A stimulus usually associated with stimulation of the vasopressin system, systemic
hyperosmotic challenge, in fact also excites oxytocin neurones and increases oxytocin
secretion; the firing rate of putative oxytocin neurones is gradually increased in
response (Brimble and Dyball, 1977; Blackburn et al, 1987). The mechanism by
which oxytocin neurones are excited involves die region anterior and ventral to die
diird ventricle (AV3V region) which is composed of cirumventricular organs for
which die blood-brain barrier is less exclusive. The AV3V region mediates a tonic
excitatory drive to oxytocin neurones and seems to relay to oxytocin neurones any
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changes in systemic osmolality (Russell et al, 1988). However, the magnocellular
neurones themselves are osmosensitive: bathing of slices of hypothalamus containing
supraoptic nucleus with a hyperosmotic medium causes depolarisation of the
membrane intracellularly recorded magnocellular cells which still occurs in tire
absence of any synaptic input (Mason, 1980; Abe and Ogata, 1982; Andrew and
Dudek, 1983; Mason et al, 1983; Andrew and Dudek, 1984; Bourque, 1989). The
innate osmosensitivity of supraoptic magnocellular neurones is thought to be fully
expressed only in the context of tire full complement of normal synaptic inputs,
including the AY3V region, which by their positive drive perhaps amplify tire
osmosensitivity already present (Dyball and Leng, 1990).
The identification of neurones was enabled further by the classification of electrical
activity in the supraoptic and paraventricular nuclei into three categories: phasic
(periods of activity interspersed with periods of silence, Wakerley and Lincoln,
1971b), continuous or slow-irregular activity whose parameters have been defined
elsewhere (Wakerley et al, 1978). Later studies have confirmed that phasic activity is
almost always associated with vasopressin-containing neurones in vivo (Yamashita et
al, 1984) and in vitro (Yamashita et al, 1983; Cobbett et al, 1984) and whilst
vasopressin neurones may be silent or may exhibit slow-irregular and continuous
electrical activity, they are characterised by phasic activity when stimulated
appropriately with an osmotic stimulus or by haemorrhage (Wakerley et al, 1975;
Brimble and Dyball, 1977; Poulain et al, 1977). So, it is now possible with this
foundation laid to identify neurones as oxytocin- or vasopressin-secreting with some
confidence and thus to more accurately ascribe properties to one or the other cell type.
These methods of identification of oxytocin neurones were made use of in all
electrophysiological experiments which contribute to this Thesis such that conclusions
could be drawn about the population of oxytocin neurones selectively.
1.2. Exogenous opiates, endogenous opioids and the regulation of oxytocin secretion
Although opiate effects upon vasopressin release were investigated with some
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vigour (De Bodo, 1944; Duke et al, 1951; Giarman and Condouris, 1954; Schneider)
and Blackmore, 1955; Inturrisi and Fujimoto, 1968) an interaction between morphine
and oxytocin was not investigated until as late as 1978 when Haldar and Sawyer found
that subcutaneous administration of morphine in lactating mice inhibited weight gain
by suckling young (an index of milk ejection from the mammary gland). This was not
die result of a loss of sensitivity of die mammary gland to normal levels of circulating
oxytocin as exogenous oxytocin produced similar results in terms of pup weight gam
indicating that mammary gland milk content in control and morphine-injected groups
was die same. The conclusion was that morphine inhibited the release of oxytocin hi
response to die suckling stimulus in die lactating mouse (Haldar and Sawyer, 1978).
This finding was later extended to die rat (Clarke et al, 1979). More broadly, oxytocin
secretion stimulated by suckling, by angiotensin II and cholinergic drugs is inhibited
by of exogenous opiates including morphine and opioid peptides (Haldar et al, 1982;
Russell and Spears, 1984).
Endogenous opioids appear to inhibit die release of oxytocin from die
neurohypophysis as revealed by naloxone (Bicknell and Leng, 1982). There is
evidence that aldiough endogenous opioids inhibit oxytocin secretion at the level of
die neurohypophysis, morphine does not act there to inhibit release (Coombes and
Russell, 1989) but diat morphine can act at the cell bodies of these neurones to inhibit
electrical activity. This is contrary to what was concluded from an earlier study in
which intracerebroventricular morphine (2-4/xg) failed to inhibit the bursting activity
or background activity of identified oxytocin neurones during suckling (Clarke et al,
1979). Aldiough opioids were later shown to indeed act at die posterior pituitary
directly to inhibit oxytocin but not vasopressin release (Bicknell and Leng, 1982) the
conclusion from die above study that opioids act at the level of die posterior pituitary
but not at the perikarya to inhibit oxytocin release has been contradicted by hi vitro
experiments in which opioid peptides reduced the background electrical activity of
some paraventricular neurones (Muhledialer et al, 1980; Pittman et al, 1980) and of
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putative oxytocin neurones in the supraoptic nucleus (Arnauld et al, 1983; Wakerley
et al, 1983; Pumford et al, 1987; Inenaga et al, 1990). In addition still more recent
work has shown that intracerebroventricular morphine does in fact inhibit the
electrical activity of identified oxytocin neurones in the virgin female rat at doses
lower (0.5-1/xg i.c.v.) than those used by Clarke and coworkers (Leng and Russell,
1989). It is well established that there are opiate receptors in the posterior pituitary
(Simantov and Snyder, 1977; Lightman et al, 1983a; Lightman et al, 1983b) which
are predominantly or exclusively /c-opiate receptors (Bunn et al, 1985; Herkenham et
al, 1986; Stojilkovic et al, 1987; Sumner et al, 1990). The receptors are functional, as
the selective /c-opiate receptor ligand, U50,488H causes a dose-related inhibition of
electrically-evoked oxytocin release which was naloxone-reversible (Zhao et al,
1988a). Although opiate receptors are present on pituicytes in the rat posterior
pituitary (Lightman et al, 1983a; Lightman et al, 1983b), they have also been
localised on the terminals of oxytocin/vasopressin-secreting neurones
(neurosecretosomes) in the porcine and bovine posterior pituitary (Falke and Martin,
1985; Pesce et al, 1987) and these receptors have been shown to be functional in the
rat posterior pituitary neurosecretosomal fraction in terms of inhibition of oxytocin
release (Zhao et al, 1988b). In the same study, the fx-opiate receptor agonist, DAGO
was inneffective in inhibition of oxytocin release. These data suggest that the
inhibitory effect of morphine thought to occur at the posterior pituitary (Clarke et al,
1979) probably occurred by an action at the /c-opiate receptor subtype in the posterior
pituitary, or that there was some inhibition of perikaryal electrical activity by
morphine which was not evident from the neurones detected in the study.
Opiate effects at tire cells bodies (Muhlethaler et al, 1980; Pittman et al, 1980;
Amauld et al, 1983; Wakerley et al, 1983; Leng and Russell, 1989; Inenaga, 1990;
Leng et al, 1990) are explained by the presence of both /x- and /c-opiate receptors
(Clark et al, 1986; Mansour et al, 1986; Tempel and Zukin, 1987; Mansour et al,
1988; Sumner et al, 1990; see also Chapter 5). Inputs to the supraoptic and
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paraventricular nuclei are also possible sites of morphine action. The median preoptic
nucleus and the subfornical organ, in, or projecting through the AV3V region
respectively, provide a tonic excitatory drive to oxytocin neurones (Leng et al, 1988;
Russell et al, 1988) and there are opioid receptors in the AV3V region (Mansour et al,
1987; Conrath and Cupo, 1989; Sharif and Hughes, 1989; Sumner et al, 1990; see
Chapter 5) which contains morphine-sensitive cells (Buranarugsa and Hubbard, 1979).
So, morphine and other opiates might act here to inhibit oxytocin release by reducing
the electrical activity of the syntliesising neurones. Still, when oxytocin neurones are
tonically driven by stimulation of the AV3V region, morphine is still able to inhibit
the electrical activity of SON oxytocin neurones (Leng and Russell, 1989). So a part
of tire acute inhibitory action of morphine is mediated by a direct action upon the cell
bodies of oxytocin neurones.
1.3. Magnocellular oxytocin neurones: a neurosecretory system where tolerance to and
dependence upon opiates develops
Although morphine given acutely by i.c.v. injection causes depression of oxytocin
secretion and inhibits the electrical activity of oxytocin neurones (Russell, 1989), after
5 days of morphine given by i.c.v. infusion, oxytocin secretion is normal and in
lactating rats the milk-ejection reflex returns to normal after 2 days (Bicknell et al,
1988a) indicating tolerance to an initial inhibitory action of i.c.v. morphine. This
tolerance is not explained by enhanced production of oxytocin (Bicknell et al, 1988b)
and neuronal content of oxytocin mRNA does not alter in morphine-tolerant rats
(Sumner et al, 1989). The density of /x-type opioid receptors in the supraoptic nucleus
is reduced after chronic morphine treatment and this might contribute to the observed
tolerance (Sumner et al, 1990).
As well as tolerance, dependence develops to this regime of i.c.v. morphine
(Bicknell et al, 1988a; Rayner et al, 1988; Leng et al, 1989b). This is revealed after
the administration of naloxone which precipitates 'withdrawal excitation' rather than
reversal of morphine inhibition. The firing rate of identified oxytocin neurones rises
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to 350% control firing rate and oxytocin secretion increases by 80-fold (Bicknell et al,
1988a). There is no tolerance to or dependence upon morphine demonstrable at the
posterior pituitary (Bicknell et al, 1985b) and morphine does not act here acutely to
inhibit oxytocin secretion (Coombes and Russell, 1989) and therefore is unlikely to
chronically. So, morphine tolerance and dependence are manifested at the cell bodies
of oxytocin neurones where opiate receptors of the p- and /c-subtypes exist (see earlier
Introduction and Chapter 5). However, tolerance and dependence do not develop
opiate receptors in the posterior pituitary, which, being primarily or exclusively of the
x-subtype (Bunn et al, 1985; Herkenham et al, 1986; Stojilkovic et al, 1987; Zhao et
al, 1988b; Sumner et al, 1990) would bind morphine, a relatively selective agonist at
the /x-type opiate receptor, poorly. The fact that a 350% increase in firing rate
produced a 800% increase in oxytocin secretion is explained by the increased
efficiency with which oxytocin is released as firing rate increases, frequency
facilitation which has already been demonstrated for oxytocin neurones (Bicknell,
1988 and see Chapter 2). That the firing pattern elicited by naloxone after 5 days of
i.c.v. morphine is sufficient to account for the observed disproportionately high
secretion of oxytocin was confirmed by use of the recording of an oxytocin neurone
withdrawing from chronic i.c.v. morphine after naloxone to stimulate the
neurohypophyseal stalk in a morphine-naive control rat. The same profile of oxytocin
release was obtained as was seen originally in the morphine-tolerant rat (Bicknell et al,
1988a).
This Thesis extends some of the above findings by the use of morphine and
U50,488H to invesigate opiate effects upon the cell bodies of oxytocin neurones in
this neurosecretory system. Because of the accessibility of these neurones as well as
the relatively advanced state of current understanding of their function, the study of
opiate effects in the supraoptic nucleus offers the opportunity to understand in greater
depth the mechanisms of both acute and chronic opiate action on neurones. Given the
presence of endogenous opioid peptides both centrally and peripherally in relation to
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these neurones, the potential role that endogenous opioid peptides might play, should
tolerance to and dependence upon them develop in a manner similar to that seen with
morphine, must be a point of speculation.
Possible means by which oxytocin neurones adapt to chronic morphine exposure
are investigated in this Thesis (see Chapters 3, 4 and 5) including the possible
involvement of the AV3V region in the expression of dependence (see Chapter 6).
Tolerance to i.c.v. morphine in terms of the electrical activity of oxytocin neurones is
quantified (see Chapter 1). Whether tolerance to chronic i.c.v. morphine confers
tolerance to U50,488H, the selective agonist acting at the /c-opiate receptor subtype
acutely injected intravenously was also investigated (see Chapter 2).
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CHAPTER 1
TOLERANCE TO MORPHINE IN OXYTOCIN NEUROSECRETORY NEURONES IN THE RAT:
QUANTIFICATION OF TOLERANCE IN TERMS OF NEURONAL ELECTRICAL ACTIVITY
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1.1. INTRODUCTION
Morphine inhibits the secretion of oxytocin (OT) (Grell et al, 1988) as illustrated
by its effect on the milk ejection reflex (Haldar and Sawyer, 1978) and on parturition.
Parturition is slowed by either peripheral or intracerebroventricular (i.c.v.)
administration of morphine without an effect on the sensitivity of the uterus to OT and
this effect is reversed by naloxone or OT administration (Russell et al, 1989a). The
milk-ejection reflex in the lactating rat is inhibited by acute i.v. morphine and this is
not by an action at the mammary gland which remains sensitive to exogenous OT
(Russell and Spears, 1984). Morphine was reported to act at tire posterior pituitary in
die lactating rat without any effect on die electrical activity of OT neurones in the
supraoptic nucleus (SON), eidier on their background activity or on die high
frequency bursting diat precedes a milk-ejection (Clarke et al, 1979). The conclusion
from diis study was diat morphine acts exclusively at die posterior pituitary to prevent
OT release from neurosecretory terminals by the uncoupling of normal stimulus-
secretion mechanisms. Although /c-opiates do act at the posterior pituitary to inhibit
the release of OT by an action at the /c-receptor (Zhao et al, 1988b) known to exist in
the posterior pituitary (Bunn et al, 1985; Herkenham et al, 1986; Sumner et al, 1990)
diere are few if any /*-type opiate receptors in the posterior pituitary (Bunn et al, 1985;
Herkenham et al, 1986; Sumner et al, 1990) and there is no evidence for ji-receptor
mediated inhibition of OT release upon stimulation of die pituitary stalk in vivo
(Coombes and Russell, 1988). As morphine is a highly selective ligand at the ji-
receptor widi very low relative affinity for the /c-receptor (Kosterlitz, 1985) then it
seems highly improbable that morphine does act at this site primarily to exert its
undisputed inhibitory influence on OT secretion (Wakerley et al, 1983).
We determined to re-examine the effects of morphine on die cell bodies of OT-
secreting neurones located hi the SON.
Dependence develops to chronic morphine hi terms of electrical activity of OT
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neurones of the SON and this is expressed upon administration of die opiate
antagonist, naloxone. Identified OT neurones respond with a large increase in firing
rate and this is accompanied by a massive and sustained secretion of OT into die
plasma. During the process of chronic morphine infusion according to our protocol,
the development of tolerance is apparent. Tolerance is evident when after an initial
dose of drug, subsequent doses must be increased in order to achieve die same effect
as that of the first dose, that is, diere is a loss of effectiveness of the drug widi repeated
administration (Jaffe, 1985). In the OT secreting system, tolerance is suggested by the
resumption of die milk-ejection reflex in the post-parturient lactating rat and by
normal plasma levels of OT hi lactating rats (Bicknell et al, 1988a; Rayner et al,
1988) showing that morphine infused i.c.v. became less potent with time in these
respects. Tolerance is incomplete however as a large enough intravenous dose of
morphine was still inhibitory to die milk-ejection reflex in 5-day i.c.v. morphine-
infused lactating rats (Rayner et al, 1988). Up to this point tolerance was inferred
from behavioural and endocrinological indices.
hi diis study the primary aim was to confirm and quantify tolerance to i.v.
morphine, in terms of electrical activity of identified OT neurones of die SON of rats
treated chronically widi i.c.v. morphine sulphate thus locating opiate effects as
centrally-mediated. Second, confirmation was sought diat dependence upon morphine




Virgin female Sprague Dawley rats were used; housed at 21-23°C and allowed
food (standard breeder diet) and tap water ad libitum; they were kept under a 13h/l lh
light/dark cycle.
1.2.2. Preparation for electrophvsiology
1.2.2.1. Control group
Virgin female Sprague Dawley rats (mean body weight ± SE: 273 ± 5.8g, n=19)
were anaesthetised with ether and placed into a stereotactic frame. The dorsal skull
was exposed in the mid-line and 1.3mm holes drilled through the bone lateral to the
cannula placement to take two stainless steel screws (3.2mm x 10 BA). A guide hole
(1.0mm) was also drilled through which to introduce the infusion cannula. The
infusion assembly was constructed as follows: the stainless steel cannula was made
from a 1cm length of 21gauge tubing bent at 90° 4.5mm from its tip and bevelled at
45°. This was attached to a 18cm coiled length of polythene tubing (1.2mm o.d.,
0.76mm i.d.) which was attached at the other end to a microsyringe. The whole
assembly was positioned close to the skull and the stainless steel cannula inserted
vertically into the right lateral cerebral ventricle (2mm right lateral, 3mm posterior to
bregma according to the atlas of Konig and Klippel (1963)). Once in place, dental
acrylic was applied to the surface of the skull, to cover the protruding cannula and the
screws, there to provide anchorage, and it was left for several minutes to harden. An
osmotic minipump (1/xl/h, Alzet 2001, Alza Corp.) was placed subcutaneously in the
subscapular region, the microsyringe detached and the cannula connected instead to
the minipump. The infusion assembly was filled with sterile pyrogen-free water
(vehicle).
1.2.2.2. Chronic i.c.v. morphine-treated group
Virgin female Sprague Dawley rats (mean body weight ± SE: 268 ± 6.8, n=17)
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were anaesthetised with ether and cannulated intracerebroventricularly, as described
above. Morphine sulphate B.P. was dissolved in sterile pyrogen-free water and
filtered (Millex-GS, 0.22/mr, Millipore S.A.). All dilutions were made from this stock
solution which was kept at 4°C. The minipump was filled with a 50mg/ml solution of
morphine sulphate and primed in 0.9% saline overnight at room temperature. The
infusion cannula was filled with morphine sulphate solution in increasing
concentration (10^g/li for 40h, 20/ig/h for 40h and 50^g/h for 40h), separated by IfA
air bubbles in order to increase the degree of tolerance achieved over the 5 days.
1.2.3. Electrophysiology
On the sixth day of i.c.v. infusion rats were anaesthetised with urethane (ethyl
carbamate, 1.25g/kg i.p.) and the trachea and a jugular vein cannulated. The rat was
mounted in a stereotactic frame and the right SON and neurohypophyseal stalk were
exposed surgically (ventral surgery performed by Dr G. Leng; Leng, 1981). A
concentric bipolar stimulating electrode (SNEX 200, Rhodes Medical Instruments)
was placed on the neurohypophyseal stalk and a glass micropipette filled with 0.9%
saline (20-40 MOhm) was placed under visual control into the SON to record
extracellularly from antidromically-activated neurones. Neurones were antidromically
activated by stimulation of the neurohypophyseal stalk (1ms matched biphasic pulses
<lmA peak to peak, 0.3Hz) and a measure of threshold voltage to activation made.
Recorded neurones were tested for constant latency to antidromic activation and by
the collision test to confirm their uninterrupted projection to the posterior pituitary.
Thus neurosecretory neurones in the SON exclusively were identified and tested. The
study was primarily concerned with putative OT-secreting neurones, so any neurones
considered to be firing phasically (alternating periods of activity at >3Hz and
quiescence for >5 seconds) which are putative vasopressin-secreting neurones
(Poulain and Wakerley, 1982) were not studied beyond the initial control periods.
Recordings of non-phasic neurones were made and stored on video tape in digital
format via a modified pulse code modulator for later analysis. At tire same time, spike
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activity was used to trigger a digital pulse via a Unilab Interface. The time between
pulses was measured with a BBC B+ microcomputer with software written for this
application (Richard Bunting, Dept. Neuroendocrinology, A.F.R.C. Institute of
Animal Physiology and Genetics Research, Babraham, Cambridge) and frequency
histograms based on the number of pulses registered in 30 seconds (or an alternative
bin duration) were generated. Firing rate was recorded for at least 10 minutes to
establish a stable control period and morphine sulphate in 0.9% saline was injected via
the venous cannnula in increasing dose: 1, 10, 50, 100, 500, 1000/xg/kg up to a
maximum dose of 5mg/kg in an injection volume of 500/xl/kg. If a previously active
neurone became silent for tire 10 min following drug injection, or tire upper limit of
tire dose range was reached, naloxone was administered (up to 5mg/kg i.v.). The mean
firing rate for tire 10 minute period corresponding to a particular drug was calculated
and a significant change in firing rate was defined by tire separation of the 95%
confidence bands about the mean firing rate for control and test periods. Each test
period mean firing rate was also expressed as a percentage of the control mean firing
rate. Due to tire lengthy protocol, units were occasionally 'lost' usually due to
mechanical problems. In such instances, data was collected from another cell in tire
same rat and this was included only if tire preceding dose had not affected the original
cell and tire next two doses of morphine were ineffective against tire cell under test,
suggesting that the threshold for inhibition was not reached.
1.2.4. Statistical analysis
The threshold effective dose of morphine to inhibition for tire i.c.v. morphine and
i.c.v. vehicle-treated groups were compared with the Wilcoxon test for independent
samples and by the proportion of cells affected at each dose.
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1.3. Results
1.3.1. Characteristics of supraoptic non-phasic putative oxytocin neurosecretory
neurones
1.3.1.1. Vehicle-infused rats
Control period recordings were taken from 59 cells in 17 i.e.v. vehicle-infused rats.
21 (35.6%) fired phasically and were classified as putatively vasopressinergic, 25
(42.4%) fired continuously at >2Hz and were classified as putatively oxytocinergic, 9
(15.3%) fired below 2Hz and irregularly and 4 (6.8%) were silent.
Mean ± SE latency to antidromic activation in active non-phasic cells was 13.7 ±
0.8 ms (n=24 cells; 17 rats) and the mean ± SE threshold voltage for antidromic
activation was 27.8 ± 5.7 V (n=12 cells).
The mean ± SE basal firing rate of active non-phasic cells was 4.6 ± 0.6 Hz, n=30.
1.3.1.2. Morphine-infused rats
In 17 morphine-infused rats control period recordings were taken from 72 cells. 27
(37.5%) were phasic (not significantly different from the i.c.v. vehicle-treated group),
21 (29.2%) were continuously firing at > 2 Hz (not significantly different from the
1.c.v. vehicle-treated group), 13 (18.1%) fired at less than 2 Hz (not significantly
different from the i.c.v. vehicle-treated group) and 11 (15.3%) were silent (not
significantly different from i.c.v. vehicle-treated group).
Mean + SE latency to antidromic activation of non-phasic cells was 13.0 ± 1.0 ms
(n=23 cells; 15 rats; not significantly different from the i.c.v. vehicle-treated group)
and mean + SE threshold voltage to antidromic activation was 38.1 ± 5.9 V (n=ll
cells; not significantly different from the i.c.v. vehicle-treated group).
The mean + SE basal firing rate of active non-phasic cells was 3.5 + 0.7 Hz (n=28
cells in 17 rats; P < 0.05 vs. i.c.v. vehicle-treated group).
Silent and slow-irregularly firing neurones are identifiable as oxytocinergic or
vasopressinergic only upon excitation when the firing pattern of one or other cell type
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is adopted. Silent cells could not be tested anyway, because the inhibitory effects of
morphine were under study. However, some cells from the slow-irregular category
were tested in the i.c.v. morphine-treated group. The difference in mean firing rate of
active non-phasic cells between groups was the result of the reduced firing rate of cells
firing at less than 2Hz in the i.c.v. morphine-treated group.
1.3.2. Characteristics of supraoptic phasic putative vasopressin neurosecretory
neurones
The mean + SE basal firing rate in the i.c.v. vehicle-treated group was 4.2 + 0.6
Hz (n=19 cells in 9 rats) and in the i.c.v. morphine-treated group, 6.4 ± 0.7 Hz (n=19
cells in 14 rats). The mean + SE latency to antidromic activation was 14.6 ± 0.9 ms
(n=12 cells) and 11.7 ± 0.5 ms (n=22 cells) in i.c.v. vehicle- and i.c.v. morphine-
infused rats respectively (P < 0.05). The mean threshold voltage to antidromic
activation was 27.8 + 4.1 V and 26.7 ± 5.6 V (n=17 cells, not significantly different).
1.3.3. Effects of i.v. morphine on non-phasic putative oxytocin supraoptic neurones in
i.c.v. vehicle-infused rats
Only inhibitory effects of i.v. morphine were seen.
The cumulative threshold dose of morphine needed to inhibit significantly the 6/7
continuously active neurones that responded was from 1/ig/kg to 161/zg/kg (median
dose: 20/xg/kg, 7 rats; see Figures. 1.3.3.1. and 1.3.5.2.). At a cumulative dose of
161 j^g/kg, all 6 neurones were markedly inhibited. The mean + SE firing rate of
these 6 neurones was 4.4 +1.1 Hz. The control firing rate of the neurone that did not
respond to morphine was 14.0 Hz and was possibly an excited phasic neurone. The
effect of morphine was evident within 30 seconds of i.v. injection of morphine. At the
highest doses used, firing rate was reduced by a mean + SE of 91.6 + 3.3% (n=6
cells).
In those cells tested with naloxone HC1 (5mg/kg), firing rate was restored to 97.7 ±
12.4% (n=4) of the control firing rate. There was no evidence of overshoot of the
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firing rate to beyond that seen in the control period.
41
Figure 1.3.3.1.(overleaf) I.c.v. vehicle-infused group: summary of firing rate changes
Each histogram is the record of one neurone in one rat which had received an i.c.v.
infusion of vehicle over the previous 5 days and was then urethane-anaesthetised for
extracellular recording from identified neurones in the SON.
Firing rate of putative OT neurones is expressed as a percentage of the control
firing rate measured in 30sec bins during a control period of at least lOminutes. The
intravenous dose of morphine is given on the horizontal axis in /xg/kg and ranges from
1/xg/kg to 5000/xg/kg at 10 minute intervals. Inhibition was defined as the firing rate
during any 10 minute drug treatment period for which the 95% confidence bands
about the mean did not overlap with those of the control period. Statistically
significant inhibitions are marked with an asterisk. The control period firing rates
were a) 9.3Hz b) 4.4Hz c) 2.3Hz d) 2.2Hz e) 3.8Hz f) 4.55Hz g) 14.0Hz. All cells
except one (g) were significantly inhibited by 161/xg/kg morphine or less.
Naloxone (NAL) where given fully reversed the acute inhibitory effects of
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1.3.5. Effects of i.v. morphine on non-phasic putative oxytocin supraoptic neurones in
i.c.v. morphine-infused rats
The mean + SE basal firing rate of these neurones was 3.2 ± 1.2 Hz (n=9, 8 rats;
not significantly different from the i.c.v. vehicle-treated group). Of this group, 5
neurones fired continuously at >2 Hz(mean ± SE firing rate 4.9 +1.8 Hz) and 4 were
slow-irregular cells (mean ± SE firing rate 1.0 ± 0.15 Hz).
Only 4/9 non-phasic neurones were inhibited by morphine; the cells which did not
respond received a cumulative dose of i.v. morphine of 161/xg/kg (1 cell), 661 pig/kg (2
cells), 6661pig/kg (1 cell) and 9110pig/kg (1 cell). The threshold cumulative dose of
i.v. morphine to inhibition in those cells which were inhibited was 661 pig/kg (1 cell),
1660/xg/kg (1 cell), 6.600mg/kg (1 cell) and 6.661mg/kg (1 cell). The median
threshold cumulative dose to inhibition was 1660/xg/kg (n=9 cells; significantly
greater than in the i.c.v. vehicle-treated group, P = 0.01). Whereas at a cumulative
dose of <= 161 /xg/kg 6/7 cells tested in the i.c.v. vehicle group were inhibited, none
from the i.c.v. morphine-infused group were inhibited in a dose-dependent way (see
Figures 1.3.5.1. and 1.3.5.2.).
At the highest dose of i.v. morphine used, 6.661mg/kg, the firing rate was reduced
by 54.2% + 10.8% (mean + SE; n=5 cells, significantly different from the i.c.v.
vehicle-infused group at lower doses, see above, P < 0.02).
At low doses of i.v. morphine excitatory effects were seen in 5/9 non-phasic cells
(to 128.6 + 8.9% control mean firing rate at 11, 60, 161, 500 and 661pig/kg). Of these
cells however none remained excited at the threshold cumulative dose to inhibition for
the morphine-infused group as a whole, 1660/xg/kg if tested at that dose (3 cells). Two
cells were lost at 161 yizg/kg and 661 pig/kg and were excited by those doses, so reversal
of the initial excitatory effect was not demonstrated.
Naloxone (5mg/kg i.v.) produced withdrawal excitation compared with the control
mean firing rate. In the first 10 minutes after naloxone mean firing rate was increased
to 260.4 + 31.3% of mean control firing rate (P < 0.01, Student's paired t-test, n=4)
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and this was significantly different from the response in the i.c.v. vehicle-infused
group (P < 0.01, Student's unpaired t-test and Wilcoxon test for independent samples).
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Figure 1.3.5.1/overleaf) I.c.v. morphine-infused group: summary of firing rate
changes
As in figure 1.3.3.1., each histogram is the record of a single neurone in one rat
which in this case had received a 5-day i.c.v. infusion of morphine sulphate in
increasing dose and was then anaesthetised with urethane. Intravenous morphine was
given at 10 minute intervals and firing rate collected in 30 sec bins for calculation of
firing rate over the lOminutes. A significant change was denoted by separation of the
95% confidence bands of the control firing rate and those of any drug treatment
period. Only one neurone was inhibited by 161/xg/kg morphine or less but this effect
did not appear to be dose-related (cf. neurones from the i.c.v. vehicle-infused group).
5 cells were excited by low doses of morphine. Naloxone (NAL; 5mg/kg) produced
hyperexcitation in all cells tested in this group. Control firing rates were a)3.1Hz b)
2.3Hz c) 3.6Hz d) 3.5Hz e) 12.1 Hz f) 1.5Hz g) 0.85Hz h) 0.8Hz i) 1.0Hz. Cells a) - e)
were classified as continuous putative OT neurones; neurone f) although slow-firing
was classified as putatively oxytocinergic by its response to naloxone and neurones g)
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Figure 1.3.5.2. Comparative dose response relations for supraoptic putative oxytocin
neurones from 5-dav i.c.v. vehicle-infused and 5-dav i.c.v. morphine-infused rats
Horizontal axis denotes cumulative dose of morphine (jig/kg i.v.) and the vertical
axis, the proportion of neurones in each group which were inhibited by a given
intravenous dose of morphine. At 161 /zg/kg morphine most of the neurones in the





The protocol used lasted at least 80 minutes and longer if the naloxone response
was followed beyond the initial 10 minutes. It was not always possible to complete
the protocol on one cell. If a cell responded maximally to morphine before the end of
the full dose range was reached, then no further dose of morphine was injected and the
inhibitory response was instead challenged with naloxone. Recordings were
occasionally abandoned part way through if it became apparent that the cell under
study was a phasic, putatively vasopressinergic cell and therefore of no further interest
in this particular study. Some recordings were 'lost' as a result of sudden mechanical
damage to the cell. The region of the SON is highly vascularised (Akmayev, 1971).
The surgical approach requires that the dura be incised discretely over a small part of
the nucleus to allow passage of the pipette into the body of the nucleus. The stability
of recordings seemed to be partly compromised by the degree of exposure of the tissue
and this was always minimal. However, sudden movement of the pipette tip, which is
very flexible laterally and may be close to pulsating capillaries, may account for the
physical damage to neurones which suddenly emitted an injury discharge. Other cells
were characterised by an extracellular spike which diminished in height gradually
throughout the protocol in a way that appeared to be independent of drug treatment.
This seemed to be a result of subtle movement of the cell in relation to tire pipette, as
advancing the pipette towards the cell could restore the quality of the recording.
However, once in the nucleus, it was impossible to move die pipette in more than the
one plane and this means that if a cell was moving away from the pipette laterally dien
no amount of advancing or retracking could restore the recording. In such cases, the
protocol was abandoned as the signal-to-noise ratio became so small diat reliable
discrimination of the spike was no longer possible.
Some movement was probably due to tissue swelling that arose widi repeated
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penetration of tire nucleus. Searches were confined to one or two tracks through tire
nucleus to minimise tissue swelling. This is not only advantageous in terms of making
stable recordings, it also improves the chances of recording from physiologically "near
normal" cells.
With the first cell lost, a replacement cell in tire same nucleus was sought and tire
protocol continued, but not restarted, as it was a cumulative regime and the time lapse
between 'losing' a recording and finding a replacement cell was usually too short.
The plasma half-life of morphine in the rat is 1-2 hours for the fast phase and 10 hours
for tire slower phase (Berkowitz et al, 1974), so administering morphine every 10
minutes in increasing dose would result in its accumulation in tire plasma: hence tire
expression of dose as cumulative rather than discrete.
In order to maximise tire usefulness of these part records, a procedure was
determined to select out records from which data could be legitimately extracted for
mean control firing rate, median threshold effective dose and degree of reversal with
naloxone, even after tire administration of preceding doses. If a rat was exposed to up
to 661/xg/kg morphine or more (chosen retrospectively as being tire likely threshold
effective dose of morphine to inhibit these cells) and the cell lost then any subsequent
recording did not contribute to calculation of control firing rate, threshold effective
dose, or reversal of morphine induced inhibition with naloxone. If the last dose was
less than 661/rg/kg, and tire next dose injected inhibited tire new cell, no measure of
threshold dose to inhibition was obtained. Should the first dose of the resumed regime
not have inhibited tire new cell, but a higher dose did and a dose related trend was
apparent, then it was judged that the threshold dose to inhibition had not been reached
for the new cell and it was then estimated.
For 1 cell in tire control group, (Figure 1.3.3.l.b) the rat received 1/rg/kg morphine
more than 15 minutes before the 'control period' for this cell was recorded and the cell
only later responded to i.v. morphine at 50/xg/kg with a significant inhibition; for this
cell then the 'control rate' was that measured long after tire original lowest dose of
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morphine. The mean control firing rate of the remaining 6 cells was 6.0 ± 1.9 Hz and
the median firing rate 4.2 Hz. The mean firing rate is relatively high because of one
fast-firing cell which had a control firing rate of 14.0 Hz and this cell did not respond
to morphine. The control firing rate of cell b) (see Figure 1.3.3.1.), was 4.4 Hz.
In the chronic i.c.v. morphine-treated group, the control periods of 3/9 cells were
after lowest doses of morphine: cells d), c) and b) (see Figure 1.3.5.1.): Cell d) (see
Figure 1.3.5.1.) this rat received up to 11/xg/kg more than 20 minutes before the tested
cell was recorded. Although at 50/ig/kg there was a 'significant' inhibition of firing
rate, there was no dose related inhibition and a cumulative dose of 661/xg/kg was not
inhibitory compared to the 10 minute 'control period' for this cell. This suggests that
the threshold inhibitory dose was not reached within the schedule and certainly not
prior to the 'control period'. Cell c) (see Figure 1.3.5.1.): this rat received a
cumulative dose of 161 /xg/kg 8 minutes before the commencement of the 'control
period' recording for this cell. None of the other cells in this group were inhibited at
this dose. The next dose, 500^g/kg was not inhibitory but excitatory and it was not
until 5mg/kg (6500/xg/kg cumulative dose) that this cell was inhibited. Clearly there
was no evidence of the threshold inhibitory dose having been reached before the
5mg/kg dose at the end of the protocol. Cell b) (see Figure 1.3.5.1.): this rat received a
single dose of 1 yu.g/kg morphine i.v. 15 minutes before the start of the 'control period'
for this cell. No inhibition was evident until a cumulative dose of 1660/xg/kg was
reached. Indeed, this cell was excited by cumulative doses of 60/xg/kg and 160pig/kg,
confirming that the threshold inhibitory dose probably was not 1 ^g/kg. The mean
firing rate of the remaining 6 cells was 3.2 ± 1.8 Hz and the median firing rate 1.2 Hz.
The control firing rates for the three above mentioned cells were 3.5, 3.6 and 2.3 Hz
respectively. These values are well within the expected range for control cells from
this group. From these cells therefore, data for control firing rate, threshold inhibitory
dose and degree of naloxone reversal were obtained.
1.4.2. Effects of i.v. morphine on putative oxytocin cells from vehicle-infused rats
Acute i.v. morphine given to control (vehicle-infused) virgin female rats inhibited
die spontaneous activity of antidromically-identified continuously-firing (putative
oxytocin (OT)-secreting) neurones of die SON. These cells were exquisitely sensitive
to morphine which was effective at a threshold dose of 60 /xg/kg (n=5/6 cells affected;
1 cell: 120/xg/kg; 1 cell unaffected). This dose of morphine is much lower dian diat
required to inhibit the milk-ejection reflex, which reflects OT release in response to
suckling (Russell and Spears, 1984; Clarke and Wright, 1984) but perhaps diis is not
surprising since low-dose electrophysiological effects are very short lived and are
unlikely therefore to discemably affect the milk ejection reflex. Since morphine does
not inhibit the release of OT evoked by stimulation of die pituitary stalk in lactating
rats using a similar surgical technique and protocol (up to 5mg/kg; Coombes and
Russell, 1988), and opiate inhibition of OT release at die level of the posterior
pituitary is via die /c-type opiate receptor (Bicknell et al, 1985a) it follows that die
primary, if not exclusive action of morphine in these experiments is at die cell bodies
of oxytocinergic neurosecretory neurones in the SON or upon afferents to the nucleus.
This concept is contrary to diat of an earlier report (Clarke et al, 1979), which
suggested that opiates act exclusively at die terminals of diese neurones in die
posterior pituitary to impair normal stimulus-secretion coupling, but is consistent widi
later experiments in die hypodialamic slice (Wakerley et al, 1983) which showed
inhibitory effects of morphine upon putative OT neurones of die SON. Perhaps then
the powerful stimulation to OT neurones upon activation of die milk-ejection reflex is
too robust to be influenced by these transient electrical events occurring in die SON.
Morphine is a highly selective ligand for the ju-type opiate receptor with negligible
affinity for die <5- or /c-type opiate receptor (Kosterlitz, 1985). At die low doses used
hi die control group of rats, it is therefore most likely to be acting at a /x-type receptor
radier than at die /c-type, bodi of which we have found in the SON (Sumner et al,
1990; see Chapter 5) contrary to another report (Mansour et al, 1988).
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In confirmation of this assumption, naloxone, which is an opiate antagonist with a
10-15 fold preference for the rather than the k- or 5-opiate receptors (Kosterlitz,
1985; Leslie, 1987) was effective at antagonising profound inhibition by doses of
morphine up to 6661/xg/kg. Naloxone was effective even at 100/xg/kg in one cell (see
Figure 1.3.3.1.d), which had been inhibited to 9.2% control firing rate by a cumulative
dose of 161/xg/kg morphine i.v.. Naloxone reversed this inhibition and restored the
firing rate to 98.7% control firing rate, hi another cell (see Figure 1.3.3.l.c), a lower
dose still of naloxone was used to partially reverse the morphine induced reduction in
firing rate: after inhibition to 18.4% control firing rate by a dose of morphine of
161/xg/kg i.v., naloxone (50/ig/kg) restored activity to 34.3% control firing rate.
Unfortunately, higher doses of naloxone could not be tested hi this cell as the
recording was susequently lost. These two examples illustrate the sensitivity of
neurones recorded hi control rats to low doses of naloxone, consistent with an action
through a /i-type opiate receptor to antagonise morphine-induced inhibition of these
neurones at the level of the cell bodies or at afferent inputs to the SON, such as the
SFO which also contains opioid receptors (Mansour et al 1987; Conrath and Cupo,
1989; Sharif and Hughes, 1989).
This result is corroborated by in vitro studies using die coronal hypodialamic slice
containing SON (Pittman et al, 1980; Wakerley et al, 1983; Pumford et al, 1987).
The cell bodies of putatively oxytochiergic neurones identified by firing pattern were
inhibited by bath-applied opiates in a naloxone reversible way. Although some
structural integrity remains in diis preparation, afferents coursing over long distances
hi a different plane are transected and this mainly leaves a local afferent input. The
site of action of opiates in die hypothalamic slice preparation and of i.c.v. morphine hi
the present experiments is not clear. It is certainly however a central site.
hi most cells, it was thought more prudent not to try to demonstrate die receptor
subtype likely to mediate the morphine inhibition, by testing low doses of naloxone as
discussed above as this is not best investigated by this approach anyway. What was
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more telling was the fact that maximal doses of naloxone did not evoke electrical
activity beyond that measured during the control period for that cell i.e. there was no
evidence of acute dependence. In cells from control rats tested with naloxone, the
mean firing rate was 97.7 ± 12.4% ± SEM control firing rate (n=4). This was not due
to an inadequate dose of naloxone. The dose used, 5mg/kg, is a large dose, widely
used which remains selective for opiate receptors. Naloxone therefore was simply
antagonising tire accumulated circulating concentration of i.v. morphine in tire control
rats. So, within tire time course of this protocol, acute dependence upon morphine did
not develop. Additionally, it appears that there is no endogenous opioid inhibitory
tone regulating these neurones as naloxone did not cause an overshoot in electrical
activity. This contrasts with tire inhibitory /c-opioid tone demonstrated in tire posterior
pituitary which results from dynorphin co-release with vasopressin which then acts
upon opiate receptors on OT cell terminals to inhibit release (Zhao et al, 1988b).
Figure 1.4.2.1. was constructed from data drawn from tire present series of
experiments alone. Data from the present series of experiments were combined with
those from the series of experiments described in Chapter 2 (where neurones were
tested with acute i.v. U50,488H instead of acute i.v. morphine) in order to increase
group size and make trends more apparent and these data were used to construct
Figure 1.4.2.2.. The results from this second series of experiments are fully described
in Chapter 2. It was thought acceptable to include control data as U50,488H effects
would not need to be considered and to include data on naloxone reversal and
withdrawal as the responses of neurones after U50,488H were similar to those in tire
present series. So, in the vehicle-infused group, naloxone caused a reversal of opiate
(morphine or U50,488H) inhibitory effects to 90.3 ± 14.8% control firing rate and in
the 5-day morphine-infused group, to 337.4 ± 138.75% control firing rate. It appears
therefore that the effects of U50,488H are also readily reversed by naloxone in the
protocol and its inclusion did not impair the ability of naloxone to reverse acute effects
of opiate nor its ability to precipitate a full withdrawal response to chronic i.c.v.
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morphine. Considering then the overall firing rate of continuously-firing neurones in
tire SON after naloxone, as depicted in Figure 1.4.2.2.a): although tire control firing
rate in tire absence of naloxone was similar in the vehicle-infused and tire morphine-
infused groups, there was a marked increase in firing rate of putative OT neurones in
tire nrorphine-infused group after naloxone (P=0.027, Wilcoxon, significantly
different from tire control group). This indicates that the supraoptic nuclear firing rate
is raised significantly by administration of naloxone; it is not a response confined to a
small number of neurones and is confirmation that this change in activity probably
accounts for the increase in plasma OT already reported elsewhere (Rayner et al,
1988).
Acute tolerance to opiates has been reported in vitro (Gahwiler, 1981). Had
tolerance developed during tire i.v. administration of morphine to control rats, a trend
in response unrelated to dose might have been expected. In fact, the response to i.v.
morphine followed a predictable pattern of ever increasing magnitude of inhibition of
firing rate as tire dose administered was increased (see Figure 1.3.3.1.). The onset of
tolerance does not seem to occur for some time in chronic i.c.v. morphine-treated rats
(Rayner et al, 1988). It is several days before a rat receiving a chronic i.c.v. infusion
of morphine solution in increasing dose seenrs to recover from the initially sedative
action of morphine, the disruption of normal behaviour patterns and core body
temperature elevation and the normal operation of the milk-ejection reflex, mediated
by OT secretion. So, although the time course of the development of tolerance to and
dependence upon morphine was not studied by interrupting this 5 day procedure at
intervals to make assessment, it does not exist noticably until day 2-3 of i.c.v. infusion.
This observation agrees with the absence of acute tolerance described above.
1.4.4. Effects of i.v. morphine on putative oxytocin cells from chronic i.c.v.
morphine-infused rats
Although successive increasing doses of morphine were increasingly effective once
tire threshold dose of morphine was given, as in the control group, the threshold dose
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of morphine was markedly different, indicating tolerance to i.v. morphine in these
cells or their inputs after chronic i.c.v. morphine infusion. Control cells responded
with a median threshold effective inhibitory dose of 20/xg/kg morphine. At the
median cumulative dose of 161^g/kg 6/7 control neurones were significantly
inhibited. Chronic i.c.v. morphine treated cells however, were inhibited by morphine
at the higher cumulative threshold dose of 1660/zg/kg. At the median cumulative dose
of 161/ng/kg only 1 cell from this group was inhibited but not in a dose-related way.
On this basis, the two groups were quite different (P=0.01, Wilcoxon).
There were excitatory effects of morphine at low doses which were succeeded by
inhibitory effects at higher doses, where tested, in the morphine-infused group. These
excitatory events were not seen in neurones from die vehicle-infused group (but see
Chapter 3). The observation of opiate-induced excitation is not unprecedented. In
cultured dorsal root ganglion neurones, opiates cause a prolongation of the action
potential at nanomolar doses whilst shortening the action potential at micromolar
doses in the same cell. This direct effect is achieved by modulation of a voltage-
sensitive potassium or calcium channel (ji- or /c-ligand respectively) first one way, by
low doses and dien in the opposite way by higher doses of die same opiate (Crain and
Shen, 1990). By extrapolation, shortening of the action potential would reduce
voltage-dependent calcium entry into the terminals of neurones thus affected,
impairing calcium-dependent neurotransmitter release; inhibition of neurotransnitter
release is typically associated with opiates. Conversely, where opiates at low doses
prolong die action potential, die same argument implies diat opiates might directly
facilitate neurotransmitter release. As well as the direct excitatory effects described
above, opiates do have indirect excitatory effects in hippocampal slices for example,
which involve interaction with inhibitory GABAergic synapses (Bradley and Brookes,
1984). So bodi direct and indirect excitation are possible. In dorsal root ganglion
explant chronically exposed to IpM DADLE, the acute action potential-shortening
properties of the opiate (at 10pM) were diminished in most neurones whereas die
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prolongation of the action potential after DADLE was seen more often (Crain et al,
1988). This implicates these excitatory events in tolerance as well as the more well
documented inhibitory events in this system. As these excitatory events were not seen
in the vehicle-infused group this perhaps suggests that the expression of this response
to opiates has developed with tolerance and might be a marker of tolerance in
supraoptic neurones. However, group sizes are perhaps too small to draw this
conclusion firmly. More experiments with vehicle-infused rats might confirm or
refute this. In particular, it would be necessary to explore the occurrance of the
excitatory response at much lower doses of morphine in the vehicle-infused group. If
the inhibitory response to morphine undergoes adaptive change, so might die
excitatory response to morphine and so as the direshold cumulative dose to inhibition
in die vehicle-infused group is much lower than that in the morphine-infused group,
then perhaps so is die direshold excitatory response. It might therefore be
demonstrated frequently at a lower dose range starting at lng/kg. As low dose
excitation was not anticipated when the experiments were designed and as the primary
aim of the series was to define die difference in die direshold dose to inhibition for
morphine, then the phenomenon was not investigated further. So, whedier die
excitatory events are also affected by chronic opiate exposure awaits further study.
This prolongation of the action potential in dorsal root ganglion cells is meaningful
in terms of neurotransmitter release. Enhancement of the capsaicin-evoked release of
substance-P from primary afferent fibres by ^-opioid receptor agonists in rat spinal
cord has been described (Pohl et al, 1989) and Sweeney and co-workers have
demonstrated naltrexone-reversible opiate enhancement of endogenous adenosine
from rat spinal cord synaptosomes hi vitro (Sweeney et al, 1989). The biphasic
response of some supraoptic neurones in this study was likewise seen in enteric
ganglia where electrically-evoked enkephalin release is bimodal in response to p.-, 8-
and K-opiate receptor selective ligands. It is conceivable therefore that the OT
neurosecretory system might respond to these excitatory low doses of morphine with a
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measurable increase in the plasma concentration of OT. Whether this response occurs
in response to endogenous opiates under certain physiological conditions is not
known. The excitatory and inhibitory effects of the x-opiate receptor agonist
U50,488H both on firing rate of putative OT neurones and on plasma OT are
considered hi a later chapter (see Chapter 2).
hi terms of basal electrical activity, the firing rate of non-phasic neurones from the
control group was 4.6 ± 0.6 Hz (mean ± SEM) and from the i.c.v. morphine-treated
group 3.5 ± 0.7 Hz (P<0.05, Wilcoxon). This value was constructed from continuous
and slow-irregular neurones. Phasic (vasopressin) cells had similar control firing rates
between the i.c.v. vehicle- and i.c.v. morphine-infused groups.
The spectrum of activity seen in 5-day vehicle-infused and 5-day morphine-infused
groups was compared to see if the proportions of the four types of activity differ as a
result of chronic i.c.v. morphine treatment (Figure 1.4.4.1.). After i.c.v. morphine
treatment, the proportion of continuous neurones decreased and the proportion of
silent neurones increased, though neither significantly so, reflecting a trend hi the
activity profile downwards. Whether this trend reflects a real change which would
have achieved statistical significance in a larger sample of cells is not clear. The same
trend was not seen hi phasic (vasopresshi) cells which were recorded hi similar
numbers between groups (Figure 1.4.4.1.). Because there is no difference in the
proportion of cell types between groups, it appears that tolerance to i.v. morphine hi
OT cells of the chronic i.c.v. morphine-treated group is complete.
We have recently reported no difference hi plasma OT concentration in conscious
rats treated chronically with i.c.v. morphine as compared with untreated rats (Sumner
et al, 1990); other reports indicate a slight depression after urethane anaesthesia hi
plasma OT concentration after the 5 day i.c.v. morphine infusion (Bicknell et al,
1988a; Sumner et al, 1989). Normal secretion of OT in chronic i.c.v. morphine-
infused rats is not the result of hicreased synthesis: the OT mRNA content of these
neurones is unchanged (Sumner et al, 1989) also, OT content hi the magnocellular
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nuclei and posterior pituitary in the lactating rat after 5 days of i.c.v. morphine is
unchanged from control. OT release is not enhanced: the proportion of total OT
content in isolated posterior pituitary released upon electrical stimulation is not altered
(Bicknell et al, 1985b). Additionally, there were no differences in antidromic latency
or threshold to activation for continuous neurones, suggesting that changes in axon or
axo-somatic properties of conduction are not involved in adaptive changes with
chronic morphine. These results suggest therefore that decreased effectiveness of i.v.
morphine in the i.c.v. morphine-treated group at inhibition of supraoptic OT neurone
elecrical activity could account for tolerance in the OT neurosecretory system. The
dose response relation shifted to the right after chronic i.c.v. morphine reflecting that
higher doses of morphine were needed to achieve the same inhibitory effect as the
range of doses in the control group (Jaffe. 1985; see Figure 1.3.5.2.). A shift to the
right has been reported for locus coeruleus neurones in vitro which become tolerant to
morphine (North, 1988).
Interestingly the maximum dose of morphine used in the chronic i.c.v. morphine-
treated group only depressed firing rate by a mean of 54% (n=5; 6661/xg/kg and
9110^g/kg in one cell). One possible explanation of this phenomenon is that there are
changes in the receptor/opiate interaction such that the full agonist response of near
100% inhibition of electrical activity in control cells (produced by occupancy of a
small percentage of available receptors) is replaced with a partial agonist response
which could never, even given maximal occupancy of receptors, stimulate a full
response. Thus a 100% inhibitory response would not be attainable via receptors
exposed chronically to opiate. This would result in a levelling off of the dose response
relation prematurely. This switch from full to partial agonist by i.v. morphine would
be explained by a change in the receptor conformation or post-receptor mechanisms.
The drug would be said to be of lower efficacy (the 'strength' of a drug-receptor
complex to evoke a response; Stephenson, 1956). In order to test this hypothesis, an
extended range of doses of morphine could be used in a series of similar experiments.
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Whether the shortfall in effect could be accounted for by insufficient opiate to occupy
'spare' receptors (Stephenson, 1956) or whether in fact the receptor pool is fully
occupied and the response still not 'maximal' could be assessed. However, as I was
also keen to demonstrate the naloxone-induced hyperexcitability of chronic i.c.v.
morphine treated neurones, to highlight the development of dependence, the
administration of very high doses of morphine to define the maximally effective dose
might have impaired the naloxone response, thus calling into question the existence of
dependence. So, this was not pursued in the present study.
An alternative explanation for the reduced level of 'maximal' inhibition in the
chronic i.c.v. morphine-treated group could be that chronic morphine exposure
enhances the capacity of the liver to metabolise circulating morphine, so that much
higher doses of morphine are required to achieve the same bioavailability. Indeed
methadone induces liver enzymes to enhance its own metabolism (Anggard et al,
1975). This is an unlikely scenario as it has been shown in rats that tire development
of tolerance does not alter the plasma half-life of morphine in rats (1-2 hours for the
fast phase and 10 hours for the slower phase) and morphine can be detected in the
plasma 20 days after removal of morphine pellets, so complete elimination is a slow
process (Berkowitz et al, 1974). Morphine is mainly inactivated by conjugation to
form morphine glucuronide, which is excreted in the bile and by the kidneys. Some
hydrolysis of the glucuronide occurs in the gut with subsequent reabsorption. This
enterohepatic circulation can cause the persistence of morphine.
The adaptive changes at the receptor or in post-receptor mechanisms that constitute
tolerance could be explained in several ways. Neurosecretory neurones or their inputs
may lose functional opiate receptors; existing opiate receptors may have a decreased
affinity for the ligand thus necessitating a larger dose of opiate to achieve the same
effect; coupling of receptors to intracellular mechanisms might be impaired, reducing
the effectiveness of the ligand-receptor interaction, or an endogenous opiate antagonist
may be produced which will compete with circulating opiate for receptor occupation.
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In a recent study, we have reported by quantitative receptor autoradiography a
selective down-regulation of the ^c-type opiate receptor in the SON of 5-day i.e.v.
morphine-treated rats (Sumner et al, 1990; see Chapter 5). This might contribute to
the observed tolerance but the importance of the reduction in size of the pool of
'spare' receptors (Stephenson, 1956) and die relative importance of affinity changes
must be considered. I have not investigated these aspects. As I was able to
substantially inhibit neurones from chronic i.c.v. morphine-treated rats widi high
doses of morphine, this suggests that there is a pool of functional receptors similar in
size to that in the control rat such that a near maximal response could be elicited. As
mentioned earlier, the use of much higher doses of morphine hi a similar series of
experiments would indicate the true size of die pool of functional receptors.
Abruptly precipitated withdrawal from chronic morphine by naloxone in diis group
of rats produced a dramatic increase in firing rate which contrasted sharply widi the
control group response (P<0.01, Student's t-test and Wilcoxon). This appears not to
be die just die reversal of accumulated intravenously-administered morphine. In die
10 minutes following naloxone injection, mean firing rate was increased to 260.4 ±
31.3% of mean control firing rate (P<0.01, Student's paired t-test, n=4). This
'wididrawal excitation' has been shown to adequately account for the observed
hypersecretion of OT in the lactating rat on naloxone-precipitated withdrawal of
chronic morphine (Bicknell et al, 1988a) and diese results suggest that not only has
tolerance developed within this schedule but dependence as well.
Part of this withdrawal excitation is mediated at a site or sites outside the blood-
brain barrier (see Chapter 6). This is the conclusion from a study using a naloxone
salt, naloxone methyl bromide, which does not cross the blood-brain barrier when
given i.v. but which precipitated a partial withdrawal response in OT neurones after 5
days of i.c.v. morphine treatment (Bicknell et al, 1987a; Russell et al, 1989b).
Morphine could be acting at several sites to acutely inhibit the activity of OT
neurones, apart from die neurones themselves or local inputs. The subfornical organ
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(SFO) and the region anterior and ventral to the third ventricle (AV3V region) contain
opiate receptors (Mansour et al, 1987; Conrath and Cupo, 1989; Sharif and Hughes,
1989) and project to supraoptic OT neurones providing a tonic excitatory input
(Russell et al, 1988; Leng et al, 1989a). However, tonic activity resulting from
stimulation of this excitatory input can be inhibited by i.v. morphine (Leng and
Russell, 1989) suggesting some modulation more locally to the neurosecretory
neurones. Indeed, in vitro experiments in the rat hypothalamic slice containing SON
have suggested opiate inhibition of OT cells occurs in or close to the nucleus (Pittman
et al, 1980; Wakerley et al, 1983; Pumford et al, 1987). Wherever the opiate receptors
are, they must be of sufficient number and have access to post-receptor mechanisms
because withdrawal elicits massive activation of receptors, evidenced by the increase
in electrical activity of OT neurones. The mechanisms of tolerance and dependence
are not necessarily related and an explanation for either need not encompass the other
(Wuster et al, 1985). It has been suggested that tolerance might be the result of an
uncoupling of the receptor from post-receptor mechanisms thus reducing the pool of
available functioning receptors (Wuster and Costa, 1984) and that dependence on the
other hand might follow hypertrophy of intracellular mechanisms in response to
continuing inhibition as a counteractive measure and that this requires an intact
neuronal system and enough functioning receptors to mediate this inhibition, as when
withdrawal is precipitated, the full response in reverse, and more is expressed through
functioning receptors. Whilst I always saw tolerance together with dependence in this
study, it is difficult to explain tolerance and dependence in terms of a unitary response
and they have been shown to be dissociated in other systems (Christie et al, 1987).
The experiments described hi later Chapters looking at changes in receptor density and
the involvement of G-proteins in mediating the acute effects of morphine in these
neurones shed more light on possible mechanisms which undergo adaptive change in
response to chronic opiate.
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Figure 1.4.2. l.a) Firing rate (Hz) of putative oxytocin neurones from 5-day i.c.v.
vehicle-infused and 5-dav i.c.v. morphine-infused rats
Data were drawn from the two series of experiments described in Chapters 1 and 2
respectively.
The first point illustrated by this histogram is that initial firing rate is not different
between the i.c.v. vehicle-infused and the i.c.v. morphine-infused groups (4.7Hz and
2.6Hz respectively; n.s., unpaired two-tailed t-test). To make the comparison,
neurones from which a record of control firing rate had been obtained in the vehicle-
infused groups from Chapters 1 and 2 contributed to a mean value for initial firing
rate, hence the large group size (n=30). However, of neurones tested in the i.c.v.
morphine-infused group, only neurones which received naloxone (5mg/kg) after
completion of the acute i.v. morphine regime (i.e. neurones from the series of
experiments described here in Chapter 1) were included in this particular comparison,
hence the small group size (n=4).
The second point illustrated by this histogram is that for those neurones in the i.c.v.
morphine-infused group which underwent a regime of i.v. morphine and went on to be
tested with naloxone, firing rate was significantly elevated compared to the pre-
naloxone firing rate (from 2.6Hz to 7.1Hz; P=0.02,1-tailed paired t-test, n=4).
Figure 1.4.2, l.b) Percentage of control firing rate for both i.c.v. vehicle- and i.c.v.
morphine-infused groups before and after naloxone
Data contributing to this histogram were derived solely from the experiments
described here in Chapter 1.
In the i.c.v. vehicle-infused group there was no difference between the pre- and
post-naloxone firing rate of the 5 neurones which were tested with naloxone (post-
naloxone firing rate was 93.0% of pre-naloxone; n.s., unpaired 1-tailed t-test).
However, the post-naloxone firing rate of the 4 neurones tested in the i.c.v. morphine-
infused group was significantly greater than the post-naloxone firing rate of die 5
neurones measured in the i.c.v. vehicle-infused group (260.4% vs. 93.0% of their pre-
naloxone control values respectively; P=0.0004, unpaired 1-tailed t-test).
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Figure 1.4.2.2. Comparison of pre- and post-naloxone firing rates
The comparison of pre- and post-naloxone firing rates in this figure includes cells
drawn from a series of experiments using intravenous U50,488H (see Chapter 2) in
place of morphine within the same protocol. Therefore in 5 of these cells naloxone is
given after a series of doses of U50,488H.
a) Firing rate (Hz) of putative oxytocin neurones from 5-day i.c.v. vehicle-infused
and 5-day i.c.v. morphine-infused rats. Firing rate is not different between vehicle-
and morphine-infused groups (Wilcoxon). Pre- and post-naloxone firing rates are
significantly different in the i.c.v. morphine-infused group (Wilcoxon, P=0.008).
Post-naloxone firing rate is also different from the control firing rate for the i.c.v.
vehicle-infused group (Wilcoxon, P=0.027).
b) Percentage of control firing rate for both i.c.v. vehicle- and i.c.v. morphine-
infused groups before and after naloxone. Post naloxone firing rate is not different
from control for die i.c.v. vehicle-infused group. As stated above, pre- and post-
naloxone firing rates are significantly different from die i.c.v. morphine-infused group
(Wilcoxon, P=0.008) and post-naloxone firing rate for the i.c.v. morphine-infused
group is significantly greater dian the post-naloxone firing rate hi the i.c.v. vehicle-
infused group (Wilcoxon, P=0.0007).
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Figure 1.4.4.1. Comparison of the distribution of electrical activity in supraoptic
nuclei from 5-day i.c.v. vehicle-infused rats and 5-day i.c.v. morphine-infused rats
The proportion of continuous and phasic neurones are similar in the i.c.v. vehicle-
infused group. After chronic morphine infusion the proportion of neurones in all 4






(After Poulain and Wakerley, 1982)
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CHAPTER 2
THE EFFECTS OF U50,488H ON OXYTOCIN NEUROSECRETORY NEURONES IN
MORPHINE-NAIVE AND CHRONIC I.C.V. MORPHINE-INFUSED RATS: DOES CROSS-
TOLERANCE DEVELOP IN TERMS OF NEURONAL ACTIVITY?
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2.1. INTRODUCTION
Subtypes of opioid receptors were first postulated by Martin in 1967 to explain the
dual action of nalorphine in man, where it antagonised morphine analgesia but was
analgesic itself. The existence of the /c-opioid receptor was thought to account for this
observation (Martin, 1967). Opioid receptors fall into 3 subtypes, n, 5 and k
historically defined by different pharmacological profiles of opioid ligands hi
neurophysiological and behavioural tests in the spinal dog (Gilbert and Martin, 1976;
Lord et al,1977) and their prototype ligands are morphine, DADLE (D-Ala2, D-Leu5-
enkephalin) and ketazocine respectively. Each subtype of receptor binds endogenous
opioids with varying degrees of affinity: j8-endorphin, Met-enkephalin and Leu-
enkephalin to the ^-receptor and dynorphin to the k-receptor (Corbett et al, 1982;
Kosterlitz and Paterson, 1985).
There are /c-opioid receptors in the SON (Clark et al, 1986; Mansour et al, 1986;
Mansour et al, 1987; Tempel and Zukin, 1987) and we have found both and k-
opioid receptors in the SON (Sumner et al, 1990; see Chapter 5). Both morphine
(Pittman et al, 1980; Wakerley et al, 1983) and the /c-opioid receptor agonist,
U50,488H (tra/is-(±)-3,4-dichloro-7/-methyl-/V-(2-[l-pyrrolidinyl]cyclohexyl)
benzeneacetamide, methane sulphonate salt) acutely affect the electrical activity of
oxytocin (OT)-secreting neurones (Russell et al, 1989b) and the OT-secreting system
develops tolerance to chronic i.c.v. morphine (Bicknell et al, 1988a; Rayner et al,
1988; Sunnier et al, 1989; Leng et al, 1990; see also Chapter 1).
Tolerance i.e. loss of effect of the opioid with repeated administration requiring
higher doses to be used to produce the same initial effect, develops to selective ligands
binding at all 3 receptor subtypes including to endogenous opioid peptides (Christie et
al, 1982; Redmond and Krystal 1984; Sivam and Ho, 1984).
Cross-tolerance can occur between drugs acting at the same or at similar receptor
sites and this is seen when a system made tolerant to one drug by chronic
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administration exhibits tolerance to another drug to which the system has not
previously been exposed. Cross tolerance involving two drugs is indicative of either a
shared receptor site or of shared membrane/post-receptor mechanisms i.e. of some
interaction between two distinct receptor sites (Wuster et al, 1983).
Morphine binds most avidly to the ^-opioid receptor and U50,488H to the K-opioid
receptor and both are high affinity agonists at their respective receptor sites with very
little affinity for the other opioid receptor sites (Kosterlitz, 1985; Lahti et al, 1985;
Clarke and Pasternak, 1988). Lack of cross-tolerance has been reported between
U50,488H and morphine but does occur between morphine and less highly selective k-
opioid agonists such as ethylketocyclazocine and the prototype /c-opioid agonist
ketazocine in mice (Von Voightlander and Lewis, 1982).
Tolerance has been described to the ju-opioid receptor agonist morphine when
chronically administered in the rat by i.c.v. infusion, in terms of plasma OT
concentration and in terms of the electrical activity of the OT-secreting neurones of
the SON (Leng et al, 1990 and Chapter 1).
The question of whether tolerance to i.c.v. morphine in the rat confers tolerance to
the K-opioid receptor agonist U50,488H in terms of electrical activity of OT-secreting
neurones of tire SON is addressed in this Chapter. A preliminary account of this study




Virgin female Sprague-Dawley rats were used; housed at 21-23°C and allowed
food (standard breeder diet) and tap water ad libitum; they were kept under a 13h/l lh
light/dark cycle.
2.2.2. Preparation for electrophysiology
2.2.2.1. Control group
Under ether anaesthesia, virgin female Sprague-Dawley rats (weight: 273.0 ± 6.0g,
n=19) were implanted with an i.c.v. cannula into the right lateral cerebral ventricle,
which was attached to an infusion assembly consisitng of a polythene cannula and
osmotic minipump (Alzet 2001, Alza Corp.), filled with sterile pyrogen-free water
(vehicle) to be infused at 1/d/h for 5 days. Full details are contained in Chapter 1.,
Section 1.2.1..
2.2.2.2. Chronic i.c.v. morphine-treated group
Virgin female Sprague-Dawley rats (weight: 268.0 ± 6.8g, n=17) were
anaesthetised with ether and carmulated with an i.c.v. chronic infusion assembly which
delivered morphine sulphate solution (in sterile pyrogen-free water) over 5 days in
increasing dose (10/xg/h for 40h, 20/ig/h for 40h and 50/xg/h for 40h). See Chapter 1,
Section 1.2.2. for full details.
2.2.3. Electrophysiology
Methodology was as detailed in Chapter 1 in most respects. Briefly, On the sixth
day of i.c.v. morphine infusion, rats were anaesthetised with urethane (ethyl
carbamate, 1.25g/kg i.p.) and the trachea and a jugular vein cannulated. The right
SON and pituitary stalk were exposed by ventral surgery and a concentric bipolar
stimulating electrode placed on the pituitary stalk to antidromically-activate SON
neurones projecting to the the posterior pituitary (ventral surgery performed by Dr G.
Leng). Extracellular recording of spontaneous and antidromically-activated electrical
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activity was made with 0.9% NaCl-filled glass micropipettes (20-40MOhm).
Putatively oxytocinergic neurones were selected for experiment and tested with i.v.
U50,488H (in 0.9% NaCl, diluted to give an injection volume of 500/il/kg; a gift from
Upjohn or from Sigma Chemical Co.) given in increasing dose (1, 10, 50, 100, 500,
1000jug/kg up to a maximum dose of 5mg.kg) at 10 min intervals and when
appropriate, naloxone hydrochloride (lOmg/ml, 5mg/kg) was injected to end the
protocol. Determination of threshold effective dose was made and the results treated
in the same way a those given in Chapter 1.
2.2.4. Blood sampling
Virgin female Sprague Dawley rats (weight: control group (received no low doses
of U50,488H), 269.4 ± 4.1g, n=10; experimental group (received low and high doses
of U50,488H), 262.5 7.6g, n=10) were anaesthetised with urethane (1.25g/kg i.p.) and
a femoral vein and artery cannulated for injection of U50,488H or saline and for blood
sampling (0.25ml into a heparinised syringe). After 2-3 hours equilibration, die
protocol was started. The protocol is illustrated in Table 2.2.7.. Samples 2, 4 and 6
were followed immediately with a dose of U50,488H in 500^1/kg or with the same
volume of 0.9% saline according to the schedule. The doses of U50,488H were
selected to test possible stimulatory effects of low doses. Rats were assigned at
random to the control or experimental groups (n=10 for each group). Samples were
collected into 1.5ml Eppendorf tubes were centrifuged to separate off plasma which
was transferred into 1.5ml Eppendorf tubes and frozen at -40 °C for later
radioimmunoassay of oxytocin content.
2.2.5. Radioimmunoassay
The full method used for oxytocin radioimmunoassay is contained in Chapter 4,
section 4.2.2.1. and calculation of results in 4.2.2.3.. The method used was a
modification of that described by Higuchi (Higuchi et al, 1985) and was expertly
carried out by Chris Chapman, Dept. Neuroendocrinology, AFRC, Institute of Animal
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Physiology and Genetics Research, Babraham, Cambridge. The sensitivity of the
assay was 0.2-0.4pg/tube. The intra-assay coefficient of variation (the sample
standard deviation expressed as a percentage of the sample mean) was calculated
from:
a/n x 100,
where a=sample standard deviation and /*=sample mean of all intra-assay standards.
In this case the intra-assay coefficient of variation was 7.6%.
2.2.6. Statistics
Statistical comparison of groups was performed as for vehicle-infused and
morphine-infused groups in Chapter 1, by the Wilcoxon test for independent samples
and by comparison of the proportion of neurones inhibited at a given dose.
Comparison of pre- and post-naloxone firing rate was made with Student's paired
t-test, one- and two-tailed. Where firing rate was expected to rise after naloxone,
according to previously published reports, I thought it justified to use a one-tailed
comparison. Where no hypothesis existed I applied a two-tailed t-test. The results of
both one- and two-tailed comparisons are given in the Results section even where a
one-tailed comparison was the test of choice. Student's unpaired two-tailed or one-
tailed t-test was used to compare the percentage change in firing rate after naloxone
between the i.c.v. vehicle-infused and the i.c.v. morphine-infused groups.
Because of small sample sizes for the comparison of pre-/post-naloxone effects,
data were pooled with those from Chapter 1, (where rats received acute i.v. morphine
instead of i.v. U50,488H) and any changes tested. The results for both the original and
die pooled data were expressed (see Results section).
Where Student's t-test was used to make comparisons the samples were all tested
for normality by comparison with a theoretical normal distribution widi die
Kolmogorov-Smirnov one sample test. All samples were normally distributed
according to this test.
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2.3.1. Characteristics of supraoptic non-phasic putative oxytocin neurosecretory
neurones
2.3.1.1. Vehicle-infused rats
This summary of observations on general activity was obtained from data pooled
between this study and that in Chapter 1 and the proportion of cell types recorded,
mean firing rate, latency to antidromic activation and threshold voltage to antidromic
activation are all detailed in Chapter 1, Section 1.3.1.1..
2.3.1.2. Morphine-infused rats
The summary of these data is detailed in Chapter 1, Section 3.1.2..
2.3.2. Characteristics of supraoptic phasic putative vasopressin neurosecretory
neurones
The summary of these data is given in Chapter 1, Section 3.2..
2.3.3. Effects of i.v. U50.488H on supraoptic non-phasic putative oxytocin neurones
in i.c.v. vehicle-infused rats (see Figure 2.3.3.1.)
Both excitatory and inhibitory effects of i.v. U50,488H were seen according to
dose. The cumulative threshold dose of U50,488H to inhibit significantly 7/8 putative
oxytocin neurones that responded was from 1/xg/kg to 1661/xg/kg (median dose:
11 /xg/kg, 8 cells). The mean ± SE firing rate of these 7 neurones was 4.85 ± 1.4 Hz.
The control firing rate of the neurone that did not respond was 1.3 Hz (Figure l.h.)
and thus was not identified as putatively oxytocinergic or vasopressinergic. The mean
± SE firing rate of all 8 neurones in this group was 4.4 ±1.3 Hz. The effect of
U50,488H was evident within 30 seconds of injection.
The highest doses used varied according to the responsiveness of individual cells to
U50,488H and was between 161 peg/kg and 6661 /xg/kg. Where the cumulative dose
exceeded 661/xg/kg (i.e. the cell was kept for most of the protocol) firing rate was
reduced by a mean ± SE of 94.0 ± 2.4% (n=5 cells; 2 other cells were maximally
75
inhibited at less than 661/ig/kg; 1 cell already described above, was not inhibited even
at the maximal dose used).
At low doses of U50,488H excitatory effects were seen in 3/8 cells tested for
cumulative threshold dose to excitation with U50,488H at 1-10/zg/kg. The remaining
cells showed either no change from the control firing rate over this dose range, or
inhibition. Of 3 further cells which did not contribute to the estimation of threshold
cumulative dose to inhibition because the recordings were lost early on in the protocol,
2 were excited by U50,488H at a threshold dose of 1/xg/kg whilst one cell was neither
excited nor inhibited at 1/xg/kg. Thus, in total, 5/11 cells tested were excited by low
doses of U50,488H. Cells excited by U50,488H in low doses were always inhibited at
higher doses where tested, indicating a biphasic response.
Whilst 3/8 cells in this group (5/11 cells overall) were excited by U50,488H at 1-
10/ig/kg (3 at lptg/kg and 2 at 10 jug/kg overall), 5/8 cells (5/11 cells overall) were
significantly inhibited in this dose range (2 at 1/ag/kg and 3 at 10/xg/kg).
In those cells tested with naloxone HC1 (5mg/kg) after inhibitory doses of
U50,488H had been given, firing rate was restored to 90.3 ± 14.8% (n=5) of the
control firing rate. There was no evidence of overshoot of the firing rate to beyond
that seen in the control period.
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Figure 2.3.3.1/overleaf) I.c.v. vehicle-infused group: summary of firing rate changes
Each histogram is the record of one neurone in one rat which had received an i.c.v.
infusion of vehicle over die previous 5 days and was then urethane-anaesdietised for
extracellular recording from identified neurones in the SON.
Firing rate of putative OT neurones is expressed as a percentage of the control
firing rate measured in 30sec bins during a control period of at least lOminutes. The
intravenous dose of U50,488H is given on the horizontal axis in /xg/kg and ranges
from l^g/kg to 5000/ig/kg at lOminute intervals. Inhibition was defined as die firing
rate during any lOminute drug treatment period for which the 95% confidence bands
about the mean did not overlap with those of the control period. Statistically
significant inhibitions are marked with an asterisk. The control period firing rates
were a) 4.4Hz b) 3.0Hz c) 11.75Hz d) 0.9Hz e) 1.8Hz f) 7.2Hz g) 4.9Hz h) 1.3Hz. All
cells except one, (h), were significantly inhibited by 161/ng/kg U50,488H or less. At
low doses U50,488H was excitatory (see cells f), g) and h)).and this effect was
reversed hi two of these cells tested at higher doses (f) and g)).
Naloxone (NAL) where given fully reversed die inhibitory effects of U50,488H but
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2.3.4. Effects of U50.488H on plasma oxytocin concentration in normal rats
U50,488H was not effective in decreasing the plasma oxytocin concentration
within the dose range investigated (see Figure 2.3.4.1.).
U50,488H produced no measurable effect on basal oxytocin secretion under
urethane anaesthesia at l^g/kg i.v. compared to the first 2 control samples in this
group or compared to the equivalent plasma sample in the control group (Wilcoxon
test for independent samples).
Injection of U50,488H at 10/zg/kg resulted in a rise in plasma oxytocin
concentration to 42.10 ± 5.66pg/ml, 475.8% pre-U50,488H control (8.85pg/ml)
concentration (P=0.004, significantly different from its pre-U50,488H control value,
Wilcoxon signed rank test). The next dose of U50,488H, lmg/kg, given to both
groups resulted in no change in the control group against its own control value but in
the group already given the low doses of U50,488H, plasma oxytocin was still
increased compared to the pre-U50,488H control value (P=0.027, Wilcoxon signed
rank test). However, after lmg/kg U50,488H plasma oxytocin concentration did not
differ significantly between groups.
Finally, naloxone (5mg/kg) given to the group given low and high doses of
U50,488H alone, resulted in a rise in plasma oxytocin which was significantly greater
than its pre-U50,488H control value (P=0.004, Wilcoxon signed rank test) and from
the equivalent sample from the control group (P=0.0008, Wilcoxon test for
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SAL SAL U50 SAL
1000
Figure 2.3.4.1. Effects of U50.488H on plasma oxytocin concentration in normal rats
Virgin female Sprague Dawley rats were anaesthetised with urethane and blood
sampled via a femoral artery (0.25ml sample volume). Injections were made via a
femoral vein and injection volume was 500/*l/kg. The y-axis denotes plasma oxytocin
concentration (pg/ml) as measured by radioimmunoassay. The 'control' group was
injected with only one (high) dose of U50,488H (diluted in 0.9% saline) and 0.9%
saline in place of the lower doses of U50,488H and in place of naloxone, according
to the protocol in the Methods Section of this Chapter. The U50,488H-treated group
was injected with U50,488H in increasing dose and finally with naloxone (5mg/kg).
Plasma oxytocin increased significantly in the U50,488H-treated group after lO^tg/kg
U50,488H. Naloxone provoked a statistically-significant rise in plasma oxytocin
concentration in the U50,488H-treated group (P=0.004 vs. its pre-U50,488H control
value, Wilcoxon signed rank test) but not in the control group.
Abbreviations: SAL: 0.9% saline; NAL: naloxone; U50: U50,488H.
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2.3.5. Effects of i.v. U50.488H on supraoptic non-phasic, putative oxytocin neurones
iii i.c.v. morphine-treated rats (see Figure 2.3.5.1.)
The mean ± SE basal firing rate of these neurones was 3.0 ± 0.9 Hz (n=8; not
significantly different from the i.c.v. vehicle-treated group, Wilcoxon). Of this group,
5 neurones fired continuously (mean ± SE firing rate 4.4 ± 0.9 Hz) and 3 were slow-
irregular cells (mean ± SE firing rate 0.8 ± 0.06 Hz).
U50,488H inhibited 7/8 of these non-phasic neurones. These 7 cells were inhibited
over a range of threshold cumulative dose of i.v. U50,488H of 11 yu.g/kg to 1661/xg/kg.
The median threshold cumulative dose of i.v. U50,488H to inhibition was between
161 Atg/kg and 661/xg/kg U50,488H) in 8 cells (not significantly different from the
i.c.v. vehicle-treated group, Wilcoxon test for independent samples).
At the highest dose of i.v. U50,488H used, 6.661mg/kg, the firing rate was reduced
by 70.3 ± 18.1% (mean ± SE; n=5 cells, not significantly different from the i.c.v.
vehicle-infused group, Wilcoxon test for indpendent samples).
At low doses of i.v. U50,488H excitatory effects were seen in 4/8 non-phasic cells
(to 181.1 ± 29.7% control mean firing rate at a threshold dose of 1, 1, 11, 61 jigjkg).
Of these cells however only one (Figure 2.3.5.l.e)) remained excited at the threshold
cumulative dose to inhibition for the morphine-infused group and this cell was excited
more so than any other cell in this group, to 267.4% control firing rate at the threshold
cumulative dose to excitation, 1 jug/kg. It was inhibited significantly at 1661/xg/kg
U50,488H and was profoundly inhibited by 6661 ^g/kg by 99.4%. The dose response
relation shown in Figure 2.3.5.2. suggests that there is a difference in responsiveness
between tire two groups, but looking closely at the threshold response of neurones
reveals the explanation. Where cells were excited by U50,488H at low threshold
doses (1-10/xg/kg for the vehicle-infused group and 1-61/xg/kg for the morphine-
infused group) this was not reversed to inhibition until 50 and 1000^ig/kg (2 cells) for
the vehicle-infused group and 500, 1000 and 1000/ng/kg (3 cells) for the morphine-
infused group. This contributes to the slight shift in the threshold response to
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inhibition for the morphine-infused group which nevertheless is not statistically
significant.
Figure 2.3.5.3. illustrates the difference in response between the acute i.v.
morphine-treated (see Chapter 1) and the acute i.v. U50,488H-treated chronic i.c.v.
morphine-infused groups at 161^g/kg. Where 8/8 neurones failed to respond to acute
morphine at this dose, the majority of neurones tested were inhibited significantly by
U50,488H indicating no effect of chronic i.c.v. morphine on the responsiveness of
non-phasic neurones to the k-receptor agonist, U50,488H while a profound effect was
seen on the responsiveness to acute morphine.
Naloxone (5mg/kg i.v.) produced withdrawal excitation compared with the pre-
U50,488H control mean firing rate. In the first 10 minutes after naloxone mean firing
rate was increased to 337.4 ± 138.8% of mean control firing rate (P < 0.03, Student's
paired one-tailed t-test, n=5) whereas the firing rate after naloxone in the i.c.v.
vehicle-infused group was 90.3% control firing rate (not significantly different,
Student's paired two-tailed t-test). The percentage change in firing rate after naloxone
was not significantly different between the two groups however (P=0.057, Student's
unpaired one-tailed t-test). This comparison suffers from small sample sizes as not all
cells could be tested with naloxone.
When data from the rats which received acute i.v. morphine (Chapter 1) instead of
i.v. U50,488H were pooled with the present data, and the comparison of the pre-/post-
naloxone change in firing rate made between these enlarged groups, they were shown
to be different (P=0.009, Student's unpaired two-tailed t-test; P=0.004, Student's
unpaired one-tailed t-test). Likewise, the degree of statistical significance achieved
for the comparison of pre-/post-naloxone firing rate in the i.c.v.-morphine-infused
group was greater (P=0.002, Student's paired two-tailed t-test; P=0.001, Student's
paired one-tailed t-test) when data were pooled but the comparison of pre-/post-
naloxone firing rate in the i.c.v. vehicle-infused group still did not attain significance
(P=0.12, Student's paired two-tailed t-test).
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Figure 2.3.3.1 .(overleaf) I.c.v. vehicle-infused group: summary of firing rate changes
Each histogram is the record of one neurone in one rat which had received an i.c.v.
infusion of vehicle over the previous 5 days and was then urethane-anaesthetised for
extracellular recording from identified neurones in the SON.
Firing rate of putative OT neurones is expressed as a percentage of the control
firing rate measured in 30sec bins during a control period of at least lOminutes. The
intravenous dose of U50,488H is given on the horizontal axis in ^g/kg and ranges
from 1 jug/kg to 5000/xg/kg at lOminute intervals. Inhibition was defined as the firing
rate during any lOminute drug treatment period for which the 95% confidence bands
about the mean did not overlap with those of the control period. Statistically
significant inhibitions are marked with an asterisk. The control period firing rates
were a) 4.4Hz b) 3.0Hz c) 11.75Hz d) 0.9Hz e) 1.8Hz f) 7.2Hz g) 4.9Hz h) 1.3Hz. All
cells except one, (h), were significantly inhibited by 161/zg/kg U50,488H or less. At
low doses U50,488H was excitatory (see cells f), g) and h)).and this effect was
reversed in two of these cells tested at higher doses (f) and g)).
Naloxone (NAL) where given fully reversed the inhibitory effects of U50,488H but















































































































.c.v. vehicle —infused group (n = 8)





















Dose U50.488H {/ig/kg i.v.)
Figure 2.3.5.2. Comparative dose response relations for supraoptic putative oxytocin
neurones from 5-day i.c.v. vehicle-infused and 5-day morphine-infused rats
Horizontal axis denotes cumulative dose of U50,488H (/xg/kg i.v.) and the vertical
axis, the proportion of neurones in each group which were inhibited by a given i.v. dose
of U50,488H. The responsiveness of neurones recorded in chronic i.c.v. vehicle-infused
rats to i.v. U50,488H was not different from that in rats chronically i.c.v. infused with
morphine as indicated by their median threshold inhibitory doses which were not different
(Wilcoxon). The apparent lack of response in the chronic i.c.v. morphine-infused group
to low doses of U50,488H is explained by the occurrence of low-dose excitation such that
relatively high doses of U50,488H were required to subsequently inhibit electrical activity
(see text).
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Figure 2.3.5.3. Comparison of the proportion of putative oxytocin neurones inhibited by
161ug/kg of either i.v. morphine of i.v. U50.488H in chronic i.c.v vehicle-infused and
chronic i.c.v. morphine-infused rats
These data are derived from both Chapters 1 and 2. A comparison is made of the
effectiveness of i.v. morphine (a ^-opioid receptor-selective agonist) and i.v. U50,488H (a
/(-opioid receptor-selective agonist) both at 161/j.gJkg to inhibit the electrical activity of
putative OT neurones in morphine-naive and chronic i.c.v. morphine-infused rats. Witi 1st
i.v. morphine loses its inhibitory potency at this dose in rats treated chronically with
morphine (due to tolerance) U50,488H remains as effective in both morphine-naive and
chronic i.c.v. morphine-infused rats, indicating that cross-tolerance has not developed to




Details of difficulties associated with the recording procedure are given in the
Discussion section, Chapter 1. The procedure which enables neurones recorded part
way through an interrupted protocol to be used in assessment of threshold
inhibitory/excitatory dose of U50,488H is as described in the Discussion section of
Chapter 1. In the vehicle-infused group, three cells fell into this category: a), g) and
h). The control period of cell a) was recorded at least 50 minutes after the injection of
U50,488H at 1/ig/kg. Cell g) was recorded more than 40 minutes after the injection of
U50,488H at l^g/kg. Cell h) was recorded after ll^g/kg U50,488H 47 minutes
previously. All three cells were considered to be either unaffected or sufficiently
recovered from any effect of such low doses of U50,488H as to be within die limits of
the control firing rate.
2.4.2. Effects of i.v. U50.488H on supraoptic putative oxytocin neurones from i.c.v.
vehicle-infused rats
Acute i.v. U50,488H given to i.c.v. vehicle-infused rats was sometimes excitatory
at low doses and was inhibitory at higher doses. The threshold cumulative inhibitory
dose of U50,488H was 11/ig/kg i.v. and this compares well widi diat for i.v. morphine
in vehicle-infused rats, <= 60/xg/kg in those cells affected, as described in the
previous Chapter. There are /c-type opiate binding sites in die SON defined by
autoradiography (Mansour et al, 1986; Tempel and Zukin, 1987; Mansour et al,
1988; Sumner et al, 1990) as well as dynorphin binding sites (Clark et al, 1986).
U50,488H is a highly selective ligand at the /c-opioid receptor with a poor affinity for
ix- and 5-opioid receptors (Von Voightlander et al, 1983; Kosterlitz, 1985; Clarke and
Pasternak, 1988; Leff and Dougall, 1989) but U50,488H will activate ^-opioid
receptors at high concentrations and under suitable conditions (Leff and
Dougall,1989). The putative endogenous ligand for the /c-opioid receptor is dynorphin
87
(Corbett et al, 1982; Gerstberger and Barden,1986) which has been found in die SON
by immunocytochemical (Watson et al, 1982) and in situ hybridisation (Lightman and
Young, 1987) studies. Dynorphin has also been shown to be inhibitory to supraoptic
neurones in vitro in the rat hypothalamic slice preparation and we have shown that
U50,488H is inhibitory to these neurones, again in die hypothalamic slice (Russell et
al, 1989b). So, it was not surprising to discover that U50,488H was inhibitory to these
neurones in this preparation.
More surprising was the incidence and the degree of low dose excitation seen with
U50,488H. In diose cells excited by U50,488H at a low dose (1-10/xg/kg, 3/8 cells),
inhibition was always produced at a higher dose where tested, indicating a biphasic
effect of the k-receptor agonist on factors controlling the electrical activity of
supraoptic non-phasic neurones. Opiates can be indirectly and, contrary to long held
opinions, directly excitatory to neurones. Indirect excitation is achieved by opioid
inhibition of an inhibitory synaptic drive as occurs in die hippocampus
(Ziegelgansberger et al, 1979; Robinson and Deadwyler, 1981; Siggins and
Ziegelgansberger, 1981; Bradley and Brookes, 1984; Neumaier et al, 1988;
Swearengen and Chavkin, 1989). There is a well documented inhibitory GABAergic
input to the neurones of die SON (Randle et al, 1986; Theodosis et al, 1986; Buijs et
al, 1987; Renaud, 1987; Sakaue et al, 1988) which might be inhibited by U50,488H,
but an interaction between opioids and GABA synapses has not been demonstrated for
diese neuroendocrine cells.
The second possible scenario, direct opioid excitation, arises from
electrophysiological studies of dorsal root ganglion cells in culture where prolongation
of action potential duration by low (nanomolar) concentrations of /i- and 5-opioid
agonists occurs by a direct action, as synaptic connections are not present. The effects
of ix- and <5- agonists are attributed to a decrease in a voltage sensitive K+ conductance
whereas the prolongation of the action potential by the x-opioid agonist U50,488H is
apparently the result of an increase in a voltage sensitive Ca2+ conductance. If the
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change in duration of the action potential is interpreted in terms of its effect upon the
voltage-sensitive calcium entry necessary for neurotransmitter release from nerve
terminals, then the prolongation or shortening of the action potential can be thought of
as evidence of "excitation" or "inhibition" respectively (see Chapter 1, p56 for more
detail; for review see Cram and Shen, 1990). In these cells the "excitatory" and the
"inhibitory" effects seem to be mediated by modulation in opposite directions of a
given current. That is, the action potential prolongation by /x-opioids at nanomolar
concentrations is due to the impairment of a K+ current whilst at micromolar
concentrations /x-opioids increase the same K+ current. Similarly, K-opioids at
nanomolar doses facilitate a Ca2+ current whilst at micromolar doses inhibit that same
current (Werz and Macdonald, 1984b; Werz and Macdonald, 1985; North, 1986;
Shen and Crain, 1989; Shen and Crain, 1990b). The excitatory component of this
biphasic response to opioids cannot be dissociated: excitation by an opioid is always
followed at higher concentrations by inhibition in these neurones. Such mechanisms
have not been studied in SON neurones.
Although no evidence is available concerning identification of possible opioid
receptor subtypes which might mediate this biphasic response, the antagonism of the
response by l-10nM naloxone suggests that opioid receptors do mediate both die
excitatory and the inhibitory components (Shen and Crain, 1989). Evidence for two
types of opioid receptor or one receptor linked to two distnict post-receptor
mechanisms, mediating the excitatory and the inhibitory responses comes from work
once again in dorsal root ganglion cells in which opioid induced prolongation of die
action potential is blocked by Cholera toxin which ADP-ribosylates the stimulatory
GTP-binding protein (G-protein), Gs (Shen and Crain, 1990a; Sawchenko and
Gerfen, 1985). Similarly, die shortening of the action potential by opioids at higher
concentrations involves a G-protein, but this time Gi or Go (two different inhibitory
G-proteins which are sensitive to pertussis toxin). This is shown by the prevention of
opioid induced action potential shortening by pertussis toxin which ADP-ribosylates
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Gi and Go. Adding to this picture, a cAMP-dependent protein kinase in dorsal root
ganglion cells mediates DADLE-induced prolongation but not shortening of the action
potential (Chen et al, 1988). The implication is that excitatory events produced by
opioids in these sensory neurones are mediated by receptors positively coupled via a
Gs-type G-protein to adenylate cyclase and cAMP-dependent voltage-sensitive ionic
conductances leading to shorter duration action potentials and a propensity for
increased firing rate, whereas inhibitory effects of opioids are mediated by opioid
receptors linked to Gi or Go and voltage-sensitive ionic conductances which are
probably not linked to changes in intracellular cAMP.
U50,488H does not alter the intracellular waveform of action potentials in locus
coeruleus neurones in the range 0.01-l^M. The EPSP resulting from stimulation of
afferent inputs was depressed and no IPSP was elicited by U50,488H suggesting a
presynaptic site of action on excitatory afferent terminals. No biphasic response was
seen (McFadzean et al, 1987).
Morphine (lOOpM-lOnM) certainly affects the calcium-dependent potassium
conductance in myenteric plexus neurones, where it is reported to prolong the after-
hyperpolarisation following an evoked train of action potentials in a naloxone-
reversible way (Tokimasa et al, 1981) but examination was not made of tire effect of
morphine on the shape and duration of tire spontaneous action potential itself in this
study.
Perhaps modulation of the action potential duration occurs in supraoptic neurones
thus accounting for tire excitatory effects seen there with low doses of U50,488H.
This phenomenon was not investigated in depth in the present studies as recordings
were extracellular and changes in action potential duration do occur with changes in
firing rate in supraoptic neurones (Andrew and Dudek, 1985; Bourque and Renaud,
1985) making it difficult to differentiate the effect of U50,488H on action potential
duration directly from any indirect effect following excitation or inhibition of firing.
But there was no discernable difference in action potential duration between groups.
90
An earlier report, again using extracellular recording techniques in vivo reported no
gross changes in the action potential duration after chronic morphine (Bicknell et al,
1988a). Comparison of extracellular action potential duration before and after
application of U50,488H where this induced a significant excitation, revealed no
discernible change in these neurones and so does not occur where excitation is clearly
demonstrated.
There is no further evidence to support or refute the existence of spike-broadening
at low doses and shortening at higher doses of opiates from intracellular recordings.
Indeed, this finding in dorsal root ganglion is not supported by similar results in
hippocampus with /c-opioid receptor agonists (Bradley and Brookes, 1984).
Additionally, there is as yet no evidence in the OT-secreting neurones of the SON
for the presence of the subtypes of opiate receptor proposed to account for the
biphasic effect. There are opioid /c-type receptors in the SON although the neural
elements possessing the receptors have not been defined (Clark et al, 1986; Mansour
et al, 1986; Tempel and Zukin, 1987; Mansour et al, 1988; ) and the terminals of
these neurones in the posterior pituitary do possess functional /c-opioid receptors
(Zhao et al, 1988b). Our own work has confirmed tire presence of n~ and /c-opioid
receptors in the SON (Sumner et al, 1990; see Chapter 5) but no breakdown of these
subtypes to reveal the presence of further putative subtypes was attempted. There is a
growing literature describing these putative subtypes of /c-opioid receptor (Zukin et al,
1988; Traynor, 1989; Clark et al, 1989; De Costa et al, 1989; Rothnran et al, 1989;
Rothman et al, 1990). These studies of subtypes of opioid receptors present in tire
SON might be extended by creating suitable binding conditions with irreversible
ligands and selective ligands to the putative subtypes of k- and the /^-opioid receptors
to determine whether these subtypes of receptor are present. Assigning function to
these binding sites to provide an excitatory and an inhibitory opiate /c- or /r-opioid
receptor might prove more difficult.
The presence of putative subtypes of k- and /r-opioid receptors would also assist in
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explaining the biphasic response to opiates by an indirect effect on an inhibitory input.
If one subtype of /c-receptor was located presynaptically on an inhibitory terminal and
the other post-synaptically on a magnocellular neurone, then it is conceivable that if
the presynaptic receptor had a higher affinity and was therefore activated at a low dose
of U50,488H (below the threshold for activation of the post-synaptic receptor) this
would result in excitation of the postsynaptic element by disinhibition. At higher
doses of U50,488H, the lower affinity postsynaptic receptor might be activated and
mediate a direct inhibition of the soma so profound as to overcome the excitatory
response to disinhibition. This hypothesis would be best investigated in vitro under
conditions of synaptic blockade with a high Mg2+ medium, which if the hypothesis is
accurate, should eliminate the excitatory phase of the biphasic response to U50,488H.
If however, this is a direct effect through postsynaptically located receptors as in
dorsal root ganglion cells, then synaptic blockade would presumably only remove any
inhibitory and excitatory tone to these neurones and the acute effects of applied
U50,488H would be unimpaired. An intracellular study in rat locus coeruleus with
U50,488H where no low dose excitation was seen, does not disprove the presence of
the x-type of opioid receptor postsynaptically although it suggests that it is most likely
to be located presynaptically (McFadzean et al, 1987). Further work to locate more
precisely the subtypes of opiate receptor that might exist in the SON would take this
area of discussion beyond speculation where for the moment it remains.
Because the low dose excitation with U50,488H was seen equally often in neurones
from morphine-naive and morphine-tolerant rats, the phenomenon cannot be
associated with the tolerant/dependent state exclusively and the mechanism of low
dose excitation seems to be an acute opiate effect mediated at k- and the ju-type opiate
receptors (see Chapter 1).
The fact that this low dose excitation by U50,488H was meaningful in terms of
plasma OT concentration suggests its importance. Although the dose of 1/xg/kg i.v.
did not elevate plasma OT, the next dose of 10/u.g/kg did so significantly (P= 1.2x10-5,
92
Wilcoxon test for independent samples). These two doses were used as they
constituted the range of threshold excitatory dose of U50,488H in terms of electrical
activity of the OT-secreting neurones in the SON. It is not surprising that the lowest
dose of 1/xg/kg was not effective at raising plasma OT concentration as it was
excitatory only in a minority of neurones tested and the plasma response reflects die
combined activity of all OT-secreting neurones in the SON and PVN. In diis group it
was noticable that whilst 3/8 cells were excited by U50,488H at between 1-lO^g/kg
i.v. (1 at 1/ig/kg and 2 at 10/ig/kg) 5/8 cells were significantly inhibited in this dose
range (2 at 1 jug/kg and 3 at 10/ig/kg) so the lack of plasma response at 1jug/kg is not
surprising as the electrical response is mixed. Given this, it was somewhat unexpected
diat die plasma response to 10jug/kg U50,488H was so marked (see Figure 2.3.4.1.) as
again it was excitatory in only half of the neurones in the electrophysiological study.
At 10/xg/kg U50,488H the activity of die 2 cells excited was increased to a mean of
117.0 ± 0.13% control firing rate, whilst the activity of die 3 cells inhibited at
10yug/kg was reduced to 65.1 ± 17.1% control firing rate. This reflects an equivocal
response in terms of die overall activity in the SON after U50,488H at 10/ig/kg and
does not tally widi the plasma response, as plasma OT was raised to 42.1 ± 5.7 pg/ml,
diat is to 475.8% control plasma OT concentration (P= 1.2x10-5, significantly different
from the control plasma OT concentration, Wilcoxon test for independent samples;
control is the mean of plasma samples 1 an 2). This could be accounted for in two
ways: firstly, the sample of neurones randomnly selected might simply be
unrepresentative of the full spectrum of activity and responsiveness of OT-secreting
neurones in the SON and PVN or secondly, the effect of increasing firing rate from a
basal level might be a more potent influence on OT secretion than inhibition of
activity by a similar degree is on reduction in plasma OT.
The latter suggestion is supported by the plasma response to a dose of U50,488H of
lmg/kg i.v. which in terms of electrical activity is profoundly inhibitory to these
neurones: of 4 cells tested at this dose in the vehicle-infused group, 1 cell was not
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inhibited and remained unaffected at 5mg/kg. The 3 cells inhibited were inhibited to
12.6 ± 1.2% control firing rate. However, plasma OT in the control group which
received lmg/kg U50,488H was 10.4 ± 1.3pg/ml and this was not significantly
different from the control value, derived from plasma samples 1 and 2, 10.2 ±
0.2pg/ml (Wilcoxon test for independent samples). This contrasts with the effect of
the same dose of U50,488H given to the U50-treated group, after which plasma OT
concentration was 15.1 ± 1.7pg/ml which is still significantly different from the
plasma value for the control group at this dose (P= 1.9x10-3, Wilcoxon test for
independent samples). Presumably this dose of U50,488H, so powerfully inhibitory to
die cell bodies of these neurones in the SON, is antagonising the excitatory effect of
die previous dose, which might explain why the plasma OT concentration remains
slightly elevated compared to the control group. Unfortunately there is no data on
how long the increase in plasma OT would be expected to last for after 10/ig/kg
U50,488H as the protocol hi die electrophysiological study precluded an assessment of
die duration of effect of this dose beyond lOmin and the blood sampling study did not
contain a time control to investigate this aspect. U50,488H would be expected to
persist from the previous injection however and therefore to possibly be maintaining
OT secretion at an elevated level. So perhaps U50,488H at lmg/kg inhibits electrical
activity and OT secretion most effectively if it is already stimulated but is impotent to
further depress OT release from basal levels. Insertion of a time control at this point
in the protocol would have been helpful in resolving this point.
So these data suggest that the excitatory electrical response to U50,488H more
potently influences OT secretion than does the inhibitory electrical response under
basal conditions. Of course this conclusion assumes drat OT-secreting neurones in die
other major nucleus, the PVN, behave similarly and this could be investigated.
The effect of electrical activity on OT release has been studied (Bicknell, 1988) and
it seems that frequency-dependent modulation of OT release occurs such that the
terminals of OT neurones in the neurohypophysis release OT more efficiently as
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frequency increases: 'frequency facilitation'. This phenomenon might help to
illuminate the observed disproportionate effectiveness of increasing firing rate on OT
release that is demonstrated by the electrophysiological and blood sampling studies.
The effect of naloxone on plasma OT concentration in the blood sampling study is
also interesting. The plasma OT concentration in the control group as expected, did
not change after isotonic saline injection (high dose of U50,488H only). The low and
high dose U50,488H-treated group received naloxone (5mg/kg) however and this was
followed by a rise in plasma OT to 1134% of its basal control value (P=1.2xl0-5,
Wilcoxon test for independent samples, against its control and P=7.7xl0-4, Wilcoxon
test for independent samples against equivalent control group sample). This can be
accounted for by naloxone-reversal of endogenous opioid inhibition of OT secretion
known to occur at the neurohypophysis under urethane anaesthesia in otherwise
normal conditions (Sumner et al, 1989). It does not result from excitation of cell
bodies in the SON as there was no evidence for this in the electrophysiological study
in i.c.v. vehicle-infused rats. In these experiments naloxone restored firing rate to 90.3
± 14.8% control firing rate with no evidence of overshoot in activity indicating no
dependence upon U50,488H given acutely or upon any tonically active endogenous
opioid acting at the level of the cell bodies in the SON.
2.4.3. Effects of i.v. U50.488H on supraoptic putative oxytocin neurones from i.c.v.
morphine-infused rats
There was no evidence of tolerance to i.v. U50,488H after chronic i.c.v. morphine
infusion. I conclude from these data (see Figure 2.3.5.3. for comparison of acute U50,
488H and acute morphine effects on OT neurones in chronic i.c.v. morphine-infused
rats) that tolerance to morphine cannot be conferred to U50,488H in this
neuroendocrine system.
Cross-tolerance occurs when the development of tolerance to one opioid is
accompanied by tolerance to another opioid. Where tolerance and dependence occur
together as in OT-secreting neurones, the following definition of cross-dependence is
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helpful: "the ability of one drug to suppress the manifestations of physical dependence
produced by another and to maintain the physical dependent state...this can be partial
or complete and the degree is more closely related to pharmacological effects than to
chemical similarities...in general, any potent morphine-like opioid will show cross
depndence with other opioids that act on the same receptors" (Jaffe, 1985). It is on
this basis that methadone is used in "substitution treatment" for morphine addiction as
it also acts on the /x-opioid receptor and can prevent the onset of the morphine
withdrawal syndrome. Methadone does have a withdrawal syndrome of its own but
because it is longer-acting than morphine it produces a longer-lasting but much less
intense withdrawal syndrome - tire rationale behind its use. Generally, the
development of cross-tolerance suggests strongly that the two opioids are acting at the
same type of receptor (Wuster et al, 1983) or that the receptors interact to affect each
others avidity for its ligand.
In rat brain membranes in vitro which were acutely exposed to /x- and 5-receptor
ligands, there is evidence of a non-competitive interaction between tire two binding
sites and the authors of this study propose an opioid receptor complex with both /x-
and 5-receptors which can interact thus allowing the receptor complex to activate
intracellular mechanisms differentially according to tire nature of the ligand(s) bound
(Rothman et al, 1985). Morphine-dependent mice are cross-tolerant to the pupillary
effects of Met-enkephalin and DADLE, both of which act at the 5-opioid receptor
primarily (Ben-anr and Korczyn, 1986). Similarly, there is cross-tolerance between
tire /x-opioid receptor agonist, nrorphiceptin and DPDPE, a highly selective 5-opioid
receptor agonist acting at the rat spinal cord to produce analgesia (Russell et al, 1986).
These findings are opposed in another study, this time in mice, where i.c.v. morphine
does not confer cross-tolerance to DPDPE in terms of analgesia (Heyman et al, 1986).
This may be due to species variation as other studies in mice are in agreement with
this study. Cross-tolerance does not develop between tire /x- and tire 5-opioid receptors
in mouse vas deferens when the ^-receptors are chronically stimulated in vivo with
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morphine sulphate and then challenged in vitro with Leu-enkephalin which interacts
with the 5-opioid receptor (Illes et al, 1980). Nor does cross-tolerance develop
between sufentanyl (/x-receptor agonist) and D-Ala2' D-Leu5-enkephalin (5-receptor
agonist) in the same preparation (Schulz et al, 1980).
It seems that in the rat at least, there is some overlap in the characteristics of the 5-
and /x-opioid receptors and their physiological roles. Perhaps species differences,
dissimilar protocols and models and the use of different "selective" ligands in tire
various studies has resulted in a confusing picture concerning this point.
In the isolated mouse vas deferens taken from chronically opiate-treated mice,
cross-tolerance was investigated between tire /x-, k- and the 5-opioid receptor agonists,
sufentanyl, etlrylketazocine and DADLE, respectively (Wuster et al, 1981).
Preparations made tolerant to tire /x-opioid receptor agonist, sufentanyl, showed no
signs of cross-tolerance to other receptor subtype-selective ligands and similar results
were obtained using preparations rendered tolerant to tire k- and the 5-opioid receptor
ligands. Similar results were obtained in isolated guinea pig ileum and in intact
animals (Schulz et al, 1981). So cross-tolerance does not always occur between
opioids. If tire three accepted subtypes of opioid receptor shared a common
transduction system in the membrane, then one would expect tolerance in one receptor
subtype to result in tolerance to the other two subtypes which had not themselves been
chronically exposed to their selective ligands. This did not occur and therefore the
subtypes of receptor are distinct in this respect. In this system, there was likewise no
evidence of cross-tolerance: the two receptor subtypes under study appear to use
independent transduction mechanisms.
There is however other recent evidence pointing to some degree of interaction
between the ji- and the x-opioid receptor subtypes. The chronic coadministration of
U50,488H with morphine blocks the expected development of tolerance to morphine
analgesia in the rat. The loss of morphine analgesia consequent to the development of
tolerance to morphine is reversed transiently by the acute administration of U50,488H
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but morphine analgesia induced by acute morphine administration is not affected by
acute U50,488H (Yamamoto et al, 1988). There is clearly then some interaction
between the ju-opioid agonist morphine and the K-opioid agonist U50,488H in terms of
tolerance to analgesia but exactly what this constitutes is not known. The previous
report proposes that there is a receptor interaction and supports this hypothesis with
similar experimental results in mice (Tulunay et al, 1981; Schmauss and Herz, 1987)
and binding studies which have demonstrated interactions between ^-opioid binding
sites and K-opioid binding sites by a non-competitive mechanism (Garzon et al, 1982).
Other reports observe cross-tolerance between a /^-selective and a K-selective ligand in
rats (Petrie et al, 1982; Hong et al, 1986). The "selective" /c-opioid receptor ligands in
these studies were ethylketocyclazocine and dynorphin(l-13) neither of which act
exclusively at the /c-receptor (Kosterlitz and Paterson, 1985) which implicates the
possibility of action at other opioid receptors in the development of cross-tolerance.
In fact there are many reports describing lack of cross-tolerance development between
/x-selective agonists and /c-selective agonists in rats (Young and Khazan, 1984; Barr et
al, 1986; Bhargava et al, 1989) in mice (Mansour and Valenstein, 1986; Solomon et
al, 1988) guinea pigs (Schulz et al, 1981a; Schulz et al 1981b; Vaught, 1981; Von
Voightlander and Lewis, 1988) and pigeons (Craft et al, 1989). The problem of ligand
selectivity in investigating this phenomenon was highlighted by Von Voightlander and
Lewis who demonsrated cross tolerance between morphine and ethylketocyclazocine
and ketazocine but no cross-tolerance to the highly x-selective agonist, U50,488H
(VonVoightlander and Lewis, 1982).
Given these scenarios for the /i- and the 5-receptors and fi- and /c-receptors, die
discovery of cross-tolerance between morphine and U50,488H in this neurosecretory
system was conceivable. However, it seems that in OT-secreting neurones of die
SON, the two receptor types are sufficiently distinct to allow no mutual interaction
during the process of the development of tolerance to morphine at the ^-receptor. I
have not investigated whether there is any acute interaction.
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As stated earlier, cross-tolerance usually infers some overlap in the recognition
process between different receptor types for their ligands and fi- and /c-opioid
receptors are distinguished very well in other systems: the basis for their separate
classification originally according to the binding of selective ligands (Robson et al,
1980) and to the selective development of tolerance (Wuster et al, 1983). So the
present findings accord with the concensus in the literature.
One could speculate that there might be tolerance to endogenous opioids acting at
die ^-opioid receptor with no effect on endogenous ligands acting at the /c-opioid
receptor such that upon opiate withdrawal, precipitated by naloxone, the removal of
opiate restraint on the OT-secreting system might be superimposed upon a similar
withdrawal mediated through the endogenous opioid system. This could be
investigated by in situ hybridisation of the endogenous opioid mRNA before and after
the onset of tolerance and after precipitated withdrawal from morphine to assess
adaptation in endogenous opioid systems. There is experimental support for this
scenario. Chronic exposure to morphine has resulted in cross-tolerance to the
endogenously produced opioids, Met-enkephalin, Leu-enkephalin and /3-endorphin
(Sivam and Ho, 1984) and physiological stimulation thought to activate the enhanced
release of endogenous opioids results in the development of tolerance to exogenous
morphine in mice with withdrawal-like behaviour (Christie et al, 1982). This
possibility raises the question of tolerance to and dependence upon endogenous opioid
peptides occurring under certain physiological conditions when opioid restraint is
undesirable or when there is a need to abruptly produce a hyperresponsiveness in a
system normally under opioid restraint. This has been postulated to be of importance
in the OT-secreting system during the build up to and at the time of parturition in the
rat when OT release must be tightly controlled and finally substantially increased
(Jones and Summerlee, 1986; Bicknell et al, 1988a).
The low dose excitation seen in the i.c.v. vehicle-infused group was also seen in the
i.c.v. morphine-infused group, in half of cells tested at 1-10/xg/kg U50,488H. This
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phenomenon cannot be associated with the development of tolerance uniquely as it is
seen equally often in vehicle-infused rats.
There is some evidence for the binding of the /c-opioid selective ligand U50,488H
to the ^-opioid receptor under suitable conditions when it can act as a receptor
antagonist (Gillan et al, 1981; Corbett and Kosterlitz, 1986). One consequence in this
protocol could be some reversal of morphine dependence by acute U50,488H with a
resultant degree of excitation, seen only in full after the administration of the opiate
antagonist naloxone. This seems unlikely as the effect is observed only at low doses
and not at higher doses. The effect would be expected to increase in degree with
increasing dose if it was explained simply by antagonism of morphine dependence at
tire ^-opioid receptor. So, tire possible explanations above to account for low dose
excitation also apply to the same phenomenon in the i.c.v. morphine-treated group and
this suggests that this mechanism is not affected by adaptive changes that constitute
tolerance to morphine in this neurosecretory system.
Naloxone produced withdrawal excitation similar to that described in the previous
Chapter and this confirms dependence. It can also be assumed that tolerance to
morphine would have been present in these experiments although this was not tested:
tire protocol was identical to that in Chapter 1 in which tolerance was demonstrated to
morphine, apart from the acute administration of U50,488H instead of morphine and
the range of activity of non-phasic neurones in these experiments was similar to
control. The acute administration of U50,488H does not appear to have impaired or
enhanced the expression of the withdrawal response.
In conclusion then, tolerance is not conferred to the /c-opioid receptor-selective
agonist, U50,488H after chronic activation of the ^-opioid receptor by the selective
agonist morphine in the OT neurosecretory system.
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CHAPTER 3
DOES ACUTE MORPHINE ACTION ON OXYTOCIN NEUROSECRETORY NEURONES IN VIVO
INVOLVE A PERTUSSIS TOXIN-SENSITIVE G-PROTEIN?
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3.1. INTRODUCTION
The acute effects of opiates are mediated through opiate receptors of which there
are three widely recognised subtypes, pi, k and 5, as defined by the differential affinity
with which highly selective ligands bind to them (Gilbert and Martin, 1976; Lord et
al, 1977). Activation of neuronal opiate receptors has been reported to lead to a
variety of cellular events including the inhibition of adenylate cyclase (AC) activity
(Collier and Roy, 1974; Sharma et al, 1975a; Sharma et al, 1975b; Klee and
Nirenberg, 1976; Lampert et al, 1976; Goldstein et al, 1977); increase in a membrane
potassium conductance resulting in membrane hyperpolarisation and causing a
reduction in spontaneous activty or a reduction in the amount of neurotransmitter
released (for a review see, North, 1986); changes in a membrane calcium conductance,
again potentially leading to a decrease in the level of spontaneous activity and to a
reduction in neurotransmitter release, by agonists at the pi-type opiate receptor acting
by an indirect action on the conductance (Tokimasa et al, 1981; North and Williams,
1985) or via the /c-type opiate receptor by a direct action (Werz and Macdonald,
1984a; Werz and Macdonald, 1984b; Werz and Macdonald, 1985) effects upon the
activity of cell phosphorylases and phosphatases which regulate enzymes,
hormone/neurotransmitter receptors and ion channels (Clark et al, 1972; O'Callaghan
et al, 1982).
A role has been defined in the last decade for a family of intramembrane GTP-
binding proteins (G-proteins), as transducing elements between a variety of receptor
molecules and their effector systems, such as AC (Bokoch et al, 1984; Neer et al,
1984; Sternweis and Robishaw, 1984; Gilman, 1986; Sternweis and Pang, 1990). G-
proteins have been implicated in the control of a range of intracellular second
messenger systems, including AC (Stryer and Bourne, 1986; Gilman, 1987),
phospholipase C (Cockcroft and Gomperts, 1985), cGMP phosphodiesterase (Stryer et
al, 1981) as well as ion channel proteins (Pfaffinger et al, 1985; Holz et al, 1986).
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They can mediate either inhibitory or excitatory events within a cell depending on the
type of G-protein and associated receptor. The stimulatory G-protein, Gs is
selectively acted upon by cholera toxin which ADP-ribosylates the GTP binding site,
enhancing its activity (Gill and Meren, 1978) and cellular events triggered by the
activation of inhibitory neurotransmitter receptors have been associated with die
'inhibitory G-protein', Gi (Milligan et al, 1986). Pertussis toxin (PT) deactivates Gi
by binding to die GTP-binding site and irreversibly ADP-ribosylating, thus preventing
the exchange of GDP for GTP which normally takes place during its activation
(Sullivan et al, 1987). Because it does not likewise affect Gs, PT differentiates
between Gi and Gs. However, PT also deactivates another G-protein found hi
abundance in neuronal tissue, Go (Sternweis and Robishaw, 1984).
The overlap hi cellular events affected by either opiate receptor activation or by G-
protein activation points to a possible connection between the two.
Acute opiate effects can be impaired by PT treatment. (Abood et al, 1985;
Aghajanian and Wang, 1986; Crain et al, 1987; North et al, 1987; Duman et al,
1988; Parolaro et al, 1990).
These observations implicate a PT-sensitive G-protein, Gi or Go in post-receptor
transduction for opiates. Pursuing this possibility furdier, odier studies have identified
chronic opiate effects on the dynamics of inhibitory G-proteins (Lang and Schulz,
1989; Nestler et al, 1989). These findings corroborate the concensus to date, that an
inhibitory PT-sensitive G-protein is involved in post-opiate receptor transduction.
So, of particular interest is the potential role these G-proteins might play in die
physiological adaptation diat occurs in some cells when exposed chronically to opiates
- tolerance widi associated dependence, given diat in oxytocin-secreting cells of die
SON, tolerance develops to chronic i.c.v. morphine in terms of firing rate (see Chapter
1). The possibility arises diat this adaptation involves regulation of an associated G-
protein. It has yet to be shown however that opiate receptors associated widi diese
cells or with neurones which project to the SON are linked to a PT-sensitive G-protein
103
at all and the primary aim of the present study was to investigate this question.
A protocol similar to that already used earlier (see Chapters 1 and 2) was used to
test the sensitivity of these neurones to the /x-selective agonist, morphine and to the k-
selective agonist, U50,488H given acutely by i.v. injection after pretreatment with
i.c.v. 0.9% saline in the control group or after i.e.v. PT in the treated group. Thus it
was hoped also to describe any difference between the n- and /c-opiate receptors





Virgin female Sprague Dawley rats (200-250g; Bantin and Kingman) were housed
at 21-23°C and allowed food (standard breeder diet) and tap water ad libitum; they
were kept under a 13h/l lh light/dark cycle (on 08.00, off 21.00).
3.2.2. Intracerebroventricular injection of pertussis toxin or 0.9% saline
Purified pertussis toxin (lyophilised in phosphate buffered saline) was a gift from
Dr J.H. Freer, Microbiology Dept., University of Glasgow. Three days before the day
of experiment, rats were injected i.e.v. with 5/xl 0.9% sterile pyrogen-free saline or
with 7/xg PT in 5ml 0.9% sterile pyrogen-free saline acutely as follows: under ether
anaesthesia rats were placed in a stereotactic frame and the skin overlying the skull
incised. The surface of the skull was cleared of tissue and bregma and lambda
visualised and used as reference points to level the skull. A hole was then drilled at
the coordinates 0.6mm caudal and 1.6mm lateral to bregma. The injectate was
contained in a Hamilton 5/xl 'through the needle' microsyringe (#7005; Hamilton) and
was injected via a 600/im o.d. needle lowered to 4.5mm below the skull surface to
enter a lateral cerebral ventricle. The incision was then sutured and the rat allowed to
recover. Rats were weighed daily to monitor their well being (after initial greater
weight loss than controls, the PT-injected rats recovered and appeared healthy on the
day of experiment).
3.2.3. Electrophysiology
Rats were anaesthetised with urethane (ethyl carbamate, 1.25g/kg i.p.) and the
trachea and an external jugular vein cannulated. The rat was mounted in a stereotactic
frame and the right SON and the neural stalk exposed by ventral surgery (ventral
surgery was performed by Dr G. Leng; Leng, 1980). A concentric bipolar stimulating
electrode was placed on die pituitary stalk to deliver pulses (1ms matched biphasic
pulses <lmA peak to peak, 0.3Hz) designed to antidromically activate neurones
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projecting from the SON to the posterior pituitary. A glass micropipette filled with
0.9% saline (20-40MOhm) was placed under visual control into the SON to record the
activity of antidromically-activated supraoptic neurones. The criteria used to select
only putative OT neurones in the SON described in Chapter 1 also applied here.
Recordings were made and stored on videotape in digital format via a modified
pulse code modulator for later analysis. Online analysis was performed using
software written for this application (R. Bunting, Dept. Neuroendocrinology, AFRC
Institute of Animal Physiology and Genetics Research, Babraham, Cambridge; see
Chapter 1) and the interval between consecutive spikes measured and averaged in 30
second bins for the construction of histograms. Firing rate was recorded for at least 10
minutes to establish a stable control period and to identify the cell, then morphine
sulphate B.P.(Pharmacy, Royal Infirmary of Edinburgh) or U50,488H (Upjohn Ltd. or
Sigma Chemical Co.) both in 0.9% saline were injected i.v. in increasing dose: 1, 10,
50, 100, 500, 1000 and 5000//g/kg in an injection volume of 500/d/kg. When the end
of the protocol was reached or when a maximal inhibition was achieved, naloxone
HC1 was injected i.v. (5mg/kg; Sigma Chemical Co.).
The criteria for experimenting upon cells newly recorded if tire original cell was
lost after the drug protocol had already started, are outlined in Chapter 1. Suffice to
say the history of the population of neurones in each rat was always carefully
considered (as before, see Chapter 1) when interpreting the results obtained from an
individual experiment.
Separation of tire 95% confidence bands between the control period and the drug
treatment period was used as a measure of the significance of a response.
3.2.4. Statistics
Comparison was made of the threshold cumulative inhibitory dose of morphine or
U50,488H between treatment groups using the Wilcoxon test for independent samples.
Comparisons were also made of tire degree of inhibition at given doses of morphine or
U50,488H by comparison of mean firing rate after drug, again between treatment
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groups. Comparison was also made where possible of threshold voltage and latency to
antidromic activation. Where sufficient data on electrophysiological properties
(before drug injection) were unavailable for analysis for the control i.e.v. 0.9% saline-
injected group, data from an untreated control group was used as indicated in the
Results section of this Chapter.
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3.3 Results
3.3.1. I.c.v. 0.9% saline-injected control group
3.3.1.1. General activity observed
In this group information was not sought from cells that were not tested and details
of only one untested cell were noted; this was a phasic cell with a latency to
antidromic activation of 16.6ms and a threshold voltage to antidromic activation of
34V. Of the 6 cells tested, 5 were continuous (mean firing rate 2.7 ± 0.3 Hz), firing at
more than 2 Hz. One cell was classed as slow-irregular, firing at 1.96 Hz.
3.3.1.2 Characteristics of non-phasic putative oxytocin neurosecretory neurones
For non-phasic neurones (ie. continuous and slow-irregular), mean ± SE firing rate
of active neurones was 2.6 ± 0.3 Hz (range 1.96 - 4.0 Hz; 1<2 Hz; n=6 cells, 5 rats).
Mean ± SE latency to antidromic activation was 17.9 ± 1.5 ms (n=5 cells, 5 rats).
Mean ± SE threshold voltage to antidromic activation was 35.6 ± 17.0 V (n=5 cells, 5
rats).
3.3.1.3. Effects of i.v. morphine on non-phasic putative oxytocin supraoptic neurones
in i.c.v. 0.9% saline-injected rats
Acute doses of morphine and U50,488H are expressed as cumulative doses and this
is justified in Chapters 1 and 2.
Both inhibitory and excitatory effects of morphine were seen. The effect of
morphine was evident within 30 seconds of injection.
The cumulative threshold dose of morphine to significantly inhibit the 5/6 cells
inhibited by morphine was between 11 and 261/xg/kg (median cumulative threshold
inhibitory dose: 61/xg/kg). At a cumulative dose of morphine of 161/xg/kg, 5 cells
tested were inhibited significantly to 25.7 ± 11.7% control firing rate (CFR; see Figure
3.3.1.4.). The mean firing rate of the 5 neurones that were inhibited by morphine was
2.3 ± 0.1 Hz (range 1.96 to 2.46 Hz). The CFR of the cell that did not respond to
morphine at this dose was 4.0 Hz. At the higher cumulative dose of 661^g/kg
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morphine, 6 cells were inhibited to 4.85 ± 1.0% CFR. At tire highest doses used, at or
above 161 /xg/kg, (between 161 and 761 pig/kg) firing rate was reduced to a mean of
4.4% (n=5).
At 1/xg/kg morphine, 2 of 5 cells tested were excited significantly, 3 were
unaffected and none were inhibited. At 10/rg/kg morphine, 2 of 5 cells tested were
excited significantly, 2 were unaffected and 2 were inhibited significantly. The 2 cells
excited at 1 peg/kg were also excited at 10/rg/kg morphine. They were both inhibited
by higher doses of morphine. None of these cells was tested with U50,488H, since
they were strongly inhibited by morphine.
hi those cells tested with naloxone HC1 (5mg/kg), firing rate was restored to 116.5
± 14.3 % CFR (n=4).
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Figure 3.3.1.4.("overleaf) Pertussis toxin control group: summary of firing rate
changes
Each histogram is the record of a single neurone in one rat which had received a
single i.c.v. injection of 5/d 0.9% sterile pyrogen-free saline 72hours prior to die day
of experiment. Rats were anaesthetised with urethane and a supraoptic nucleus
exposed for electrophysiological recording from putative oxytocin neurones.
Morphine (M) was given i.v. in increasing dose and firing rate collected in 30sec bins
for calculation of 10 minute mean firing rate. A significant change in firing rate was
denoted by separation of 95% confidence bands about the control firing rate and diose
of any drug treatment period. A significant difference is marked with an asterisk. At
low doses, morphine was sometimes excitatory (see cells b) and c)) but at higher doses
was inhibitory.
The control period firing rates were a) 2.4Hz b) 2.0Hz c) 2.4Hz d) 2.5Hz e) 4.0Hz
and f) 2.2Hz.



































































3.3.2. I.c.v. pertussis toxin (TP-injected group
3.3.2.1 General activity observed
As a large set of data about the range and types of activity observed in the control,
i.c.v. saline-injected group was not collected, comparison was made between the
untreated control group of Chapter 1 which underwent a similar protocol, and the i.c.v.
PT-treated group of this series. The assumption of equivalence between the i.c.v.
saline-injected group and the untreated control group is supported by comparison of
the available data common to the two groups - i.e. from the i.v. morphine-tested cells,
a comparison of CFR, before the application of drugs. In addition latency to
antidromic activation and threshold voltage to antidromic activation were observed,
although die latter two variables were not of primary interest. For firing rate, latency
and threshold voltage, in no instance did comparison between the untreated control
group and the i.c.v. 0.9% saline control group achieve statistical significance
(significance level 95%, allowance made for 3 comparisons, Wilcoxon).
In 10 i.c.v. PT-treated rats, control period recordings were made from 30 cells. 14
(46.7%) were continuous (not significantly different vs. untreated control group),
firing at more than 2Hz. 5 (16.7%) fired at less than 2Hz and were classed as slow-
irregular cells (not significantly different vs. untreated control group). 6 (20.0%) fired
phasically (not significantly different vs. untreated control group) and 4 (13.3%) were
silent (not significantly different vs. untreated control group). In all the above tests,
allowance was made for multiple comparisons and a level of significance of 95% was
chosen.
3.3.2.2 Characteristics of non-phasic putative oxytocin neurosecretory neurones
For non-phasic cells (i.e. continuous and slow-irregular), meantSE firing rate of
active non-phasic cells (including slow cells) was 4.7±0.7 Hz (range 0.26-8.20,
2<lHz, 5<2Hz; n=19 cells, 10 rats; not significantly different vs untreated control
group, Wilcoxon; not significantly different vs i.c.v. saline-injected control group,
Wilcoxon). MeaniSE latency to antidromic activation was 12.2±1.0 ms (n=16 cells,
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10 rats; not significantly different vs control group, Wilcoxon; not significantly
different vs i.c.v. saline-injected control group, Wilcoxon). Threshold voltage to
antidromic activation could not be measured in this group due to lack of the necessary
apparatus. In all statistical tests, allowance was made for multiple comparisons and
where necessary a level of significance of 95% chosen.
3.3.2.3 Characteristics of phasic putative vasopressin neurosecretory neurones
ThemeaniSE CFR was 6.1±3.2 Hz (range 1.42-15.42, 0<lHz, l<2Hz; n=4 cells, 2
rats; not significantly different vs untreated control group). Mean ± SE latency to
antidromic activation was 14±1.0 ms (n=6 cells, 2 rats; not significantly different vs
control group).
3.3.2.4 Effects of i.v. morphine or U50.488H on non-phasic putative oxytocin
supraoptic neurones in i.c.v. pertussis toxin-treated rats
Both inhibitory and excitatory effects of morphine were seen. The effect of
morphine was always evident within 30 seconds of injection.
The cumulative threshold dose of morphine to significantly inhibit the 7/8 cells
which responded was between 1 and 1661/xg/kg morphine, median cumulative
threshold inhibitory dose was 11 ptg/kg (not significantly different vs i.c.v. saline-
injected control group, Wilcoxon).
At a cumulative dose of morphine of 161 /zg/kg, the firing rate of 6 cells tested was
reduced following morphine to a mean of 89.29 ± 11.8% CFR (1 neurone from these 6
was not inhibited at this dose). Compare this with that for the control group: all 5
neurones were significantly inhibited at 161 /xg/kg morphine to a mean of 25.7 ±
11.7% CFR (P=0.014, Wilcoxon). The mean firing rate of the 5 control neurones
which were inhibited by morphine at 161^g/kg in the i.c.v. PT-treated group was 4.6
± 0.6 Hz, (range 3.08-5.85 Hz) which was significantly higher than that for the control
group (P=0.042 vs i.c.v. saline-injected control group, n=5 (CFR control group: 2.3 ±
0.1 Hz) Wilcoxon). The CFR of the neurone that did not respond to morphine at
161jug/kg was 3.0 Hz.
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At the higher cumulative dose of 661/^g/kg morphine, 6 cells in tire PT-treated
group were tested (4/6 were inhibited significantly) and tire mean firing rate of these 6
after morphine was reduced to 83.05 ± 19.4% CFR whereas in tire control i.c.v. 0.9%
saline-treated group, all 4 cells were inhibited to 4.85±1.0% CFR (P= 0.014,
Wilcoxon). So, although the proportion of neurones affected at these two key doses
were similar between groups, and tire median threshold inhibitory dose was not
different between groups, tire degree of inhibition at a given dose of morphine,
compared to the CFR was substantially greater in the i.c.v. 0.9% saline-treated group
compared with the i.c.v. PT-treated group.
At tire highest doses used, at or above 161/xg/kg (between 161 and 6661/ug/kg)
firing rate was reduced to a mean of 50.3% (n=6). This compares with 4.4% in 5
control cells.
At 1/ug/kg morphine, 3/7 cells tested were excited significantly, 3 were unaffected
and one cell was inhibited. At 1 Optg/kg morphine, only one cell was excited and this
cell was not inhibited by morphine up to 161 /xg/kg. Two of tire remaining cells were
unaffected whilst four cells were inhibited at this dose. This is a similar profile of
excitation followed by inhibition to that seen in tire chronic i.c.v. morphine-infused
group described in Chapter 1, in both morphine-naive and chronic i.c.v. morphine-
infused rats after acute i.v. U50,488H as described in Chapter 2 and to that seen in the
i.c.v. saline-injected control group for this series.
Some cells were tested with both morphine and to U50,488H to assess any
difference of PT treatment on drug effectiveness. The record of these cells is given in
Figure 3.3.2.5.. In 4/5 cells tested widr both drugs, U50,488H inhibited electrical
activity more potently than morphine at either an equivalent or a higher dose.
U50,488H was capable of profoundly inhibiting the spontaneous activity of cells only
marginally affected by morphine (see Figure 3.3.2.5.). Of the 5 cells tested with
U50,488H, 4 were inhibited maximally as follows (all doses are expressed as
cumulative and a comparison is made, in brackets following, with the same cell's
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response to an equivalent dose of morphine): at a dose of 50pig/kg U50,488H, to
87.8% CFR (cf to 137.1% after 61^g/kg morphine), at 500/zg/kg U50,488H to 22.74%
CFR (cf to 111.6% after 661/xg/kg morphine), at 1.5mg/kg to 26.4% (cf to 74.4% after
1.661mg/kg morphine) and at lmg/kg to 0.83% CFR (cf to 78.4% after 1.661mg/kg
morphine). The maximum inhibition of firing rate achieved after morphine on the
other hand, was to 117.1% CFR at 161/ng/kg, 34.8% CFR at 6.661mg/kg, 68.3% CFR
at 6.661mg/kg and 76.0% CFR at 6.661mg/kg respectively for the 4 cells described
above, demonstrating a relative lack of effect of morphine upon the electrical activity
of these cells.
In cells tested with naloxone HC1 (5mg/kg), firing rate was restored to 80.8 ± 14.7
% CFR (n=4) compared to 117.4 ± 20.2 % (n=3) in the 0.9% i.c.v. saline-injected
control group (P=0.133, not significantly different, Student's t-test for unpaired
samples). So there is no evidence of withdrawal excitation in the PT-injected group.
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Figure 3.3.2.5.(overleaf) Pertussis toxin-treated group: summary of firing rate
changes
Each histogram is the record of a single neurone in one rat which had received a
single i.c.v. injection of Ijxg of pertussis toxin in 5/d 0.9% sterile pyrogen-free saline
72hours prior to tire day of experiment. Rats were anaesthetised with urethane and a
supraoptic nucleus exposed for electrophysiological recording from putative oxytocin
neurones. Morphine or U50,488H (M or U) were given i.v. in increasing dose and
firing rate collected in 30sec bins for calculation of 10 minute mean firing rate. A
significant change in firing rate was denoted by separation of 95% confidence bands
about the control firing rate and those of any drug treatment period. A significant
difference is marked with an asterisk. At low doses, morphine and U50 were
sometimes excitatory (see cells a), c), d), g) and h)) but at higher doses was inhibitory,
although the potency of morphine (but not U50,488H) was much reduced compared
with die i.c.v. saline control group.
The control period firing rates were a) 5.85Hz b) 5.45Hz c) 3.1Hz d) 3.4Hz e)
5.3Hz f) 6.5Hz g) 2.9Hz and h) 3.2Hz.
























































































































































The results suggest that the i.c.v. injection of pertussis toxin (PT) 72h prior to
testing with acute i.v. morphine impairs the powerful inhibitory action of morphine
upon the electrical activity of these neurones under control conditions. However, this
is not immediately apparent from a simple comparison of cumulative threshold dose to
inhibition for morphine.
In previous Chapters, expression of the inhibitory action of morphine or U50,488H
on identified oxytocin cells was in terms of the proportion of tested cells reaching
threshold inhibition at each dose tested. This method was sufficient to accurately
reflect the difference between control and chronic i.c.v. morphine-treated groups.
This analysis when applied to neurones in the present series of experiments however,
fails to faithfully describe the difference between the i.c.v. 0.9% saline-treated control
group and the i.c.v. PT-treated group.
So, at a dose of 161/ig/kg morphine 5 cells in the control group were significantly
inhibited whereas 5/6 neurones in the PT-treated group were significantly inhibited.
This expression is misleading since the depression in firing rate after morphine in
those cells inhibited beyond threshold in the two groups was to 25.7 ± 11.7% CFR and
89.3 ± 11.8% respectively. Similarly, at the higher dose of 661 /u.g/kg morphine, for
the 4 cells tested at this dose in the i.c.v. 0.9% saline-treated group firing rate was
reduced to 4.85 ± 1.0% CFR, all 4 cells being inhibited, but of die 6 cells tested at this
dose in the PT-treated group the mean change in firing rate was an inhibition to 83.1 ±
19.4% CFR and of the 6 cells tested, two were excited at this dose but were inhibited
significantly at the next dose of lmg/kg.
At these two doses, significant differences arose in the degree of inhibition
achieved by morphine in terms of spontaneous firing rate and I assume that these
differences would have persisted had the control group been tested at the two highest
doses of lmg/kg and 5riig/kg. As it was, because maximal inhibition was achieved at
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661^g/kg morphine, higher doses were not actually tested. These data are expressed
in figure 3.4.1..
So, the inhibitory potency of morphine is impaired after i.c.v. PT treatment: this is
likely to be the result of deactivation of a G-protein.
All G-proteins are constructed from 3 distinct components - they are
heterotrimeric. The a-subunit is the largest at 39-52KDa and it differs between G-
proteins but has a hydrophilic region which faces the inside of the cell membrane and
has access to cytosolic GTP and GDP for which it has a binding site. PT catalyses the
transfer of an ADP-ribose group onto a cysteine residue of the inhibitory G-protein Gi
and this group then interacts with the GTP binding site thus inactivating the G-protein
(Dolphin 1987; Dunlap et al 1987). The a-subunit also contains the recognition site
for the effector molecules in the membrane and cytosol which it regulates, making the
a-subunit the key regulatory component. The /3- and 7-subunits are closely associated
and hydrophobic and are embedded in the membrane. They are similar between G-
proteins and are of lower molecular weight than the a-subunit. In the inactive state,
the G-protein consists of these three components with GDP bound to the a-subunit.
The interaction of agonist with receptor facilitates the exchange of GDP for GTP.
Following the binding of GTP the G-protein dissociates into the a-subunit with
inherent GTPase activity and the /Sy-subunit. a-G-GTP can regulate tire activity of a
number of effector molecules such as adenylate cyclase (Stryer and Bourne, 1986;
Gilnran, 1987), phospholipase C (Cockcroft and Gomperts, 1985), cGMP
phosphodiesterase (Stryer et al, 1981) and potassium and calcium channel gating
molecules (Pfaffinger et al, 1985; Holz, et al, 1986). This effect is terminated by tire
hydrolysis of GTP and the reassociation of the a-subunit with free j6y- to form tire
inactive G-GDP (Dunlap et al, 1987).
The first G-protein to be described was Gs which is permanently activated by tire
catalytic transfer of an ADP-ribose group from NAD (nicotinamide adenine
dinucleotide) to the GTP binding site on the a-subunit of the G-protein by cholera
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toxin, an exotoxin from V. cholerae (Dolphin, 1987).
The toxin used in the present study, pertussis toxin, derived from Bordetella
pertussis, ADP-ribosylates the GTP binding site of Gi, an inhibitory G-protein
regulating the activity of second messenger molecules. As well as Gi, neuronal
membranes contain large amounts of a third G-protein, Go, which can also be linked
to AC and possibly to other second messenger systems. It has been implicated
particularly in the regulation of calcium channel function in neurones (Hescheler et al,
1987). Both Gi and Go are substrates for PT.
I propose therefore that a Gi/o protein is coupled to the opiate receptor through
which morphine acts in supraoptic neurones or their inputs to inhibit electrical
activity. The i.c.v. application of PT impaired this coupling such that after the
activation of die opiate receptor by morphine, a process not interfered with by PT,
transduction via Gi/o does not occur as effectively as normal. Intracellular events that
follow the activation of this Gi/o do not therefore occur to the same degree and tire
physiological response, inhibition of cell firing rate, is attenuated.
The fact that U50,488H more potently inhibited the firing rate of these cells (in 4/5
cells tested widi both U50,488H and morphine) than did morphine at either an
equivalent or even a higher dose demonstrates the striking contrast between tire
mechanism of action of these drugs. The potency of U50,488H appeared to be
unimpaired when tire effects are compared with those seen in tire untreated control
group in Chapter 2, whereas the effectiveness of morphine was very much impaired by
PT treatment, so it can be concluded that U50,488H acting at ^-receptors on OT
neurones does not act via a Gi/o protein.
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Figure 3.4.1. Comparative dose response relations for supraoptic putative oxytocin
neurones from the i.c.v. vehicle-injected and the i.c.v. pertussis toxin-injected groups
Horizontal axis denotes the cumulative dose of morphine (/ig/kg i.v.) and the
vertical axis, the percentage of control firing rate achieved at each dose of morphine.
The potency of morphine to inhibit neurones recorded in i.c.v. pertussis toxin-injected
rats was much less than that in i.c.v. vehicle-injected rats and this difference was
statistically significant at 161 /zg/kg morphine (Student's t-test).
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3.4.2. Diversity in linkage between opioid receptors. G-protein and second
messengers
pi-, 5- or K-opioid receptors can be linked to a G-protein which may regulate a
second messenger such as AC, or may be directly linked to an ion channel whose
activity can be regulated. Both these results can be the result of agonist interaction
with one of these receptors.
Various studies indicate that opioid receptors sensitive to morphine, probably pi-
opioid receptors can be linked to G-proteins.
Rat locus coeruleus neurones are hyperpolarised by morphine and this effect is
impaired by PT. Intracellular GTPyS, a non-hydrolysable form of GTP, restores the
potency of morphine, indicating a role for a PT-sensitive GTP-binding protein (a G-
protein) in the regulation of a hyperpolarising current in these cells (Wang and
Aghajanian, 1987). This current has been described for agonists at opiate pi- and 8-
receptors in guinea-pig locus coeruleus neurones as a potassium current and the G-
protein confirmed as PT-sensitive, that is Gi/o and AC does not seem to be involved in
channel regulation (Christie et al, 1987; North et al, 1987). Although AC is not
involved in acute morphine effects in locus coeruleus neurones, AC is involved in tire
response to chronic morphine, as the activity of cAMP-dependent protein kinase is
increased but cAMP-independent protein kinase activity is unchanged after chronic
morphine (Nestler and Tallman, 1988). However, changes in cAMP do not seem to be
acutely involved in the electrical response of neurones to opiates (Duggan and
Griersmith, 1979; Karras and North, 1979), and likewise, the change in cAMP after
chronic morphine described above need not be related to the electrophysiological
consequences of morphine tolerance/dependence. Chronic but not acute morphine
treatment increases levels of PT-induced ADP-ribosylation of a-subunits of Gi/o in rat
locus coeruleus neurones in a naloxone-sensitive way (Nestler et al, 1989; see later
Discussion).
Although DAGO ([D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin) and the 5-receptor
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ligand DPDPE ([D-Pen2,D-Pen5]-enkephalin) are both linked to an inhibitory G-
protein, only DAGO inhibited AC in guinea-pig striatal membranes indicating that G-
protein coupling to AC in these cells depends on the type of receptor (Satoh et al,
1990).
For guinea-pig myenteric plexus neurones, incubation of ileum with PT or
pretreatment of guinea-pigs with PT intraperitoneally reduced the inhibition of
cholinergic transmission seen with morphine, probably a result of the accompanying
ADP-ribosylation of Gi and Go in myenteric neurones. The concentration-response
curve for morphine was shifted to the right and the maximum response decreased.
The degree of attenuation of tire inhibitory potency of morphine coincided with the
degree of ADP-ribosylation of Gi or Go which were not distinguishable (Johnson et al,
1990).
Rat caudate nucleus contains opioid receptors which are linked to AC through a G-
protein (Law et al, 1981; Abood et al, 1985; Kamikubo et al, 1986).
In neuroblastoma x glioma (N x G) hybrid cells which possess only 5-opioid
receptors, DADLE inhibited a voltage-dependent calcium current (Schultz et al,
1990). This effect was not mediated by a change in intracellular cAMP or cGMP or
the phosphatidyl inositol system (McFadzean et al, 1989). PT treatment or treatment
with antibodies to ai or ao (the a-subunits of the inhibitory G-proteins Gi and Go
respectively) abolished this effect. Intracellular application of the purified a-subunit
of either Gi or Go via a patch pipette to N x G cells pretreated with PT restored the
inhibitory effect of DADLE, ao more potently than ai (Hescheler et al, 1990). These
results were augmented by a study photolabelling the ai and the ao subunits of these
cells as the opiate receptor was activated. For ao but not for ai there was a good
correlation between the ability of agonists to inhibit the calcium current and the degree
of photolabelling of the a-subunit, implicating endogenous Go but not Gi in the
transduction of this opioid effect (Hescheler et al, 1990). However, another study has
demonstrated a 5-opioid-induced inhibition of AC which is mediated by a G-protein
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(Koski et al, 1982; Kurose et al, 1983). In conclusion, Gi/o is not always linked to
AC as a post-opioid receptor mechanism.
3.4.3. Opioid receptors can be associated with the stimulatory G-proteim Gs
Adding to this already complex picture, recent work has shown that opioid
receptors do not always associate with Gi/o but can be linked to Gs which then
mediates 'excitatory' events in the neurone.
In dorsal root ganglion cells, opioid receptors mediate both "inhibitory" and
"excitatory" events through Gi/o and Gs respectively (see Chapter 1, p56 for more
detail). They are activated at different concentrations of opioid: the Gs protein
positively couples the receptor to AC and cAMP-dependent voltage-sensitive ionic
conductances whilst the Gi protein is activated at higher concentrations of opioids and
activates voltage-sensitive ionic conductances probably independently of cAMP
(Werz and Macdonald, 1985; North, 1986; Shen and Crain, 1989; Shen and Crain,
1990a).
3.4.4. G-proteins might not activate a conventional cvtosolic second messenger
system but might act on an ion channel protein directly
In addition to activation of AC and its regulatory action then on ion channels, the
possibility exists, as shown first in cardiac muscle, that G-proteins can regulate
potassium channels directly. Acetylcholine binds to a muscarinic receptor which is
coupled to a G-protein and receptor activation increases the probability of potassium
channel opening and second messengers such as cAMP, cGMP, diacylglycerol (DAG)
and calcium are not involved. Using inside-out patches of atrial membrane, the typical
response to acetylcholine is mimicked by the application of non-hydrolysable
analogues of GTP or the active components of the G-proteins themselves to the
internal side of the membrane in the absence of any second messengers. So, either a
G-protein exerts a direct effect on the channel or there is a novel intramembrane
second messenger system linked to the G-protein (Hescheler et al, 1987).
The inhibition of stimulated calcium influx by U50,488H in rat spinal cord/dorsal
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root ganglion co-cultures involves a PT-sensitive G-protein and although this might be
mediated indirectly by cAMP under conditions of neurohormonal stimulation, there
seems also to be a direct effect of the G-protein on the voltage-dependent calcium
channel (Attali et al, 1989).
Rat locus coeruleus neurones are hyperpolarised by morphine by activation of a
potassium current, an effect impaired by PT and restored by intracellular GTP7S
(Wang and Aghajanian, 1987). AC does not seem to be involved in regulation of
potassium channel function in guinea-pig locus coeruleus neurones (Christie et al,
1987; North etal, 1987).
So, Gi/o/?7 (the (3y subunit dimer of the inhibitory G-proteins Gi and Go
respectively) once liberated might act on AC or another second messenger system in
the cytosol or could act directly upon a channel protein to cause a conformational
change and therefore a change in its activity.
I have found no evidence to implicate adenylate cyclase (AC) as a post-receptor
system involved in opiate receptor transduction in isolated SON fragments (see
Chapter 4). So, it appears that morphine acts on an opiate receptor linked to a
regulatory G-protein, probably Gi or Go, in the cell membrane and that this G-protein
does not affect the activity of AC. It is not apparent from the studies in this Thesis
which other second messenger systems might be involved in /^-opiate receptor
transduction. Nor has this yet been investigated with appropriate intracellular
recording/biochemical techniques.
The existence of these many combinations of couplings between the opiate
receptors, G-proteins and AC or other second messenger, in a variety of cell types,
puts the present findings into context. It seems that how a receptor is linked to a G-
protein and then to a second messenger system in the cell depends upon the cell type.
The same receptor type might combine differently with these post-receptor elements
in different cells. So the present results, namely that the /*- but not the /c-opiate
receptor in this system is linked through a PT-sensitive G-protein to intracellular
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mechanisms excluding AC, seen on this backcloth are not surprising. What is striking
however is the contrast so clearly seen between the two subtypes of opiate receptor
present either in tire cell membrane of the OT cells themselves or in that of cells
projecting to the SON which provide a tonic drive to the OT neurones.
A similar result has been reported in hippocampal and striatal tissue derived from
guinea-pigs pre-treated with i.c.v. PT (Werling et al, 1989). The efficacy of opiates
acting at the three subtypes of opiate receptor, p-, 5- and /c- to inhibit noradrenaline
release in vitro was assessed. This system has some parallels with that of opiate
regulation of SON OT cells as more than one subtype of opiate receptor can mediate
an inhibitory response. In guinea-pig hippocampus, PT pre-treatment abolished
inhibition of noradrenaline release in response to p- and 5-agonists whilst not affecting
/c-opiate mediated inhibition. So, the p- and 5-opioid receptors in guinea-pig
hippocampus are linked to a PT-sensitive G-protein whereas /c-opioid receptors in the
same brain region are unlikely to be so linked. In rat hippocampus, striatum and
cortex, again p-receptor inhibition of catecholamine release was PT-sensitive whereas
/c-receptor inhibition was not.
3.4.5. G-proteins and tolerance
The similarity between the effects of PT on sensitivity to morphine and the effects
of chronic morphine treatment begs the question, does Gi/o-protein inactivation
explain tolerance?
With respect to the results in this Chapter with the /c-opioid receptor agonist,
U50,488H, in systems where /c-opiate receptors are shown to be linked to a G-protein,
an uncoupling of G-protein from receptor or a reduction in the number of G-proteins
available in the membrane might contribute to tolerance to a /c-receptor agonist. Such
a mechanism could not explain tolerance to chronic /c-receptor activation in OT cells
of the SON (N.B. this has still to be demonstrated) as these receptors are not linked to
a PT-sensitive G-protein. This suggests that the phenomenon of tolerance might be a
composite of a variety of mechanisms, because tolerance certainly can develop to k-
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opiate receptor agonists in other neurones (Werling et al, 1988). Indeed, we have
shown a fi-receptor density down-regulation in tire SON after chronic morphine
treatment indicating a probable contribution of this mechanism to the observed
tolerance (Sumner et al, 1990). Such a change would of course be expected to result
in reduced Gi/o-protein activation at a given morphine concentration.
Whatever the cellular mechanisms involved, the consequences of treatment with PT
have been likened to the state of tolerance which accompanies chronic administration
of opiates (Crain et al, 1986). In cortical membranes from morphine-tolerant guinea-
pigs or chronic morphine-treated 7315c pituitary tumour cells, /^-agonist binding is no
longer affected by GTP, suggesting a dissociation between the ^-receptor and G-
protein (Puttfarcken et al, 1988; Werling et al, 1989). Still more persuasive is the
evidence in rat locus coeruleus where chronic morphine treatment results in increased
levels of PT-mediated ADP-ribosylation of Gi and Go, which probably represents
increased quantities of these inhibitory G-proteins in neurones of the central nervous
system (Nestler et al, 1989). Similarly, in guinea-pig myenteric plexus neurones an
increase in Gai/Gao was demonstrated after chronic fentanyl treatment (Lang and
Schulz, 1989).
From the results presented in this Chapter with morphine, coupled with those
outlined above, it seems likely that inactivation of the G-protein or a reduction in the
number of G-protein molecules available to interact with opiate receptors could be a
mechanism underlying tolerance.
Of course, tolerance might be accounted for in isolation from dependence if the two
phenomena develop independently, (Wuster and Costa, 1984; Wuster et al, 1985;
Christie et al, 1987) by a reduction in G-protein availability. However, in OT
neurones of the SON, the existence of tolerance together with dependence has been
demonstrated, and they have not been induced independently of one another within the
protocol described in Chapter 1. With this in mind, the removal of available G-protein
(with PT in these experiments) is not sufficient to account for tolerance and
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dependence occurring together, as there was no evidence of a withdrawal response to
naloxone after PT treatment. The response to naloxone was similar in the control and
the PT-treated groups - firing rate was restored to its control level but no further.
So, G-protein inactivation or removal could be one of multiple adaptive
mechanisms that together might account for tolerance, but not dependence. Dolphin
lists 4 methods by which G-protein modification might result in up or down-regulation
of the response to receptor activation. These include a change in the ability of
receptor and G-protein to interact; a change in the GTPase activity or affinity for GTP
of the G-protein; a change in the effectiveness of the interaction between the a-
subunit of the G-protein with the effector molecule and lastly, modification of the
number and type of G-proteins available (Dolphin, 1987). Ui and coworkers (Ui et al,
1985) have described the ADP-ribosylation of G-proteins by endogenous ADP-
ribosylating enzymes. Thus, Gi is not lost but functionally inactivated by an
endogenous mechanism identical to that effected by PT. Further, the regulation of AC
in adipocytes is achieved partly by endogenous ADP-ribosylation of Gs (Jacquemin et
al, 1986). So PT imitates an existent endogenous homeostatic process which could
well contribute to the cellular basis of tolerance after chronic opiate.
In addition to this endogenous ADP-ribosylation process, G-proteins may also be
inactivated by phosphorylation by a variety of kinases (Bauer et al, 1987).
So far, I have presented evidence from the literature for association between opioid
receptors and G-proteins but have not demonstrated that the G-protein deactivated
with i.c.v. PT in this system is linked to a /x-opiate receptor and not to another
receptor. It is conceivable that a neurotransmitter receptor present in a neural pathway
relaying the effects of an acute i.v. injection of morphine to the SON OT cells is the
target for PT or more broadly, that heterologous desensitisation at several receptor
sites other than just the /x-opiate receptor occurs as the pool of available G-proteins is
depleted after PT.
Crain and coworkers using mouse spinal cord-dorsal root ganglion cultures (Crain
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et al, 1986) found that agonists at receptors other than opiate receptors which are also
linked to a PT-sensitive G-protein are less potent after PT-treatment indicating a
common pool of G-protein able to interact with a variety of receptors. This situation
cannot be ruled out in SON OT neurones but neither can it be supported with
experimental evidence from these studies. Although this possibility cannot be
discounted, because the potency of agonists at other putative neurotransmitter receptor
sites was not systematically tested, before and after PT treatment, the firing rate of OT
cells in vitro in the hypothalamic slice preparation is potently inhibited by opiates
acting at the ^-opiate receptor (Pittman et al, 1980; Wakerley et al, 1983; Pumford et
al, 1987) and that /i- and x-opiate receptors are located in the SON, although it is not
yet clear which neural elements carry them (Sumner et al, 1990). So it is probable that
a G-protein associated with supraoptic /x-opiate receptors is deactivated by i.c.v. PT
treatment, perhaps sufficiently to account for the observations described in this
Chapter, with the implications discussed above.
Although opiate tolerance has been demonstrated in cultured neurones indicating
that the necessary elements that contribute to the development of tolerance can be
present in an individual cell (Sharma et al, 1975a; Sharma et al, 1975b), tolerance
might also be the result of adaptive changes at distinct sites in the brain which
influence each other to produce the gross evidence of tolerance in terms of cell
function. The influence of the AV3V region upon the expression of withdrawal in the
chronic morphine-treated rat has been explored in this Thesis (see Chapter 6). The
tolerance of AV3V-lesioned rats to morphine could not be tested as was done in this
series of experiments, because the lesion itself removes a tonic excitatory input and
silences the SON OT neurones. This could be investigated however in AV3V-
lesioned rats given i.v. cholecystokinin to raise tire basal electrical activity to a level
upon which inhibitory effects might be seen, using a similar protocol to that used here,
(Blackburn and Leng, 1990).
If a range of doses of i.c.v. PT had been tested, to assess the maximum extent of
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PT-induced 'tolerance' attainable, it might have been possible to then predict the
likely maximal contribution of this potential adaptive mechanism to chronic opiate-
induced tolerance. However, at the dose used some morphine-induced inhibition of
spontaneous activity was seen, albeit attenuated. It seems possible therefore that
receptor down-regulation (see Chapter 5) contributes significantly to tolerance.
3.4.5. A possible mechanism for morphine-induced low dose excitation
As previously demonstrated in Chapters 1 and 2, excitatory and inhibitory effects
of morphine were seen in PT-treated rats. In the control i.e.v. 0.9% saline-treated
group excitatory effects were seen between 1 and ll^g/kg and in the i.c.v. PT-treated
group between 1 and 661j«g/kg. The threshold dose to inhibition was between 11 and
61/zg/kg in the i.c.v. 0.9% saline-treated group and between 1 and 1661/ig/kg in the
i.c.v. PT-treated group. The latter comparison is not surprising given the shift in
responsiveness to acute i.v. morphine already described earlier and illustrated in
Figure 3.4.1.. The former comparison is difficult to interpret, unless the excitatory
effects of morphine are not mediated by a PT-sensitive G-protein. In 2 PT-treated
rats, excitatory effects were seen up to 661yu.g/kg morphine. In the remainder
excitatory effects were seen between 1 and 61/ig/kg morphine which is not dissimilar
to the range observed in the control group and previously seen in Chapters 1 and 2.
Note that the lower end of this range is l/*g/kg morphine, so cells can still be
responsive at this very low dose of morphine after PT treatment. The spread of
effective excitatory doses of morphine in the PT-treated group however raises the
question, how does the deactivation of Gi/o affect the expression of the excitatory
effects of morphine? One interpretation of the results is that with the inhibitory
potency of morphine impaired after PT, the inhibition which always follows low dose
excitation with morphine is not activated until sufficient of the now scarce G-protein
becomes recruited in the usual way and this now occurs at the higher doses of
morphine. Normally the inhibitory effect of a high dose of morphine will overcome
the sometimes persistent excitatory effect of a lower dose. The low dose excitatory
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effects of morphine do not seem to involve a PT-sensitive G-protein: this would
explain the effectiveness of 1/xg/kg morphine in exciting 3 cells from the PT-treated
group. Perhaps a dual mechanism has been dissected by which morphine can act on
these neurones: an excitatory effect not involving a PT-sensitive G-protein and an
inhibitory effect involving Gi/o occurring at higher concentrations of morphine at the
receptors. This dual effect could be the result of activation of two distinct subtypes of
/x-opioid receptor to which morphine binds with differing affinity one of which
associates with a PT-sensitive G-protein and the other not and perhaps one of which is
located presynaptically and one postsynaptically. So with the receptor mediating
inhibition by morphine rendered 'tolerant' after PT, the excitatory effects mediated
usually just at low doses of morphine by the other receptor can be evoked at higher
doses because of the removal of the inhibitory restraint usually present as the dose of
morphine increases. PT treatment reduces the availability of Gi/o/3 (the /3 subumit of
the inhibitory G-proteins Gi and Go respectively; Watkins et al, 1989) and if a
stimulatory G-protein Gs was associated with the other subtype of ^-opioid receptor
proposed in this model, then as Gi/o/3 subunit levels decline, the excitatory effects
mediated by Gs might be unmasked.
This scenario is highly speculative in this instance because the number of cells
involved is small and the experiments were not designed to investigate this
phenomenon primarily. There is as yet no evidence for the existence of subtypes of
the ju-opioid receptor on these cells, although they have been postulated in other cells
(Lutzetal 1985; Pasternak and wood 1986; Rothmanetal 1987). But this intriguing
result merits more study.
Dual effects of opiates at different dose ranges have already been demonstrated in
neurones and have been explained in terms of association of receptors with different
G-proteins, Gs (a stimulatory G-protein) and Gi/o (Crain and Shen, 1990). Indeed it is
possible that when an inhibitory receptor is activated an interaction occurs between die
released /3y-subunit complex of Gi/o and free Gsa (the a subunit of the stimulatory G-
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protein, Gs) , to reduce the availability of the excitatory G-protein Gs, thus indirectly
producing inhibition (Katada et al, 1984; Nestler et al 1989). Such a hypothesis was
proposed by Nestler and coworkers based on experimental results in morphine-
tolerant rats, which showed an increase in the levels of Gia/Goa with no change in the
levels of the /3-subunits of Gi/Go. However, these results conflict partially with those
of Lang and Schulz (1989) who demonstrated not only an increase in the levels of
Gia/Goa but also an even more pronounced increase in Gi/3/Go/3 and a decrease hi
the level of Gs in guinea-pig myenteric plexus.
More problematic is the reconciliation of the effect of chronic morphine treatment
upon inhibitory G-protein levels and the effect of the same treatment upon AC
activation. The increase in Gi/o in the tolerant state would be expected to cause
attenuation of the activation of AC. In fact AC activation in both systems described
above is increased after chronic morphine treatment to 'normal' levels. Lang and
Schulz explain this paradox by implying that AC is not directly involved in the cell
response to chronic opiate whereas regulation of inhibitory G-protein is, and therefore
the change in AC observed after chronic opiate is coincidental and not a direct effect.
Nestler and coworkers on the other hand try to encompass both observations by
proposing a model by which the two systems might be so affected. If both the
stimulatory and inhibitory G-protein subunits as and ai share the same pool of (3y,
then under basal conditions, an equilibrium is established resulting in basal
concentrations of free as and ai with their resultant influence on AC. Acute morphine
would decrease the probability of association between 0y and ai and increase the
probability of association between fiy and as thus freeing relatively more ai which
would depress the activity of AC. After chronic morphine treatment, assuming that
07 is unchanged (not the case in myenteric plexus, Lang and Schulz, 1989) then, as
the quantity of ai increases, but that of as remains unchanged, 0y would associate
mainly with ai according to the equilibrium, thus freeing relatively more as to activate
AC, resulting in the observed increase in activity of AC. Again, this scheme relies
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upon the quantity of as remaining unchanged throughout, which is a point of
controversy (see Lang and Schulz, 1989). The scheme applies to Go as well and gives
rise to the idea that Gs can be regulated indirectly by controlling the levels of Gi/Go.
U50,488H was not tested over the same dose range as morphine; usually only the
second half of the dose range was tested and this only in the PT-treated group. For
this reason there is not the same information for U50,488H as exists for morphine on
low dose excitation, a feature of the effect of U50,488H on supraoptic OT cells (see
Chapter 2).
The fact that both morphine and U50,488H acted in a fully naloxone-reversible
way at usual doses of naloxone indicates that the active sites on the opiate receptors
were not in any way modified by PT treatment and this could not account for the
observed shift in sensitivity of OT cells to i.v. morphine.
Whether PT-treatment would have an effect upon the development of tolerance to
morphine (not addressed by the present study) might be answered using a similar
protocol to that used in Chapter 1, but where PT was administered simultaneously
with the start of a chronic i.c.v. infusion of morphine. This might illuminate more




intracellular camp and oxytocin and vasopressin release within the rat
supraoptic nucleus (in vitro): are they affected by acute (in vitro) or
chronic (in vivo) morphine treatment?
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4.1. Introduction
The cellular events underlying the acute and chronic effects of opiates have been
the subject of much investigation. Intracellular calcium has been implicated in the
response of cells to acute and chronic opiate exposure but the relationship is still not
clearly defined. Opiates are known to inhibit neurotransmitter release in various
systems and as neurotransmitter release is known to be a calcium-dependent process
(for review see Llinas and Heuser, 1977) the possibility that opiates inhibit the
depolarisation induced influx of calcium into nerve terminals, thus reducing
neurotransmitter release has received much support. Alternatively, the inhibition of
calcium influx by opiates could lead to membrane hyperpolarisation and relative
insensitivity of the neurone to depolarising stimuli (West and Miller, 1983).
cAMP generation has also been frequently investigated in the presence of acute and
chronic opiates and there is a strong case at least in some cells, for a role of adenylate
cyclase (AC) in mediating the effects of opiates on the cell. In the supraoptic nucleus
(SON) in vitro the opioids, met- and leu-enkephalin and /3-endorphin inhibit the
formation of cAMP (Redgate et al, 1986). Agonists at the /c-opiate receptor do not
stimulate cAMP formation in guinea pig striatal membrane (De Montis et al, 1986). <5-
opiate receptors do not occur in the SON (Mansour et al, 1987; Tempel and Zukin,
1987; Mansour et al, 1988; Sumner et al, 1990) and because of the extremely low
preference of the ligands met- and leu-enkephalin and /3-endorphin for the k-receptor
(Kosterlitz, 1985), it appears that the inhibition of cAMP generation was probably
mediated through the n~type opiate receptor. Unfortunately, a study using more
selective ligands has not been done to date in the SON. However, in the 7315c
pituitary tumour cell line, which has a population of exclusively pi-type opiate
receptors, the /x-selective agonist, Tyr-D-Ala-Gly-MePhe-Gly-ol (DAGO) inhibits AC
acutely (Puttfarcken et al, 1988). So activation of /x-type opiate receptors can lead to
inhibition of AC although this might not extend to all cell types.
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As a consequence of opiate induced changes in Ca^+ concentration or cAMP
formation , protein phosphorylation by enzymes activated by cAMP or by Ca2+ might
also be part of the cellular compensatory mechanisms that constitute tolerance and
dependence (West and Miller, 1983).
The acute and the chronic effects of opiates in neuronal and in cultured
neuroblastoma x glioma cells have been linked to changes in intracellular cAMP.
Acutely cAMP production is inhibited by opiates but with continued exposure cAMP
concentration returns to basal as a result of hyperactivity of AC (Klee et al, 1975).
The possibility of explaining tire acute effects of opiates in terms of changes in cAMP
formation and that such adaptive changes in the AC system might occur hi the
neurosecretory neurones of the SON to explain the powerful chronic effects of opiates
there, has not so far been investigated. In this study, the relatively /x-selective opiate
receptor ligand, morphine was used, which has negligible affinity for the k- or the 8-
type opiate receptor (Kosterlitz, 1985), in an in vitro tissue incubation protocol
involving the measurement of die tissue content of cAMP and the release into the
superfusate of cAMP, oxytocin (OT) and vasopressin (AVP) to answer tire following
questions:
1. Does morphine affect cAMP concentration or release in SON; that is, are /x-
opioid receptors negatively coupled to AC in this neurosecretory system as they are
elsewhere and is this effect naloxone-reversible?
2. Do the SON from morphine-treated rats have a different cAMP content to SON
derived from morphine-naive rats?
3. Do endogenous opioid peptides maintain an inhibitory tone on intracellular
cAMP concentration or on AVP or OT release within the SON?
4. Are SON prepared by this method and treated according to this protocol capable
of responding to stimulation of AC by an agent (VIP) proven stimulatory in an earlier
study in SON? This would confirm that VIP is positively coupled to AC and that the
tissue is responding as expected.
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5. Can morphine antagonise the expected stimulation of cAMP by VIP? Thus die
effect of morphine superfusion on both basal and stimulated cAMP formation was
tested.
6. Are there any changes in neuropeptide release from SON in vitro with acute
opiate exposure or in SON derived from rats chronically i.e.v. morphine-infused, after
naloxone in vitro? In vivo, there is a sharp and dramatic rise in plasma OT
concentration associated with precipitated withdrawal in chronic morphine-treated
rats. AVP release however is largely unaffected (Bicknell et al, 1987b; Bicknell et al,
1988a). With the present protocol, the question was addressed of whether OT and
AVP release from dendrites or other neural processes within the SON also occurs in
conditions designed to be similar to those described above, which provoke a
substantial release of OT into die systemic circulation.
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4.2. Methods
The study comprised two series of experiments which focussed on two aspects of
opiate action in the SON. First, acute affects of morphine, naloxone and VIP were
examined in SON derived from morphine-naive control rats (Experiment 1). cAMP
formation and OT and AVP release into the superfusate were measured.
Second, acute and chronic effects of morphine upon cAMP formation and OT and
AVP release within the nucleus were studied in SON derived from either morphine-
naive rats or from 5-day i.c.v. morphine-infused rats and finally the acute effects of
naloxone on tissue cAMP and release of OT and AVP in tissue taken from 5-day i.c.v.
morphine-infused rats (Experiment 2a and 2b respectively) were studied. The two
experimental protocols differed slightly and are dealt with separately in both the
Methods section and in the Results section.
4.2.1. Experiment 1
4.2.1.1. Animals
Rats were virgin female Sprague Dawley, housed at an ambient temperature of 21-
23 °C, allowed free access to food (standard breeder diet) and tap water and kept under
a 13/1 lh light/dark cycle. The mean ± SEM body weight of these rats was 228.7 ±
2.4g (n = 24).
4.2.1.2. Preparation of tissue
Rats were decapitated by guillotine. The skull vault was opened, the dura incised
in the midline and a transverse cut was made rostrally to the optic chiasm. The optic
nerves were cut with minimal stretching and a caudal cut made at the cerebellum, to
free the block containing the hypothalamus. The brain was drenched with ice cold
modified Yamamoto's solution and further trimmed at the optic nerves and die
mammillary bodies. This block of tissue was fixed with cyanoacrylate adhesive to die
chuck of the Vibraslice rostral end uppermost and immediately immersed in
Yamamoto's solution in the Vibraslice chamber. Coronal 500/mi sections were cut
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and the three sections containing SON were transferred to a plastic Petri dish
containing Yamamoto's solution and placed on ice. With the aid of a dissecting
microscope and using a fragment of razor blade held in a pin vice the area containing
the SON in each section was isolated. The isolated sections of SON from the left and
right hand sides of the brain were placed into separate tared inverted plastic tube caps
filled with Yamamoto's solution. Weighing was carried out once the cap was attached
to the tube and the weight of tissue calculated by later reweighing of the tube and cap
on a microbalance. The tissue was then transferred to the superfusion chamber which
was inserted into the primed superfusion apparatus and carefully sealed, excluding air
bubbles. The contralateral SON were paired as control and experimental tissues.
4.2.1.3. Superfusion apparatus
This comprised a series of chambers made of perspex and modelled from a 2ml
disposable syringe. Each chamber was 150/xl capacity. The tissue was supported on a
fine nylon mesh. The outlet of the chamber was connected via a needle connector and
polythene tubing through a holder so that after passing over the tissue the superfusate
dripped into tared plastic tubes. When sealed by careful insertion of a plunger with a
rubber O ring to make a good seal (see Figure 4.2.1.4.), each chamber was connected
via the plunger inlet independently and via a bubble trap to a line of an 8 channel
peristaltic pump (Gilson). The inlet end of each line was immersed into the
appropriate superfusion medium. Each such reservoir was gassed with
95%02/5%C02- The superfusion chambers and inlet lines were kept at 37°C in a
stirred water-jacket heated via an immersion heater, thermostatically controlled. The
bath temperature was set so that the superfusion chamber temperature, measured with
a thermocouple was 37 °C.
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Figure 4.2.1.4. Superfusion apparatus
See Methods Section 4.2.1.3. for full description. The curved arrow indicates the
inside of the 150/xl chamber bounded at its lower surface by a nylon mesh stage
resting on a rubber O-ring. The fragments of SON were placed on this surface and
then the plunger inserted to seal the tissue in. The upper surface of the chamber was
also constructed from fine nylon mesh attached to the upper O-ring. The medium
flowed from the lower surface, through the chamber and out through the upper
surface, as depicted by the vertical arrow. The lower and upper components
terminated in a male Luer fitting and needles, which were themselves connected to
inlet and outlet tubing, were attached.
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4.2.1.5. Supervision protocol
The superfusate flow rate was set for each channel at 50/d/min, calibrated
gravimetrically. The transit time of this system was estimated at 4min.
All tissues equilibrated for 90min in the chamber during which time they were
superfused either with Yamamoto's medium containing the peptidase inhibitor,
bacitracin (2.8mg/100ml; Sigma Chemical Co.; first control group) or with
Yamamoto's medium containing bacitracin together with the phosphodiesterase
inhibitor, IBMX (isobutyl methylxanthine, ImM; Sigma Chemical Co.; all other
treatment groups). The first control group was not exposed to IBMX in order to show
the degree of effectiveness of the phosphodiesterase inhibitor and to enable
comparison between Experiment 1 and Experiment 2. During the equilibration
period, no drugs were present in the superfusate. Subsequently, 5-6 serial collections
of superfusate were made from each chamber, each over lOmin, into tared 1.5ml
Eppendorf tubes. After the 30min control period during which superfusate samples
were collected for radioimmunoassay for OT and AVP drugs were added to the
superfusate for the duration of the remainder of the protocol and three lOmin
collections of superfusate made. A final collection of superfusate was made after
removal of die tissue from die chamber to provide medium blanks to check for cross
reactivity of drugs in the radioimmunoassay.
Drugs were morphine sulphate B.P. (10"5M; Pharmacy, Edinburgh Royal
Infirmary), naloxone hydrochloride (10"6M; a gift from Endo Labs, or purchased from
Sigma Chemical Co.) and vasoactive intestinal peptide (VIP; 10~6M;
human/porcine/rat (His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-
Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2), Cat. code 7161,
Peninsula Labs. Inc.), a peptide known to elevate cAMP in SON and other tissues
(Redgate et al, 1986).
141
4.2.1.6. Treatment of superfusates
The full volume of superfusate collected over lOmin was frozen at -20 °C for later
radioimmunoassay of OT and AVP. None was reserved for radioimmunoassay of
cAMP in view of the negative results from the parallel experiments (Experiment 2).
4.2.1.7. Treatment of tissues
At the end of the last lOmin collection period, the chamber was opened, the
fragments of SON were removed (and the number of fragments checked) and placed
into 500/d ice cold 70% ethanol in a chilled 1ml glass minihomogeniser, dispersed,
left for 20min in the minihomogeniser on crushed ice, then tranferred to a 1.5ml
Eppendorf tube and centrifuged for lOmin at -20°C and 6000r.p.m. (Heraeus-Christ).
The supernatants were transferred to glass flat bottomed tubes and dried in a stream of
nitrogen at 40 °C in a dry heating block. Residues were re-dissolved in 500/d lOmM
phosphate buffered saline (PBS), pH 7.4, then divided into two aliquots, frozen and
stored at -20 °C prior to assay of cAMP content. Tissue blanks were prepared
containing either PBS alone or 2/d of each of the drug solutions used (equivalent to
the volume of SON) and processed as for tissue; these were used to test for cross-
reactivity in the radioimmunoassay.
4.2.2. Radioimmunoassay for oxytocin and vasopressin
4.2.2.1 Oxytocin (OT)
The OT assay was expertly carried out by Chris Chapman, Dept.
Neuroendocrinology, AFRC Institute of Animal Physiology and Genetics Research,
Babraham, Cambridge.
a) Stock buffer:
A stock RIA buffer containing sodium phosphate 0.01M (pH 7.4), bovine serum
albumin 5mg/ml (Sigma Chemical Co.), sodium azide lmg/ml and bovine gamma




Samples were prepared as described above and slowly thawed from -20°C at 4°C,
vortexed and recentrifuged. Aliquots of 50/d were taken for radioimmunoassay. All
reagents were diluted in stock buffer apart from 30% PEG 6,000 which was diluted in
water. The RIA standard curve was constructed using synthetic oxytocin (PB2232A,
Cambridge Research Biochemicals, U.K.) which was dissolved in 0.2% acetic acid to
a final concentration of lmg/ml. This was then stored in 25/d aliquots at -20 °C.
The standard curve was contructed by making serial doubling dilutions of synthetic
oxytocin in stock assay buffer over the range 25,000 - 6 pg/ml. 50/xl aliquots of
standard and 50/d of sample were added to assay tubes in duplicate. 50/d oxytocin
antiserum (Higuchi et al, 1985) diluted in stock assay buffer to a final dilution of
1:300,000 was added to each assay tube which was then vortexed and incubated at
4°C for 24 hours. 125Iodinated oxytocin was diluted in stock assay buffer to obtain
8,000 c.p.m./50/xl and 50/d aliquots of this solution were added to each assay tube, the
tubes vortexed and incubated at 4°C for 48 hours.
At this stage, 150/tl 30% PEG 6,000 was added to each tube and the tubes vortexed
and centrifuged for 30min at 3000 r.p.m. and 4°C. The supernatant was aspirated off
and the radioactivity of tire remaining pellet counted in a gamma counter (Packard
5360 Auto-Gamma).
4.2.2.2 Vasopressin (AVP)
The AVP assay was expertly carried out by Chris Chapman, Dept.
Neuroendocrinology, AFRC Institute of Animal Physiology and Genetics Research,
Babraham, Cambridge.
a) Stock assay buffer:
A stock RIA buffer containing sodium phosphate 0.05M (pH 7.4), sodium chloride
0.1M, sodium azide lmg/ml, bovine serum albumin lmg/ml (Sigma Chemical Co.)
and bovine gamma globulin lmg/ml was used for dilutions where indicated.
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b) Assay procedure:
Superfusates, frozen upon collection were thawed slowly at 4°C prior to assay and
any precipitate removed by centrifugation. AVP was extracted (Sep-pak CI8
cartridge; Waters Associates, Millipore, Harrow, Middlesex) and the sample dried
down under vacuum (Gyrovap sample concentrator; V. A. Howe Distributors) to
remove excess methanol and acetic acid used in the extraction procedure. AVP
samples once extracted were reconstituted in 150/xl stock assay buffer and 50/xl
aliquots of this used for RIA. Synthetic AVP (PB2279A; Cambridge Research
Biochemicals, U.K.) dissolved in 0.2% acetic acid to a final concentration of lmg/ml
was used to contruct the standard curve. 10/xl aliquots of this were stored at -20 °C.
The standard curve was constructed from doubling dilutions of synthetic AVP in
stock assay buffer over a concentration range of 4,000 - 2pg/ml. 50/xl aliquots of
sample and 50/xl aliquots of standard were added to assay tubes in duplicate. 50/xl
AVP antiserum (Moore et al, 1977) diluted in stock assay buffer 1:30,000 was added
to each tube and tubes were vortexed and incubated for 24 hours at 4°C. 125Iodinated
AVP was diluted in stock assay buffer to obtain 8,000c.p.m. /50/xl and 50/xl aliquots of
this were added to each assay tube. Tubes were vortexed and then incubated for 48
hours at 4°C. 150/xl 30% PEG 6,000 was added to each tube, tubes vortexed and then
centrifuged for 30 min at 3,000 r.p.m. and 4°C. The supernatant was aspirated and the
remaining radioactivity counted in a gamma counter.
4.2.2.3 Calculation of results
The standard curve was used to measure the amount of hormone in each sample.
Also making up the standard curves were tubes containing no antiserum (as a measure
of non-specific binding), total counts tubes and total binding tubes (containing no
competing unlabelled hormone). The standard curve was linearised by computer
using the logit transformation to give a non-weighted linear equation:
logitX = logeX(l-X)-l
where X is the proportion of bound label. Unknown hormone concentrations were
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calculated from the calibration curve using the mean count from two replicate tubes
for each sample.
4.2.2.4. Assay coefficients of variation
Standard hormone solutions were assayed at 200pg/ml in tire appropriate assay
buffer. These standards were assayed as 8 sets of duplicates and the hormone
concentrations measured used to calculate the intra- and inter-assay coefficients of
variation. The intra- and inter-assay coefficients of variation (the sample standard
deviation expressed as a percentage of the sample mean) were calculated from:
cr/yu. x 100,
where a=sample standard deviation and /r=sample mean of all intra- or inter-assay
standards.
For the oxytocin RIA tire intra-assay coefficients of variation were 10.4% and
14.1% and the inter-assay coefficient of variation 9.0%. For AVP the intra-assay
coefficients of variation were 11.6% and 13.2% and the inter-assay coefficient of
variation?.6%.
4.2.2.5. Sensitivity of tire radioimmunoassays
The sensitivity for each assay was determined from 2 x the standard deviation
about tire mean of the zero binding point. For oxytocin this was 0.2-0.4 pg/tube. For
AVP sensitivity was 0.4 pg/tube.
4.2.3. Radioimmunoassay for cAMP
The assay was expertly performed by Martin Hulme, Reproductive Biology Unit,
Chalmers Street, Edinburgh.
Samples were thawed slowly at 4°C and vortexed. 100/d aliquots were taken for
radioimmunoassay.
a) Assay buffer:
Phosphate buffered saline (PBS; lOmM; pH 7.4) was used where indicated to dilute
samples and standards.
In order to make tire assay more sensitive, all tubes, including non specific binding
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(NSBs) and maximum binding (Bos) were acetylated, to make the cold cAMP
resemble the succinylated cAMP-125I-tyrosine methyl ester label (Cailla et al, 1973).
Acetylation was performed using 2.7ml triethylamine and 1.0ml acetic anhydride
made freshly prior to use of which 5/xl was added to each tube. Tubes were vortexed
and left to stand for at least 1 hour.
b) Standard curve:
The standard curve was constructed using anhydrous cAMP made up in a range of
concentrations in ethanol, evaporated under nitrogen and reconstituted in 200/xl assay
buffer. The range was lOfmol to 2500fmol cAMP/tube.
c) Assay procedure:
100/xl antiserum raised against a conjugate of human serum albumin and succinyl
cAMP (MS/1 or MS/3; Steiner et al, 1972), diluted 1:20,000 in 0.3% bovine gamma
globulin in PBS was added to all tubes in duplicate except total counts (TCs) and
NSBs. NSBs received 100/d 0.3% bovine gamma globulin in PBS instead of
antiserum.
All tubes then received lOO/id cAMP label, c 30,000cpm in PBS (iodination was by
the chloramine T method). TCs were covered with parafilm. All tubes were vortexed
and incubated overnight at 4°C. Free and bound label were separated using 1.6ml
16% polyethylene glycol 6000 (made up in distilled water). Tubes were centrifuged at
2000rpm for 30min at 4°C and the supernatant discarded. Radioactivity of die
remaining pellets was counted using a Nuclear Enterprises 1600 multihead gamma





Virgin female untreated Sprague Dawley rats were used from tire same batch and
immediately before those in 2b.. The mean ± SEM body weight of these rats was
242.7 ±4.6g(n= 10).
Experiment 2b
Virgin female Sprague Dawley rats were implanted under ether anaesthesia with an
intracerebroventricular cannula, connected via polythene tubing to a subcutaneous
osmotic minipump to deliver morphine as described in detail in Giapter 1, Methods
section. These rats were weighed daily to check their well-being and rectal
temperature was recorded daily to check that the morphine infusion system was
operating since body temperature is increased by i.c.v. morphine infusion. Mean body
weight (± SEM) of these rats was 253.7 ± 7.4g (n=6) on the day of implantation of tire
i.c.v. cannula and 258.3 ± 6.8g (n=6) on the day they were killed for collection of
SON.
4.2.4.2. Preparation of tissue
Tissue was collected and prepared for incubation as described in 4.2.1.2. in all
respects apart from tissue taken from 5-day i.c.v. morphine-infused rats which was
sectioned in Yamamoto's solution containing morphine (10~5M).
4.2.4.3. Superfusion apparatus
The apparatus used for this series of experiments was identical to that described in
4.2.1.3. and is shown in Figure 4.2.1.4..
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4.2.4.4. Superfusion protocol
All tissues were left for 90min to equilibrate in the chamber during which time drey
were superfused with Yamamoto's medium containing bacitracin (2.8mg/100ml;
Sigma Chemical Co.), but without IBMX (tissue derived from morphine-naive rats) or
with Yamamoto's solution, without IBMX but with added morphine, 10~5M (tissue
derived from 5-day i.c.v. morphine-infused group). Superfusate was collected at
lOmin intervals into tared 1.5ml Eppendorf tubes. Drugs to be acutely added were
included after the 30min control superfusate collection period and two superfusate
samples collected during superfusion with drug-containing medium.
2a) Acute and chronic effects of morphine on cAMP formation and OT/AVP
release
The chamber containing fragments of one SON (left or right, randomnly selected)
from each rat was superfused with medium as detailed above, containing morphine
(10"5M) throughout when tissue was derived from a chronic i.c.v. morphine-infused
rat. Three groups made up this series of experiments and they are listed below
together with the question they were designed to address:
i. CONTROL GROUP I:
'What are the basal levels of cAMPformation and OT/A VP release in SON?'
tissue from morphine-naive rats
no drugs in vitro
ii. CONTROL GROUP II:
'What are the acute effects of morphine on these basal levels of hormone and
second messenger production in normal SON?'
tissue from morphine-naive rats
morphine (10~4M) in vitro for test 30min
iii. I.C.V. MORPHINE-INFUSED 'CONTROL' GROUP I:
'What are the effects ofchronic morphine on cAMPformation and OT/A VP release
in SON?'
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tissue from 5-day i.c.v. morphine-infused rats
morphine (10"5M) throughout in vitro
Superfusate was changed after the first three collection periods (i.e. 30min) to
Yamamoto's medium containing morphine 10~4M (intended to maximize any acute
effect of morphine) for control group II.
2b) Effect of acute naloxone on cAMP formation and OT/AVP release in SON
taken from morphine-naive and chronic i.c.v. morphine-infused rats.
For tissue from these rats, the superfusate always contained 10"5M morphine; (this
concentration is similar to that found in the hypothalamus in vivo following i.c.v.
infusion of morphine for 5 days (Rayner et al, 1988)), but no IBMX, as described
above. The chamber containing fragments of SON (left or right, randomly selected)
from each rat was superfused with this medium until the control 30min had passed,
when for test chambers, the superfusate was changed to medium containing naloxone
10~5M as well as 10"5M morphine and two further superfusate samples collected.
So, two groups made up this series of experiments and they are listed below
together with the question they were designed to address:
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in. I.C.V. MORPHINE-INFUSED 'CONTROL' GROUP I:
'What are the effects ofchronic morphine on cAMP formation and OT/A VP release
in SON?'
tissue from chronic i.c.v. morphine-infused rats
morphine (10"5M) throughout in vitro
iv. I.C.V. MORPHINE-INFUSED / ACUTE NALOXONE-TREATED GROUP
'What are the acute effects ofnaloxone on cAMP formation and OT/A VP release in
SON tolerant to morphine after chronic i.c.v. infusion?'
tissue from 5-day i.c.v. morphine-infused rats
morphine (10"5M) throughout in vitro
naloxone (10"5M) in vitro for test 30min
Group iii. serves as a test group for experiment 2a and a control group for
experiment 2b and there were 4 groups in total studied in experiment 2. Tissue blank
channels were included in which chambers were superfused with test media in the
absence of SON to check for cross reactivity of drugs in the radioimmunoassays.
4.2.4.5. Treatment of superfusates
Superfusates were treated as described in 4.2.1.6. and some superfusate was
retained for cAMP radioimmunoassay.
4.2.4.6. Treatment of tissues
Tissues were treated exactly as described in 4.2.1.7. and tissue content of cAMP
was measured by specific radioimmunoassay.
4.2.5. Radioimmunoassay for OT and AVP
Radioimmunoassay of OT and AVP was exactly as described in 4.2.2..
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4.3. Results
4.3.1. Experiment 1: cAMP formation in SON taken from morphine-naive rats:
effects of sunerfusion with morphine, naloxone and VIP.
cAMP immunoreactivity was detectable in tissue fragments from all treatment
groups. The inclusion of the phosphodiesterase inhibitor IBMX in the superfusate of
the second control group and all subsequent treatment groups, increased cAMP
content measured under control conditions. Total cAMP was increased significantly
(P=0.03, Wilcoxon test for independent samples) upon inclusion of IBMX in the
superfusate but cAMP concentration was not significantly different (Wilcoxon test for
independent samples) to that hi the first control group (without IBMX). Total cAMP
increased to 169.8% from 416.1 ± 124.8 to 706.4 ± 98.0 fmol/SON and concentration
of cAMP to 130.9% of the value in the absence of IBMX from 464.1 ±216.3 to 607.5
± 131.6 fmol/mg tissue (not significantly different, Wilcoxon test for independent
samples).
Addition of morphine (10 5M) to the superfusate had no effect on cAMP formation
in the tissue. Total content was 792.4 ± 98.0 fmol and concentration 784.7 ± 200.4
fmol/mg neither of which was significantly higher than control values (P=0.56 for
both comparisons, Wilcoxon test for independent samples). This result agrees with
that found in experiment 2 where IBMX was not included in the superfusate: acute
exposure to morphine does not have any effect on formation of cAMP in the SON
under these conditions.
Superfusion with naloxone alone (10~6M) resulted in a slight rise in the content and
concentration of cAMP to 1025.0 ± 113.3 fmol and 847.6 ± 101.7 fmol/mg SON but
in neither case was the increase significantly beyond that of the control group:
naloxone alone had no effect on the formation of cAMP in morphine-naive tissue.
Predictably, the addition of morphine and naloxone simultaneously to the
superfusing medium had no effect on cAMP production.
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In contrast to the negative results thus far obtained, VIP caused a massive increase
in cAMP formation in terms of content and concentration. Total cAMP was 4849 ±
954.8 frnol and the concentration of cAMP was 3942 ± 816.1 fmol/mg SON, increases
to 686.3% and 649.0% control values. These two measures differed considerably
from control (P = 0.008 and P = 0.012 respectively, Wilcoxon test for independent
samples). The stimulation of cAMP production was not attenuated by the concurrent
superfusion of morphine (10 5M) and this treatment also resulted in cAMP formation
at a level greater than control at 5727 ± 1261 fmol and 5999 ± 1471 fmol/mg
respectively, 810.8 and 987.6% control values. This was different from control in
both cases (P = 0.002 and P = 0.002 respectively, Wilcoxon test for independent
samples) but not from that of VIP alone.
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Table 4.3.1.1. Experiment 1: cAMP-like immunoreactivity in SON taken from
morphine-naive rats; effects of superfusion with morphine (10~5M), naloxone (106M)
and VIP (106M).
Tissue weight Total cAMP cAMP/mg tissue
Treatment group (mean±SEM; (mean±SEM; (mean±SEM;
mg) fmol) fmol/mg)
a) control (n=6)
No drugs 0.97 416.07 464.10
(+)bacitracin ±0.14 ± 124.76 ± 216.29
(-)IBMX
b) control (n=8)
No drugs 0.86 706.39 607.48
(+)bacitracin ±0.11 ± 97.96 ± 131.63
(+)IBMX
c) (n=6)
(+)morphine 10"^M 0.84 792.44 784.68
(+)bacitracin ±0.12 ± 106.79 ± 200.37
(+)IBMX
d) (n=6)
(+)naloxone 10"^M 1.00 1024.97 847.64
(+)bacitracin ±0.17 ± 113.26 ± 101.68
(+)IBMX
e) (n=6)
(+)morphine 10"^M 0.87 815.91 778.24




(+)VIP 10-6M 0.80 4848.96 3942.29
(+)bacitracin ±0.08 ± 954.81 ± 816.13
(+)IBMX
g) (n=6)
(+)VIP 10'6M 1.00 5727.22 5999.49
(+)morphine 10"^M ±0.11 ± 1260.69 ± 1471.36
(+)bacitracin
(+)IBMX
Table 4.3.1.1. cAMP content and concentration are expressed as mean values ±
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standard error of the mean, group size, n. There was no difference from control hi the
groups exposed to opiate and/or opiate antagonist (Kruskal-Wallis) but the tissues
superfused with VIP (10 6M) responded with a dramatic increase in tissue cAMP
content and concentration (P=0.008 and P=0.012 respectively, Wilcoxon test for
independent smples). Likewise, those tissues superfused with VIP (106M) and
morphine (10"5M) simultaneously also responded with a clear increase in cAMP
content and concentration (P=0.002 and P=0.002 respectively, Wilcoxon test for
independent samples). All tissues received bacitracin. IBMX was included where
stated.
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KNNN cAMP content of SON
















Figure 4.3.1.2. Experiment 1: cAMP-like immunoreactivity in SON taken from
morphine-naive rats; effects of superfusion with morphine (MOR; 10 5M), naloxone
(NAL; 10 6M) and VIP (10 6M).
Data are derived from the previous table (Table 4.3.1.1.). Horizontal axis:
treatment groups. Left vertical axis: cAMP content of SON (pmol; diagonal shading).
Right vertical axis: cAMP concentration in SON (pmol/mg wet tissue; crosshatched
shading).
SON were equilibrated in drug-free modified Yamamoto's solution for 90min
including a 30min control period and were superfused with drug(s) diluted in the same
solution as listed, for the following 30min (morphine 10"5M, naloxone 10"6M and VIP
106M). Values represent the mean cAMP-like immunoreactivity present in the SON
at the end of the protocol, when the tissue was removed from the chamber and
collected for homogenisation and extraction of cAMP. Values are expressed both in
terms of total content and as concentration of cAMP calculated from tissue wet
weight.
There was no difference from control in the groups exposed to opiate and/or opiate
antagonist (Kruskal-Wallis) but the tissues superfused with VIP responded with a
dramatic increase in tissue cAMP content and concentration (P=0.008 and P=0.012
respectively, Wilcoxon test for independent samples). Likewise, those tissues
superfused with VIP and morphine simultaneously also responded with a clear
increase in cAMP content and concentration (P=0.002 and P=0.002 respectively,
Wilcoxon test for independent samples). All tissues received bacitracin. IBMX was
included where stated.
155
4.3.2. Experiment 1: OT/AVP release from SON taken from morphine-naive rats:
effects of superfusion with morphine , naloxone and VIP.
Oxytocin was not reliably detected in superfusates.
Arginine vasopressin (AVP) was detected in all samples. AVP concentration in the
absence and presence of IBMX with no drug treatment was 63.4 ± 19.3 and 41.8 ±
12.4 pg/30 min respectively. So, IBMX appears to have no effect on the release of
AVP under these conditions.
Looking at these two control groups, there was a steady decline in AVP release
with time. The total AVP released during the second 30 mins was 66.4 and 63.7% of
that in the first 30mins in the absence and presence of IBMX. This fall in AVP output
was reflected in the other treatment groups and in none of them did AVP release in the
second 30mins, ie. in the presence of the treatment, reach 100% that in the first
30mins.
To obtain a more accurate measure of the profile of AVP release, a comparison was
made of release over the first 30 mins and over the final 20 mins. Sample 4 was
thought to be possibly a misleading component of the release of AVP in the second 30
mins due to the time lag for the drug solution to reach the chamber and to then
equilibrate. So, the mean of the first three values and the mean of values 5 and 6 were
compared. The index generated in this way also reflects the trend with time of a fall in
output of AVP. None of the treatments resulted in deviation from the control index.
So, in terms of AVP release, morphine 10"5M alone, naloxone 10"6M alone or both
simultaneously had no effect on the release of AVP from vasopressin-secreting cells in
the SON in vitro. VIP, which had a dramatic effect on tissue content of cAMP had no
effect on AVP release in the nucleus (for summary, see Table 4.3.2.1.).
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Table 4.3.2.1. Experiment 1: AVP-like immunoreactivity in SON taken from
morphine-naive rats: effects of superfusion with morphine (10~5M), naloxone (10 6M)
and VIP (106M).
Treatment Total 1+2+3 Mean 1+2+3 Mean 5+6 Mean 5+6/
group (pg/30min) (pg/lOmin) (pg/lOmin) mean 1+2+3
(%)
a) control
no drugs 63.4 21.2 11.8 58.0
(+)bacitracin ± 19.3 ± 6.4 ±4.7 ± 12.0
(-)IBMX (6) (6) (6) (6)
b) control
No drugs 41.8 13.9 11.36 60.8
(+)bacitracin ± 12.4 ±4.1 ±3.8 ± 15.8
(+)IBMX (9) (9) (8) (7)
! c)
(+)morphine 109.0 36.6 23.0 63.0
105M ± 28.0 ±9.3 ±9.3 ± 11.9
(+)bacitracin (8) (8) (8) (8)
(+)IBMX
d) (+)naloxone
106M 104.3 34.8 9.6 48.2
(+)bacitracin ±43.7 ± 14.6 ± 3.9 ± 23.8
(+)IBMX (6) (6) (5) (5)
e)(+)morphine
105M 114.6 38.2 23.0 72.4
; (+)naloxone ± 44.3 ± 14.6 ±6.8 ±20.8




6M 59.4 19.8 14.6 66.7
(+)bacitracin ±26.2 ± 8.7 ±7.2 ± 12.6
(+)IBMX (5) (5) (5) (5)
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g) (+)VIP
10'6M 96.9 32.3 18.3 69.3
(+)morphine ± 19.8 ±6.6 ±2.9 ± 13.5
10"5M (6) (6) (6) (6)
(+)bacitracin
(+)IBMX
Table 4.3.2.1. The sum of the individual values recorded for each SON (data not
shown) for samples 1,2 and 3 was calculated and the mean of these totals for each
group expressed in the first column of figures as Total 1+2+3 (pg/30min). This gives
a grand total of AVP release during the control period. Second, the mean of samples
1,2 and 3 for individual SON was calculated and these then used to to calculate the
mean release of AVP during an average lOmin collection period for any one group.
These data are expressed in the second column as Mean 1+2+3 (pg/lOmin). Third, the
last procedure was applied to samples 4,5 and 6 to derive the data expressed in the
third column (pg/lOmin). Lastly, an index of release in the treatment period as
compared with the control period was calculated from the individual data sets
contributing to columns 2 and 3 (data not shown) and was expressed in the fourth
column as a percentage. This is meant to quantify any change in AVP release that
follows drug superfusion. There was no significant difference in AVP release
between treatment groups and control (Kruskal-Wallis). All groups received
























Figure 4.3.2.2. Experiment 1: AVP-like immunoreactivity in SON taken from
morphine-naive rats: effects of superfusion with morphine (MOR; 105M), naloxone
(NAL; 10"6M) and VIP (10 6M).
Data are derived from Table 4.3.2.1.. Horizontal axis: treatment groups. Vertical
axis: postdrug/predrug AVP release, mean percentage ± standard error of the mean
SEM). The first 30min (sample periods 1, 2 and 3) was taken as die control period to
assess basal release with any trend and during diis period. Tissues were superfused
with modified Yamamoto's solution alone and the control group went on to be
superfused with drug-free modified Yamamoto's solution. The remaining groups
were superfused for the last 30min widi morphine (10"5M), naloxone (106M) or VIP
(10 6M) and for all groups, the index of AVP release produced by comparison of diese
two periods as listed in Table 4.3.2.1. was plotted. There was no significant difference
in AVP release between treatment groups and control (Kruskal-Wallis). All groups
received bacitracin. IBMX was included where stated.
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4.3.3. Experiment 2: cAMP formation in the SON: effects of acute and chronic
morphine
4.3.3.1. Experiment 2a: effects of acute morphine (10"4M) on cAMP formation in
SON from normal rats
cAMP was not consistently detectable in the superfiisates.
In the tissue fragments superfused only with normal medium, mean (±SEM) cAMP
content was 12.2 ±1.7 pmol (n=9) and in the tissue superfused with 1CHM morphine,
14.0 ± 2.35 pmol (n=9), not significantly different (Table 4.3.3.3. and Figure 4.3.3.4.).
There was no significant effect of morphine on tissue concentration of cAMP; in the
control group this was 7.7 ±1.3 pmol/mg tissue (n=9) and in the morphine superfused
group 9.6 ± 1.2 pmol/mg tissue (n=8). In the control group the mean tissue sample
weight was 1.66 ± 0.15mg and in the morphine group, 1.55 ± 0.14mg (see Table
4.3.3.3.).
4.3.3.2. Experiment 2b: Effects of naloxone (10 5M) on cAMP formation in SON
from i.c.v. morphine infused rats
In the tissue fragments superfused with morphine (10"5M)-containing medium only,
the mean ± SEM cAMP content was 13.45 ± 1.6 pmol (n = 6) and in the tissue
superfused with naloxone-containing medium, the mean content was 15.5 ± 2.50 pmol
(n = 6; not significantly different, Kruskal-Wallis). Similarly, there were no
differences in the tissue concentrations of cAMP: these were 11.2± 1.8 pmol/mg in
the control group and 14.9 ± 2.5 pmol/mg in the naloxone-treated group. The mean
tissue weight in the control group was 1.23 ± 0.05mg and in the naloxone-treated
group was 1.1 ± 0.1 lmg. (see Table 4.3.3.3.). The lower weights in this experiment
compared with the first probably reflects more accurate trimming of the optic chiasm.
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Table 4.3.3.3 Experiment 2: cAMP-like immunoreactivity in SON taken from
morphine-naive and chronic i.c.v. morphine-treated rats; effects of superfusion with
morphine (104M/10"5M) and/or naloxone (10"5M).













































Table 4.3.3.3. Group size (n) is indicated with each group heading in parentheses.
cAMP content and concentration are expressed as mean values ± standard error of the














KSSM cAMP content in SON
































Figure 4.3.3.4. Experiment 2: cAMP-like immunoreactivity in SON taken from
morphine-naive and chronic i.c.v. morphine-treated rats; effects of superfusion with
morphine (MOR; 10-4M/10-5M) and/or naloxone (NAL; 10-5M).
Figure 4.3.3.4. Horizontal axis: treatment groups. Left vertical axis: cAMP
content of SON (pmol; diagonal shading). Right vertical axis: cAMP concentration in
SON (pmol/mg wet tissue; crosshatched shading). Treatment groups were CON:
control group I, CON MOR: control group II, ICV MOR MOR: i.c.v. morphine-
infused 'control' group I and ICV MOR MOR NAL: i.c.v. morphine-infused / acute
naloxone-treated group (see Methods Section 4.2.4.4.).
SON were equilibrated in drug-free modified Yamamoto's solution for 90min
including a 30min control period and were superfused with drug(s) diluted in the
same solution, for the following 20min (morphine, 10 4M for tissue taken from
morphine naive rats or 10 5M for tissue taken from chronic morphine treated rats;
naloxone, 105M). Values represent the mean cAMP-like immunoreactivity present in
SON at the end of the protocol, when the tissue was removed from the chamber and
collected for homogenisation and extraction of cAMP. Values are expressed both in
terms of total content and as concentration of cAMP calculated from tissue wet
weight. In no case was there a statistically significant difference between groups
(Kruskal-Wallis).
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4.3.4. Experiment 2: OT/AVP release from SON taken from morphine-naive and
chronic morphine-treated rats: effects of superfusion with morphine and/or naloxone
OT was not consistently detectable in the superfusate.
There was a trend in AVP release with time in this preparation. The release over
the first 30 mins exceeded that in the following 20 mins as indicated by the control
group values: 2.78 ± 0.76 and 1.15 ± 0.63 pg/lOmin (mean ± SEM) for the pre- and
post-treatment periods, a post-/pre-treatment index of 82.41%. The two lOmin
samples post-treatment were combined for comparison in this study with pre-
treatment values to produce the index. As an early response of cAMP was expected,
the two samples immediately after drug treatment commenced were taken for both
cAMP and OT/AVP radioimmunoassay.
Comparison of AVP release between the groups revealed significant differences
(P=0.03, Kruskal-Wallis). Superfusion with morphine at 10~4M resulted in
facilitation of AVP release in tissue taken from virgin morphine-naive rats. The index
of post-/pre-treatment mean concentration of AVP was 205.5% and this was
significantly different from control (P=0.04, Wilcoxon test for independent samples).
So acute morphine treatment increased AVP output in SON magnocellular neurones in
vitro (Table 4.3.4.1. and Figure 4.3.4.2.).
In contrast, SON taken from chronic morphine-treated rats did not show an
increase in AVP release with time. There was no discernible change in the post-/pre-
treatment index (62.0%), which was similar to control. Interestingly, the addition of
naloxone along with acute morphine to the chronic morphine-treated preparation did
not have any effect on AVP output which was similar to both untreated control and to
the chronic morphine-treated tissue superfused with morphine (see Tables 4.3.4.1. and
Figure 4.3.4.2.).
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Table 4.3.4.1. Experiment 2: AVP-like immunoreactivity in superfusate of SON
taken from morphine-naive and chronic morphine-treated rats: effects of supervision
with morphine (1Q-4M/105M) and/or naloxone (1Q-SM).









a) control 7.72 2.78 1.15 82.41
No drugs in vitro ±2.23 ±0.76 ±0.63 ± 49.61
(-)IBMX (8) (8) (8) (8)
b) control 6.64 2.31 3.15 205.5
(+)morphine 10"4M ± 1.74 ±0.59 ±0.37 ± 44.70
(-)IBMX (11) (11) (11) (10)
c) i.c.v. morphine 12.98 4.33 2.00 62.02
(+)morphine 105M ±2.54 ±0.85 ±0.56 ± 32.50

















Table 4.3.4.1. The sum of the individual values recorded for each SON (data not
shown) for samples 1, 2 and 3 was calculated and the mean of these totals for each
group expressed in the first column of figures as Total 1+2+3 (pg/30min). This gives
a grand total of AVP release during the 30min control period. Secondly, the mean of
samples 1,2 and 3 for individual SON was calculated and these then used to calculate
the mean release of AVP during an average lOmin collection period for any one
group. These data are expressed in the second column as Mean 1+2+3 (pg/lOmin).
Thirdly, the last procedure was applied to samples 4 and 5 to derive the data expressed
in the third column (pg/lOmin). Lastly, an index of release in the treatment period as
compared with the control period was calculated from the individual data sets
contributing to columns 2 and 3 (data not shown) and was expressed in the fourth
column as a percentage. This is meant to quantify any change in AVP release that
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follows drug superfusion.
The groups differed significantly (P=0.03, Kruskal-Wallis). Superfusion with
morphine (10 4M) resulted in an increase in the release of AVP. Comparison of mean






























Figure 4.3.4.2. Experiment 2: AVP-like immunoreactivity in superfusate of SON
taken from morphine-naive and chronic morphine-treated rats: effects of acute
superfusion with morphine (MOR; 10~4M/lO5M) and/or naloxone (NAL; 10"5M).
Figure 4.3.4.2. Horizontal axis: treatment groups. Vertical axis: post-drug/pre-drug
AVP release, mean percentage ± standard error of the mean. Treatment groups were
CON: control group I, CON MOR: control group II, ICV MOR MOR: i.c.v.
morphine-infused 'control' group I and ICV MOR MOR NAL: i.c.v. morphine-
infused / acute naloxone-treated group (see Methods Section 4.2.4.4.).
The first 30min (sample periods 1, 2 and 3) was taken as the control period to assess
basal release and during this period tissues were superfused with modified
Yamamoto's solution alone and the control group went on to be superfused with drug-
free modified Yamamoto's solution. The remaining groups were superfused for the
last 20min with morphine (10 4M for tissue taken from morphine naive rats or kept in
10'5M morphine throughout, for tissue taken from chronic morphine treated rats)
and/or naloxone (10-5M) and for all groups the index of AVP release produced by
comparison of these two periods, as listed in Table 4.3.4.1. was plotted. Superfusion
with morphine (10 4M) resulted in an increase in the release of AVP (P=0.04,




The protocol used in Experiment 1 differs from that used in Experiment 2 in three
respects. The phosphodiesterase inhibitor IBMX (3-isobutyl, methyl xanthine) was
included in the superfusing medium in order to preserve cAMP formed and therefore
to amplify any changes due to drug treatment (Beavo et al, 1970). In Experiment 2
this was not done to limit die possible effects of accumulating cAMP itself on the
physiology of the neurones in the SON. However, although measurable at low
concentrations in the tissue, it proved impossible to detect cAMP under these
conditions in the superfusate (which reflects cAMP release during the experiment)
and there were no changes in tissue cAMP in Experiment 2. It was considered
necessary to include IBMX in the protocol for Experiment 1.
The second change was the addition of die peptidase inhibitor bacitracin. It was
excluded from Experiment 2 because of concern over general effects on a range of
peptides known to be present in die SON, thus possibly altering the basal status of the
neurosecretory cells. It is conceivable that the maintenance of higher than normal
concentrations of OT itself may by a positive feedback mechanism alter the dendritic
release of OT in the nucleus (Theodosis, 1985; Pow and Morris, 1989). Dynorphin
too might be present in abnormally high concentrations with the implications that has
for die control of OT-secreting neurones in the SON. To avoid diese possible
interactions dierefore, bacitracin was omitted from the protocol in Experiment 2. The
release of AVP was measurable but small in Experiment 2 but die release of OT was
not reliably measurable. It was important to limit die possible breakdown of AVP
and OT to make changes after drug treatment more pronounced, so bacitracin was
included in die superfusate for Experiment 1. Comparison of AVP release over the
first diirty minutes, in the absence of IBMX and hi the absence and presence of
bacitracin revealed that bacitracin certainly prevented die breakdown of basal AVP.
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Total AVP released in the 30min control period in Experiment 2 was 7.72 ± 2.23 pg
and in Experiment 1, 63.4 ± 19.3 pg, an increase of 721.2%. A similar rise in the
concentration of dynorphin cannot be ruled out but OT was again not measurable
above blank concentrations.
Third, the collection of a 50/fl aliquot from the superfusate sample each lOmins for
cAMP radioimmunoassay was not carried out for Experiment 1 and instead of
following cAMP release, terminal tissue content and concentration were measured.
All of the superfusate sample was therefore taken for OT and AVP
radioimmunoassay.
It is questionable whether cAMP in the superfusate, if it could be measured, is a
physiological measure of cAMP accumulation in the tissue. It would certainly be a
more dynamic reflection of cAMP formation than the one measurement obtained at
tire end of the experiment of tissue content. However, it probably is not normally
released by neurones and is presumably leaking from severed axons and somas in a
iron calcium-dependent way. Throughout the duration of the experiment one would
expect tire closing of cut processes to occur, thus restricting the leakage of cAMP from
tire neurones. The profile of cAMP 'release' would therefore not simply depend upon
equilibration of intracellular cAMP with the extracellular fluid, but would depend
upon tire extent and rate of closure of cut processes. Nevertheless, large changes in
intracellular cAMP should be reflected in the superfusate.
The difficulty in measurement of cAMP in the superfusate from Experiment 2
perhaps reflects rapid constriction of severed processes but measurement of the final
tissue content is an alternative guide to any drug-induced change having occurred.
4.4.2. SON cAMP content and concentration in response to acute and chronic
morphine exposure
cAMP formation is enhanced by a variety of neuropeptides including VIP which
has been shown previously to potently stimulate cAMP formation in the SON and
PVN in vitro (Redgate et al, 1986). Conversely, the opioids met- and leu-enkephalin
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and jS-endorphin inhibited the formation of cAMP under the same conditions (Redgate
et al, 1986). Agonists at the x-type opioid receptor do not stimulate adenylate cyclase
(AC) in guinea pig striatal membrane (De Montis et al, 1986). Unfortunately a study
using more receptor subtype selective agonists in the SON has not been done. Met-
enkephalin has a preference for the 5-type opioid receptor as does leu-enkephalin
(Kosterlitz, 1985) but the absence of the 5-opioid receptor subtype in the SON
(Mansour et al, 1987; Tempel and Zukin, 1987; Mansour et al, 1988; Sumner et al,
1990) and the extremely low affinity of these agonists for the x-opioid receptor
(Kosterlitz, 1985) suggests that the inhibition of cAMP in the SON was mediated by
the ju-opioid receptor subtype. Morphine has a preference for the fi-type opioid
receptor with negligible affinity for the x-type or 5-type opioid receptors (Kosterlitz,
1985). It was expected therefore that cAMP would be depressed with acute exposure
to morphine. In neither Experiment 1 nor Experiment 2 was this the case. Morphine
was completely without effect at moderate or high concentration.
cAMP has been implicated for some time in mediating the acute effects of opiates
and by extrapolation die cellular changes diat constitute tolerance and dependence
(Collier and Roy, 1974). These experiments on neuronal cell membranes have been
corroborated in cultured neuroblastoma x glioma cells, rich in opiate receptors (Klee
and Nirenberg, 1974), which respond to acute exposure to opiates with a decrease in
intracellular cAMP. During chronic opiate exposure AC activity returned to normal
and removal of opiates led to a dramatic increase in AC activity, well beyond control
levels (Sharma et al, 1975; Traber et al, 1975; Sharma et al, 1977.). The primary
effect of inhibition of AC is a fall in die intracellular concentration of cAMP. cAMP-
dependent protein kinase activity is thus reduced and many substrate proteins remain
unphosphorylated so affecting cellular metabolism and perhaps neuronal excitability.
In the chronic presence of opiates, the homeostatic response of the cell is presumably
to re-establish the 'normal' rate of production of cAMP and so AC activity is
enhanced. Upon withdrawal of the opiate, this hypertrophy of AC becomes
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inappropriate and is reflected in the withdrawal syndrome. Here then is a possible
cellular mechanism which could mirror the electrophysiological and behavioural
parameters indicative of opiate tolerance, dependence and withdrawal.
However, these results have proved difficult to replicate in the CNS neurones
known to have opiate receptors. Nestler and Tallman have suggested that this is partly
accounted for by the heterogeneous nature of cell groups studied, rendering any
change in AC difficult to detect (Nestler and Tallman, 1988). They looked instead at
the homogeneous grouping of noradrenergic neurones in the locus coeruleus (LC) and
studied die activity of cAMP-dependent protein kinase. Opiates inhibit the firing rate
of LC neurones via G-proteins and a role for cAMP has been supported (Aghajanian
and Wang, 1986) and questioned (North et al, 1987). LC neurones become tolerant to
and dependent upon chronic opiates in terms of firing rate (Andrade et al, 1983). The
study of Nestler and Tallman has shown an increase in cAMP-dependent protein
kinase in bodi die particulate and die soluble fraction of LC, not seen in odier brain
regions examined. As the acute responses of these neurones to opiates is inhibition of
AC (Duman et al, 1987) it is assumed that this would result in less cAMP and
consequently less activated cAMP-dependent protein kinase. Thus the increase in
cAMP-dependent protein kinase activity with chronic opiate may reflect an attempt to
overcome die shortage of activated protein kinase.
The modulation of cAMP-dependent protein kinase by opiates could be mediated
by /x- or k-receptors, which predominate in the LC. Evidence from cultured
neuroblastoma x glioma cells has implicated 5—receptors in die modulation of AC
suggesting that die mechanism could involve any opiate receptor subtype. Indeed, in
die 7315c pituitary tumour cell which has a population of exclusively ^—opiate
receptors, the p-selective agonist, Tyr-D-Ala-Gly-MePhe-Gly-ol (DAGO) inhibits
AC. In cells exposed chronically to morphine (5 hours) and then exposed to [D-Ala2-
D-Leu5]-enkephalin (DADLE) diought in this system to be acting dirough a fx—opioid
receptor, AC activity was no longer inhibited indicating the development of tolerance
170
(Puttfarcken et al, 1988).
So, chronic exposure to opiates has been shown to modulate the cAMP system in
some neurones.
hi the light of this evidence for a role for cAMP in the manifestation of opiate
induced tolerance, dependence and withdrawal, the inability to detect any change in
the tissue content of cAMP in response to acute and chronic exposure to morphine and
to acute superfusion with naloxone was perplexing, but indicates that cAMP need not
be involved in altered electrical excitability of SON neurones after opiate.
AVP causes the accumulation of cAMP in punched out SON from hypothalamic
slices (Abe et al, 1983) and cAMP is thus implicated in the transduction of the
neuronal effects of AVP in the SON. There are two types of AVP receptor, one of
which is independent of AC, the V1 receptor and the other which is linked to AC, the
V2 receptor. The two appear to exist on central neurones (Abe et al, 1983). So, the
content and concentration of cAMP in the SON in vitro might be influenced by the
tissue concentration of AVP which although it remained unchanged throughout
Experiment 1, was substantially raised during the superfusion of morphine in the
Experiment 2. The cAMP content of SON treated with morphine was not different
from control. If die effect of AVP is then to increase cAMP content in die SON (Abe
et al, 1983) and the acute effect of morphine is to lower tissue content of cAMP
(Puttfarcken et al, 1988), then the unexpected observation of no change against control
could be accounted for.
Alternatively, the difficulty in measuring cAMP release in this nucleus in both
series of experiments might be due to the heterogeneous cell population: OT- and
AVP-secreting neurones which behave quite differently electrophysiologically and
pharmacologically (Poulain and Wakerley, 1982). Others looking at heterogeneous
groups of cells in the central nervous system have encountered similar difficulty in
measuring cAMP (Satoh et al, 1976; Dafny et al, 1979). So it is perhaps optimistic to
expect to see a clear cut response in terms of tissue content of cAMP in this group of
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cells although cAMP might well play a pivotal role in mediating the effects of
morphine, both acute and chronic.
However, a third possibility is that morphine might not be negatively coupled to
AC in these cells and its effects on firing rate demonstrated here, might be produced
by a different mechanism, as yet undefined. It follows therefore that the excitation
seen in vivo when these neurones, once dependent upon morphine are withdrawn,
may not be attributed to a rise in cAMP consequent to the hypothesised hypertrophy of
AC. Another mechanism may be involved (see Chapters 3 and 5).
4.4.3. AVP and OT release
AVP release was increased in Experiment 2 in response to acute morphine (10 4M)
superfusion but was unchanged in response to naloxone in tissue derived from chronic
morphine-treated rats; AVP release was also unchanged throughout Experiment 1.
The withdrawal excitation of magnocellular neurones (and inhibition of some phasic,
putative vasopressin secreting neurones) seen in vivo (Bicknell et al, 1988a) is not
accompanied by a change hi AVP release after naloxone within the SON in vitro.
It is interesting to note that although the tissue content of cAMP was dramatically
increased with VIP there was no concomitant rise in AVP release. So, cAMP does not
appear to play an important role in AVP release under these conditions. Although
there is a reported accumulation of cAMP in response to AVP superfusion in punched
out brain sections (Abe et al, 1983) the significance of cAMP accumulation evoked by
other stimuli upon AVP release is obscure. Unfortunately, the relationship between
OT release and cAMP accumulation remains unexplored due to the difficulty in
measuring OT release in these experiments.
The increase in AVP release in response to morphine in Experiment 2 is unlikely to
be a direct effect on AVP-secreting neurones. Opiates hyperpolarise central neurones
(in locus coeruleus) directly at a somatic site (Pepper and Henderson, 1980) at the
dendrites (Williams et al, 1982) and at the terminals (Nakamura et al, 1982) and these
responses were consequent to activation of a ju-type opiate receptor (Williams and
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North, 1984) which activates a potassium conductance (Williams et al, 1982). Opiates
also inhibit hormone release from magnocellular neurosecretory neurones (Bicknell,
1985; Lincoln and Russell, 1986). There are however a variety of afferent inputs to
the AVP-secreting cells some of which release inhibitory neurotransmitters (eg.
GABA) which reduce AVP release. GABA is the major inhibitory input to these cells
(Van den Pol, 1985; Randle et al, 1986; Theodosis et al, 1986; Buijs et al, 1987;
Renaud, 1987; Sakaue et al, 1988) and electrophysiological investigation has revealed
the inhibitory effect of GABA on these neurones in vivo (Arnauld et al, 1983) and in
vitro (Randle et al, 1986). Presynaptic inhibition of this input by morphine would
explain the unexpected increase in AVP release upon acute morphine superfusion.
Agonists selective for the /x-type opiate receptor have been reported to act
presynaptically to inhibit tire activity of afferents to hypothalamic neurones (Loose
and Kelly, 1989; Nikolarakis et al, 1989), although no evidence is available as yet
concerning presynaptic opiate inhibition of a GABAergic input specifically in tire
hypothalalnrus. However, there is evidence from the dentate gyrus and hippocampus
CA1 region of the rat of opioid-mediated presynaptic inhibition of GABAergic
inhibitory interneurones (Siggins and Zieglgansberger, 1981; Neumaier et al, 1988;
Swearengen and Chavkin, 1989). So, this possibility is worth consideration.
The glia within the nucleus are also worthy of mention. They have a role in
controlling the extracellular concentration of potassium (Kuffler et al, 1984). Glial
cells in the posterior pituitary receive opioidergic synapses (Van Leeuwen, 1981) and
are drought to have opiate receptors (Lightman et al, 1983b). Under conditions of
increased hormone release they expose terminals of neurosecretory neurones and
increase the area of contact with the capillary network (Tweedle, 1983). It is
conceivable that morphine might act on the glial cells of the hypothalamic SON to
alter their buffering function and drus create a more excitable environment due to a
higher than basal extracellular concentration of potassium. Perhaps in a similar way to
pituicytes in the posterior pituitary, the glia in the SON have a more direct
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involvement than buffering the environment around the neurone: by plastic changes
they might impair or improve the access of afferents to the cell bodies in the SON.
The fact that this result was not repeated in Experiment 1 could be due to the
concentration difference for morphine; a 10-fold more concentrated solution was used
in Experiment 2.
Others have attempted to measure hormone release from magnocellular
neurosecretory neurones in vitro with varying degrees of success.
There is immunocytochemical evidence for the existence of axon collaterals from
rat PVN neurones (Cobbett et al, 1983). SON neurones also appear to project axon
collaterals into the region of the SON (Hatton et al, 1983). Although OT was known
to increase the electrical activity of spontaneously-active OT neurones when injected
intracerebroventricularly (Freund-Mercier and Richard, 1981) convincing
morphological evidence for a pathway for release of OT local to the magnocellular
nuclei was not available until 1985. An immunocytochemical study of OT and AVP
distribution around and within the supraoptic nucleus of the rat revealed OT-like
immunoreactivity not only on soma and dendrites, but also rarely on 'bouton-like'
profiles mostly located in the dorsal confines of the nucleus (Theodosis, 1985). The
profiles were not dendrites, judging by ultrastructural examination and contained
50nm diameter clear vesicles and occasionally dense-cored vesicles. Several of these
immunoreactive profiles made synaptic contact with soma or dendrites also
immunoreactive for OT. A more recent immunocytochemical study has demonstrated
the competence of all parts of the plasmalemma of magnocellular neurones including
dendrites and cell bodies in the release of OT and AVP within the nucleus (Pow and
Morris, 1989). This could constitute the anatomical basis for the facilitatory pathway
for OT regulation of its own release. So, AVP and OT are released within the SON.
However, only OT is effective in facilitating its own release: AVP has no effect on OT
release. AVP release is not modified by OT or AVP itself (Moos et al, 1984).
The above mentioned study also uncovered an interesting phenomenon: in
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measuring OT and AVP release from isolated supraoptic and paraventricular nuclei
Moos and coworkers showed that OT release was always substantially less than that of
AVP. This result was not unprecedented as Chapman and coworkers had shown that
in guinea pig SON, tissue content of AVP was 5-6 times greater than that of OT and
that basal release of AVP was 10-80 times greater than that of OT (Chapman et al,
1983). In a later report (Mason et al, 1986), rat hypothalamic slices containing SON
were sampled locally over the SON and a 50-fold difference in AVP vs. OT release
was found. Given that OT and AVP are present in equimolar amounts in
hypothalamic and pituitary stores in the rat, this was unexpected. The difference is
possibly accounted for by tire existence of OT in the nucleus in an incompletely
processed form compared to AVP (Mason et al, 1986).
The difficulty in measuring OT release in vitro from the SON in the experiments
described in this Chapter was not surprising in the light of the above findings. AVP
release under basal conditions was 41.8pg/30min. This is substantially lower (21.7%)
than that measured by Moos and coworkers using a similar protocol and SON hi vitro
from male rats: tire equivalent of 192.6pg/30nrin for one nucleus. It follows that the
more marginal release of OT reported by Moos and coworkers, 58.5pg/30nrin would
be measured at approximately 12pg/30nrin. In the event, OT inrmunoreactivity was
not detectable beyond that measured in blank medium samples. However, this did not
prevent the examination of the primary objective, the effect of various treatments on
the tissue content of cAMP.
These experiments have confirmed that AVP is released within the SON and that
its release can be modified by acute morphine exposure. The significance of this
finding is not clear.
There was no evidence for a connection between tire hyperexcitation observed in
SON OT neurones made tolerant to morphine and given naloxone and modulation of
cAMP. Indeed, there was no change in tissue content of cAMP after acute or chronic
morphine, even though it was greatly stimulated by VIP. The present data suggest that
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AC plays an insignificant role in the adaptive events occurring during the development
of opiate tolerance and dependence in OT neurones of the SON and is not involved
causally in the changes in electrical activity in these neurones during exposure to
morphine and naloxone. Indeed, the action of acute opiate upon firing rate is not
correlated to changes in intracellular cAMP concentration in locus coeruleus neurones
either (Karras and North, 1979), supporting this interpretation of die present results.
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CHAPTER 5
MEASUREMENT OF CHANGES IN OPIATE RECEPTOR DENSITY IN RAT SUPRAOPTIC
NUCLEUS AND MEDIAN PREOPTIC NUCLEUS AFTER CHRONIC MORPHINE TREATMENT:
A QUANTITATIVE AUTORADIOGRAPHIC STUDY.
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5.1. INTRODUCTION
Opioid receptors can be subdivided into three widely accepted categories, fj., 8 and
k. The existence of subtypes of receptor was postulated to explain paradoxical effects
of nalorphine in man (Martin, 1967). Opioid receptors have distinct distributions in
the brain (Mansour et al, 1988), different affinity for various opioid ligands both
endogenous and exogenous (Gilbert and Martin, 1976; Kosterlitz, 1985), different
post-receptor cellular effectors and effects (see Chapter 3), different acute functional
profiles (Redmond and Krystal, 1984) and different withdrawal syndromes (Redmond
and Krystal, 1984). Opioid receptors and endogenous ligands are present in or close to
die supraoptic nucleus (SON) where oxytocin (OT)-secreting neurones have dieir cell
bodies (Clark etal, 1986; Mansour et al, 1986; Tempel and Zukin, 1987; Mansour et
al, 1988; Sumner et al, 1990) and opioids are known to modulate both OT and
vasopressin secretion (Bicknell and Leng, 1982) although die evidence for a clear
interaction widi OT neurones bodi at die level of the cell bodies and at die terminals in
die posterior pituitary is more compelling than that for the vasopressin system
(Muhlethaler et al, 1980; Pittman et al, 1980; Bicknell and Leng, 1982; Amauld et
al, 1983; Wakerley et al, 1983; Zhao et al, 1988b; Leng and Russell, 1989; Inenaga
et al, 1990; Leng et al, 1990). Both morphine and the /c-opioid receptor agonist,
U50,488H (trans-(±)-3,4-dichloro-ALmediyl-./V-(2-[l-pyrrolidinyl]cyclohexyl)
benzeneacetamide, mediane sulphonate salt) acutely change the electrical activity of
OT neurones (Pittman et al, 1980; Wakerley et al,1983; Pumford et al, 1987; Russell
et al, 1989b; Inenaga et al, 1990; Leng et al, 1990) recorded both in vivo and in vitro
in the hypothalamic slice. Morphine, when given chronically by i.c.v. infusion causes
tolerance in mechanisms controlling the electrical activity of OT neurones and also die
secretion of OT into the peripheral blood (Bicknell et al, 1988a; Rayner et al, 1988;
Sumner et al, 1989; Leng et al, 1990.). The development of tolerance to chronic i.c.v.
morphine is always accompanied by dependence in the SON OT system and diis is
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manifested by the hyperexcitation of OT neurones and the hypersecretion of OT after
the opiate antagonist, naloxone (Bicknell et al, 1988a; Rayner et al, 1988). This
withdrawal response is partly mediated through the region anterior and ventral to the
third ventricle (see Chapter 6), the AV3V region which is composed of the median
preoptic nucleus (MPN), the organum vasculosum of the lamina terminalis (OVLT)
and connections from the subfornical organ (SFO). The AV3V region is important in
die maintenance of normal body fluid balance and its ablation impairs the normal
response to a hyperosmotic challenge (Johnson and Buggy, 1978; Brody and Johnson,
1980; Blackburn et al, 1987; Russell et al, 1988). The AV3V region projects to die
SON and contains axons coursing down to the SON from the SFO (Miselis, 1981;
Renaud et al, 1983; Lind et al, 1985; Swanson and Lind, 1986). Although OT
neurones in die SON have been shown to be osmosensitive in the absence of any
synaptic input they are only fully osmoresponsive if the input from the AV3V region
is intact (Russell et al, 1988). However, ablation of the AV3V region does not impair
the activity of OT neurones during other unrelated processess such as milk-ejection in
response to the suckling stimulus or parturition (Russell et al, 1988).
Morphine binds with a high relative affinity to the /n-type opioid receptor and is
thought to act almost exclusively at this site. In Chapter 2 of the Thesis the possibility
of tolerance to chronic i.c.v. morphine at the ^-opioid receptor resulting in
heterologous tolerance at the /c-opioid receptor was examined (Leng et al, 1990).
There was no evidence of heterologous tolerance in terms of the electrical activity of
OT neurones recorded in vivo.
Using agonist ligands which are highly receptor subtype-selective, to displace die
binding of the broad spectrum radioligand ([3H](-)bremazocine) at the /a- and 5-opioid
receptors, /c-opioid receptor binding in the SON was measured - this has not been
quantified to date. No displacers were used hi the MPN where, using die broad
spectrum radioligand, [3H]etorphine, the MPN was probed for opioid receptors
without attempting to distinguish subtypes. Opioid receptor binding has not been
179
localised to MPN in studies performed to date.
Using the same technique, the question of whether receptor density in SON or
MPN was influenced by chronic i.c.v. morphine infusion was investigated, as receptor
density changes might account at least in part for desensitisation after chronic opiate.
Additionally, whether the electrophysiological results described elsewhere in this
Thesis (Chapter 2), which indicate no cross-tolerance between the and /c-opioid
receptors in terms of the electrical activity of OT neurones (receptor sensitivity), were
borne out in terms of /c-receptor density in the SON was investigated. I have gone on
in the Discussion section to speculate on possible mechanisms of regulation of opioid
receptor density.




Brain sections were derived from two groups of rats: the control group was
composed of rats (n=6, mean ± SEM body weight=288.8 ± 8.7g) taken five days
before decapitation and, under ether anaesthesia, implanted with an i.c.v. infusion
assembly driven by a subcutaneously-implanted osmotic minipump (Alzet 2001)
containing sterile pyrogen-free distilled water. For 5 days the infusate was delivered
into a lateral cerebral ventricle at 1/zl/h.
The rats in the morphine-treated group (n=6, mean ± SEM body
weight=274.8±5.1g) were taken 5 days before decapitation and under ether
anaesthesia fitted with an i.c.v. infusion assembly, as above, but containing three
sequentially increasing concentrations of morphine sulphate separated by 1/xl air
bubbles: lOyrtg/ftl, 20/^g/fil and finally 50/xg//zl each delivered over a 40h period at
1/xl/h. (The details of this procedure are given in Chapter 1).
On the day of experiment rats prepared as above were decapitated, the brain
removed and blocked coronally, including tissue 1mm anterior to the optic chiasm
through to the posterior limit of the mammillary bodies. Blocks were immediately
frozen onto a pre-cooled layer of Tissue-Tek OCT compound (Miles Laboratories) on
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a cold cryostat chuck standing on dry ice. Blocks were stored in the freezer at -20 C
before sectioning was carried out again at -20°C by cryostat (Bright Instrument Co.
Ltd. Cambs., model FS/FAS/M). 10^m sections were thaw-mounted onto acid-
cleaned, chrome alum-gelatine-subbed slides. Four sections were taken from each rat,
containing SON and four containing MPN, for each incubation category. Mounted
sections were stored at -20°C for up to 3 weeks before the next stage, incubation.
5.2.2. Ligands
The broad spectrum radioligands which were to be displaced by receptor subtype-
selective ligands were [3H]etorphine (50Ci/mmol which is equivalent to
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1.85TBq/mmol, Amersham) and [3H](-)bremazocine (21.3Ci/mmol which is
equivalent to 0.79TBq/mmol, NEN). Highly receptor subtype-selective ligands were
used as competitive displacers of these two broad spectrum radioligands to create
conditions under which one receptor subtype could be isolated for measurement. For
displacement from the /i-receptor, Tyr-D-Ala-Gly-MePhe-NH(CH2)2OH, (DAGO,
Cambridge Research Biochemicals) and for displacement from the 5-receptor, ID-
Pen2^-Pen5]-enkephalin, (DPDPE, Sigma Chemical Co.). Naloxone hydrochloride
(Sigma Chemical Co.) was used to competitively antagonise all binding.
5.2.3. Incubation procedure
The combinations of radioligand and displacers is summarised in Table 5.2.4.4.
Total binding to opioid receptors was measured using a broad spectrum [3H]-ligand
(2nM) alone. Measurement of receptor subtypes was achieved using medium
containing two unlabelled receptor subtype selective displacer ligands (2/zM each)
together with the [3H]-ligand, in order to competitively displace the [3H]-ligand from
all but one of the receptor subtypes. The concentration of displacer was chosen after
pilot experiments revealed no further displacement of [3H]-ligand at concentrations
higher than 2pM.
Pilot experiments showed more binding by [3H](-)bremazocine than by
[3H]etorphine in brain sections incubated with DAGO and DPDPE. For this reason,
measurement of /c-receptor binding was performed using [3H](-)bremazocine as the
broad spectrum ligand rather than [3H]etorphine.
The details of this procedure for the use of [3H] ligands have been optimised by
others (Bunn et al, 1985). Preincubating and incubating media were made up in
double-distilled, deionised water. Pilot experiments compared tire effectiveness of the
preincubation over a range of time, 0 to 90min for two protocols, one using
[3H]etorphine and the other [3H](-)bremazocine as the broad spectrum radioligand.
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5.2.3.1. Preincubation using [3H]etorphine
[3H]etorphine was used as the radioligand to probe for opioid receptors in the MPN
and the following protocol was used (see Bunn et al, 1985). Sections were
preincubated for 15min at room temperature in 0.05M Tris-HCl buffer, pH 7.4,
containing 0.1M NaCl and 50/iM Gpp(NH)p (5'-guanylylimido-diphosphate; to
detach bound endogenous ligands). 40/d of preincubating solution was applied as a
puddle to each section which was completely immersed. Slides were kept in moist
chambers during the preincubation period after which the puddles of preincubating
medium were tapped off the slides and replaced with incubating medium containing
[3H]etorphine ± displacer. As we looked just for overall binding to opioid receptors
in MPN and did not attempt to identify the subtypes, the only displacer used was tire
opioid antagonist, naloxone. The incubation categories were then, 1. [3H]etorphine
alone (total opioid receptor binding), 2. [3H]etorphine plus naloxone (specific opioid
receptor binding) and 3. no [3H]etorphine or displacers (chemographic control). The
sections were than incubated for lh at room temperature after which the incubating
medium was tapped off the slides and the slides in racks gently immersed hi 4
consecutive ice-cold buffer washes (0.05M Tris-HCl, pH 7.4, containing 0.19M
sucrose) for lmin each wash. Finally, sections were rinsed in ice-cold double-
distilled, deionised water to remove salts and dried in air. Sections were then stored
dessicated in light-tight boxes until autoradiography, within the next 48h. Control and
treatment pairs were processed identically and simultaneously.
5.2.3.2. Preincubation using [3H](-)bremazocine
[3H](-)bremazocine was used as the radioligand to probe for K-opioid receptors in
the SON and the following protocol was used (see Brady and Herkenham, 1987).
Sections were preincubated for 15min at 0°C hi 0.015M potassium phosphate buffer,
pH 7.4, containing 0.15M NaCl and 0.1% BSA (bovine serum albumin). Each
section was immersed in a 40/zl puddle of the preincubating medium and slides kept in
a moist chamber during preincubation. After 30mtn, the puddles were tapped off the
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sections and replaced with the same volume of incubating medium, containing [3H](-
)bremazocine ± displacers. Because we were looking for specific binding to tire k-
subtype of opioid receptor there were 4 incubation categories: 1. [3H](-)bremazocine
alone (total opioid receptor binding), 2. [3H](-)bremazocine plus naloxone (specific
opioid receptor binding), 3. [3H](-)bremazocine plus DAGO and DPDPE (specific k-
opioid receptor binding) and 4. no [3H](-)bremazocine or displacers (chemographic
control). The sections were then incubated for 3h at 0°C after which the incubating
medium was tapped off the slides and the slides mounted into racks for immersion into
4 successive baths of ice-cold buffer wash (0.05M potassium phosphate buffer, pH
7.4, without any additives), lmin each wash. Finally sections were rinsed in ice-cold
double-distilled deionised water to remove salts and dried in air. Sections were stored
desiccated in light-tight boxes until autoradiography, within 48h. Control and
treatment pairs were processed together simultaneously.
5.2.4. Control incubations
5.2.4.1. Naloxone control
One set of control incubations contained naloxone hydrochloride (2piM) together
with [3H]ligand (2nM), to confirm the nature of the receptors detected as opioid
receptors. Naloxone at up tp 20/xM did not further reduce [3H]ligand binding in pilot
experiments.
5.2.4.2. Naloxone plus displacers control
A second control series of sections was incubated with [3H]ligand plus all 3
displacers to control for any possible unexpected interaction between naloxone and the
[3H]ligand other than competition for opioid binding sites. This configuration of
ligands reduced naloxone binding and was used to assess the degree of specific
binding to opioid receptors.
5.2.4.3. Chemographic control
A third group of control sections was incubated in an identical manner to test
sections but in the absence of [3H]ligand, to test for chemographic artifacts. Because
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clusters of silver grains can occur as the result of interaction between tissue
constituents, or chemical components of the incubation medium with the photographic
emulsion, thus resulting in very reproducible false positives, these controls are
essential.
Table 5.2.4.4. Incubation protocol
Alone + 2/dM No radioligand + 2p*M







[3H]etorphine + + + -
MPN
incubation code: E EN EC
+ 2nM
[3H] (-)bremazocine + + + +
SON
incubation code: B BN BC BK
5.2.5. Autoradiography
Sections were brought to room temperature and apposed to 'Hyperfilm'-3H
(Amersham) keeping slides from control/treatment pairs of rats, similarly incubated,
adjacent. A 5pun section of a tritium standard (3H-microscales, Amersham) was
placed on each sheet of 'Hyperfilm' . The sheets of film with attached slides were
then sandwiched between mirror-coated glass plates, held in place with adhesive tape,
enclosed in light-tight wrapping and left to expose at 0-4 °C in the dark.
The exposure period of 9 weeks was determined empirically to produce measurable
grain densities over tissue sections which were below saturation, in all positive
incubations.
After exposure, the films and slides were brought to room temperature and the
slides removed for later histological preparation. The films were developed at 18°C in
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Kodak D19 developer (5min), dip-rinsed in tap water, fixed in Ilford Hypam rapid
fixer (two changes, 5 min each; 1:4 fixer:tap water), rinsed for 30mm in running tap
water and dried in air.
The sections were fixed for lOmin in acetic acid: absolute ethanol: commercial
formalin (1:17:2 by volume), washed in running water for 5min, dehydrated through a
series of alcohol baths, 2-3min in each, placed in a xylene bath for lOmin and
rehydrated through alcohol baths in reverse. After a 5-10min wash in running water,
sections were stained for 15min in 1% Cresyl Fast Violet, washed, dehydrated, in
absolute alcohol, cleared in xylene and mounted in DPX.
5.2.6. Quantitative analysis of autoradiographs
Pieces of film corresponding to the apposed slide were cut out and attached to clean
microscope slides with adhesive tape. Autoradiographs were paired with the stained
sections and examined under a binocular dissecting microscope (Wild M3,
magnification xl6) to identify the SON and MPN.
The boundaries of the SON and MPN were outlined by scoring the photographic
emulsion with a fine needle under the dissecting microscope. Silver grain density was
then measured using a Joyce-Loebl /dVIagiscan image analysing computer with video
input from a Philips black and white Video 40 camera (with a Newvicon tube)
mounted on a Vickers M17 microscope. Microscope magnification was xlO
(objective) and xl.6 (intermediate lens); the video monitor scale factor was 1.1878/mi
per pixel. A rectangular counting frame (201.63 x 133.04/nm) was defined which was
smaller than the area of the average SON so that measurements could be selectively
taken over the dorsal SON and over the area of the MPN.
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5.2.6.1. Expression of results as mean grain density
Silver grain density was calculated as, total area of silver deposit / total area of the
counting frame. A non-tissue background count was made immediately after each
tissue count, over an immediately adjacent region of film and subtracted from the
tissue count. So, for each rat, mean grain density was determined for SON or MPN hi
each incubation category. On each sheet of film, 3 measurements were taken over the
standard strip and 3 background measurements taken at the same time from adjacent
film. The background counts were subtracted from the standard counts and these 3
values averaged to produce a mean standard grain density with which to compare the
tissue counts. The specific binding to opioid receptors was calclated by subtraction of
mean grain density over the corresponding naloxone sections, if they were
significantly above background (Student's paired t-test).
Comparison of mean grain densities, thus calculated for each incubation category,
was made between the i.c.v. vehicle-infused and i.c.v. morphine-infused rats by paired
t-test, as they had been processed in pairs throughout.
5.2.6.2. Expression of results as absolute values of specific [3H]ligand binding
(fmol [3H]ligand bound/mg tissue)
Mean grain density values (naloxone control counts not yet subtracted) were then
transformed into absolute values. Grain density was measured in triplicate over each
step of the standard scale, with backgounds subtracted as already described. A mean
standard curve of grain density vs. radioactivity could then be constructed. This was
expressed in terms of its brain-grey matter-tissue equivalent using calibration
information provided by Amersham together with the standard scales (calibrated by
Geary and Wooten for Amersham). The curve was described best by the power
regression function y=A x .tB
where, y=mean grain density of a given step on standard scale
,r=radioactivity, converted to the tissue equivalent value
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A=the intersect on the y axis and
B=the intersect on the x axis
of the plot of radioactivity vs. mean grain density for the steps of the standard scale
measured. The mean standard curve thus constructed for SON and MPN fitted to the
above power function where, y=0.27 x x0-23 r=0.97
where r=regression coefficient for the curve.
Tissue radioactivity values (nCi/mg of tissue, x), were then derived from the mean
grain densities (y), using die above formula and were then converted to fmol of
[3H]ligand bound per mg of tissue, by reference to the specific activity of [3H]ligand
(see earlier). Specific binding to opioid receptors was obtained by subtracting binding
remaining in die presence of naloxone at this stage. The film does not respond in a
linear way in terms of the development of silver grain deposits upon exposure to
radioactivity. Widi diis in mind, the mean grain densities in the experimental sections
and in the naloxone control sections were both transformed to absolute values, as
outlined above, before the subtraction of the naloxone control value to obtain specific
[3H]ligand binding in fmol per mg tissue. I.e.v. morphine and control group mean




Examples of autoradiographs obtained are displayed in Figure 5.3.1.3..
5.3.1.1. Mean grain density
Specific binding (naloxone-displaceable) was over 97% total binding in SON
tested with [3H]ligand alone. There was no significant difference between the i.c.v.
vehicle-treated and i.c.v. morphine-treated rats in terms of mean silver grain density
(corrected for non-specific binding) in the B category ([3H](-)bremazocine alone) or
in die BK category ([3H](-)bremazocine + DAGO + DPDPE) for SON, indicating no
change in the density of opioid receptors detected by [3H](-)bremazocine and more
precisely, /c-opioid receptors in the SON after chronic morphine treatment (see Table
5.3.3.).
5.3.1.2. Absolute density of [3H]ligand binding
There was no discemable difference in total [3H](-)bremazocine binding (total
opioid receptors) or in selective binding to /(-receptors expressed as frnol
[3H](-)bremazocine bound per mg tissue after chronic morphine. This outcome
mirrors that already seen in terms of mean grain density (see Table 5.3.3.).
5.3.2. Median preoptic nucleus
Examples of autoradiographs obtained are displayed in Figure 5.3.2.3..
There was a significant reduction of 31% in the mean silver grain density,
measured in die MPN after chronic morphine treatment, indicating a lower overall
density of opioid receptors in the MPN (see Table 5.3.3.).
5.3.2.1. Absolute density of [3H]ligand binding
[3H]etorphine binding was diminished by 77% expressed as fmol
[3H] (-)bremazocine bound per mg tissue (see Table 5.3.3.).
189
Table 5.3.3. Mean silver grain densities and absolute specific binding of [3H]ligand
(mean ±SEM) for SON and MPN in three incubation categories












SON B 0.32±0.02 0.27±0.03 n.s.d.
(125.7±35.0) (70.9±24.8)
BK 0.32±0.01 0.30±0.02 n.s.d.
(130.4±25.6) (95.5± 16.0)
MPN E 0.36±0.01 0.25±0.02 P<0.05
(76.2±9.8) (17.5±5.2)
Data are expressed as /xm2 of silver deposit per jum2 of field; corrected for non¬
specific binding; data in parentheses are specific [3H]ligand binding expressed as
fmol ligand bound per mg tissue; n.s.d., not statistically significant.
Figure 5.3.1.3.(overleaf) K-opiate receptor binding in the supraoptic nucleus
Autoradiographs a., b. and c. represent binding categories B (total [3H] (-)bremazocine
binding), BK ([3H] (-)bremazocine + displacers, DAGO and DPDPE) and BN
([3H] (-)bremazocine + naloxone) respectively. The images become less intense from
a. to c. due to the the progressive displacement of [3H] (-)bremazocine from /z- and 5-
opioid receptors by the displacers and in c., from all specific opiate receptor binding
by the opiate antagonist, naloxone. The SON lies between the solid triangles, at the
outer edge of the optic chiasm, which forms the ventral border of the image. The
density of die image over the SON is less than that produced in other brain regions







Figure 5.3.2.3. Opiate receptor binding labelled by FHIetorphine in MPN
Figure 5.3.2.3.a represents a typical autoradiograph depicting opiate receptor
binding labelled with the broad spectrum opiate agonist radioligand [3Hjetorphine.
The limits of die MPN and the optic chiasm have been scratched upon the
photographic emulsion, using die equivalent tissue section (b.) for guidance to enable
accurate measurement of grain density. The MPN lies medially, between the anterior
commisure in diis example.
Abbreviations: MPN: median preoptic nucleus; OC: optic chiasm; AC: anterior




Hyperfilm-3H is designed to detect /3-radiation from a tritium source primarily and
is designed without an anti-scratch layer over the film emulsion to permit the closest
apposition of tissue to film. Because /3-particles will scatter on passing through film
emulsion, Hyperfilm-3H is a single-coated film resulting in a shorter path length
travelled by the jS-particles and consequently less scattering. This results hi high
resolution detection of radioactivity. However, a balance needs to be found.
Although a thin section results in good resolution, variation in section thickness is
more of a problem than with thicker sections and as quantification of these data was
important, something by way of resolution was sacrificed for the sake of accuracy in
measurement. It is only radioactivity in tissue apposing the film to a depth of about
1.5/j.m that contributes to the formation of the latent image. Emission of radioactivity
from deeper within the section is likely to be absorbed within the tissue itself.
Although different components of the tissue will absorb radioactivity to different
degrees according to their densities, and thus will cause the development of an image
that reflects a distortion of the true quantity of radioactivity in the tissue. This does
not cause difficulties in these experiments however as like areas of tissue were
compared throughout the study and silver grain density was not measured at a high
enough resolution to have to apply compensating factors to account for differential
absorption of /3-emissions by cell structures.
Because Hyperfilm-3H is so sensitive to ionising radiations, it can also suffer
fogging during storage and exposure due to silver grain activation by natural
background radiation; cosmic rays, 7-emitters in air, building materials etc., exposure
to light or to exhausted darkroom chemicals. Although during exposure, the films
were protected with several layers of wrapping, one of which was aluminium, and
during darkroom procedures only recommended safe light sources were used, all
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environmental radiation sources could not be eliminated, such as 7- and X-radiation
both of which will penetrate aluminium. Thus some unavoidable background fogging
was detected on all films.
Temperature increases the development of fogging and the recommended
temperatures were followed during all procedures to reduce this potential problem.
Pressure was evenly applied to the sheets of film with slides mounted but whilst the
pressure applied should be great enough to bring the section and film close together
thus improving the definition of silver grain development and the accuracy of the
distribution of radioactivity, it should not be so great as to cause artefactual silver
grain activation due to excess pressure.
Transfer of static electricity to the film during handling can cause artefactual
activation of silver grain. Stresses in the film can cause distortions in the distribution
of silver grain, so the film should be handled with care. Finally, positive
chemography, interaction between the film and tissue constituents, can cause an
aggregation of silver grains.
All of the above result in positive artefacts, but there are also negative artefacts.
These include moisture either on the slides or on the skin coming into contact with die
film during exposure which can fade the latent image, as can negative chemography
by an oxidative chemical reaction.
These problem areas were kept in mind and eliminated as far as possible by the use
of careful technique and appropriate controls.
5.4.2. Quantification of results
There should be if not stoichometry, at least a proportionality between the amount
of radioactivity and die number of silver grains, in order that die autoradiographic
image can be quantified. The safest way to control for this is by the use of radioactive
standards of known activity against which to measure the tissue image. Any non-
linearity in die response of the emulsion, which can occur at either extreme is thus
taken into account. The present results were expressed bodi hi terms of mean gram
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density and after transformation, as absolute values of ligand bound per mg tissue.
Both suffer some interpretive problems. The non-linearity of the responsiveness of
the emulsion at the lower and upper extremes makes the direct use of mean grain
density as an expression of receptor density inevitably flawed. Because grain density
over the naloxone controls, which are so close to background, are subtracted from
grain density over sections with [3H] ligand ± displacer, there is the potential for
inaccuracy. This is why in transforming the data to absolute values, tissue mean grain
densities were only corrected for naloxone control after both had been transformed to
fmol ligand bound per mg tissue ensuring linearity in the relation between both
quantities and accuracy. On the other hand, the use of the formula found to best
describe the standard curve to transform mean grain densities to absolute values
introduces an element of extrapolation. It was thought prudent given these potential
pitfalls in the quantification of data from this sort of experiment to express the results
both as mean grain density, the direct measure, and as ligand fmol bound per mg
tissue, the extrapolated measure.
It is clear that whilst the proportions by which changes in receptor density are
different in magnitude as expressed in the two ways, the direction of the change is the
same (see MPN Results Section). I conclude therefore that the change in receptor
density in MPN after chronic morphine treatment is a real one.
Because the quantitative receptor autoradiographic techniques and principles being
applied here to an intact cell preparation were originally developed for use in isolated
membrane preparations, there are conditions encountered here with brain sections
which need to be taken into account when drawing conclusions from the data. These
interpretive problems have been raised already (Motulsky et al, 1985; Dashwood,
1987). Because of the need to standardise results between laboratories there has been
a trend to quantification of receptor binding in tissue sections in terms of fmol ligand
bound per mg protein, an expression already commonly used in ligand binding studies
in homogenates and similar to that used here. The first difficulty arises from die non-
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random distribution of white matter in brain sections as compared with an equivalent
homogenate, which will result in differential degrees of quenching of tritium
depending upon the brain region under study. The way used to control for this in
quantifying the present results was to use a brain homogenate-equivalent calibration
factor on all mean grain densities to convert them to absolute values. For a review of
technical procedures see Rogers, 1979 and Sumner, 1988.
5.4.3. Supraoptic nucleus
The results presented here reveal that there are /c-opioid receptors in the SON.
Other studies have identified receptors of the K-subtype in the SON (Mansour et al,
1986; Tempel and Zukin, 1987; Mansour et al, 1988) and dynorphin binding sites
(Clark et al, 1986) so these results are not without precedent but the amount of binding
measured in this study, 130.4 ± 25.6 in the control group and 95.5 ±16.0 fmol/mg
tissue in the morphine-treated group cannot be compared to measurements in other
studies as the only other quantitative autoradiographic studies in hypothalamus either
probed SON but did not report a value for absolute binding of a /c-selective ligand
(Clark et al, 1986) or did not specifically probe SON for opioid receptors (Tempel and
Zukin, 1987). The technique used is a relatively low resolution technique and because
the sections were apposed to the emulsion rather than coating the sections themselves
with photographic emulsion, there is no way of identifying the elements within the
SON to which silver grains were localised and it cannot be concluded therefore if the
receptors labelled in this study are on the supraoptic neurones themselves, on the
terminals of afferents in the SON or on the surrounding glial cells, the latter being tire
case in the posterior pituitary (Lightman et al, 1983a; Lightman et al, 1983b) where
opioid receptors are also found (Simantov and Snyder, 1977). Other studies have also
failed to address this question which might be best investigated by a higher resolution
method which allows tissue counter staining to identify oxytocinergic neurones at the
same time as measuring the distribution of silver grain over opioid receptors. One
such method would involve the use of a specific monoclonal antibody to the opioid
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receptor for light microscopic visualisation of opioid receptors with simultaneous
counterstaining with an antibody against OT to enable resolution of the cellular
localisation of the receptors. Opioid receptor distribution in rat brain sections has
been investigated using such an antibody and although the data could not be
quantified, the pattern was shown to be similar to that already demonstrated by
receptor autoradiography (Hassan et al, 1989). Although antibodies specifically
directed against the three subtypes of opioid receptor are not yet available, the
antibody used in the above study could distinguish between p.jh and x-opioid receptors.
Indeed, this was the first receptor autoradiographic study to report the existence of
/x/<5-opioid receptors in the paraventricular and supraoptic nuclei (Sumner et al, 1990).
This finding was not echoed in previous receptor autoradiography studies according to
Hassan and coworkers because of the low numbers of fx/8-opioid receptors in SON and
paraventricular nucleus and the relatively low sensitivity of autoradiography
compared with immunocytochemical techniques. This explanation puts into context
the relatively moderate autoradiographic image produced over the SON in this study
in comparison with much more dense patches in the caudate putamen for example (see
Figure 5.3.1.3.). Of course, most importantly, even from this moderate image it was
possible to discern a statistically significant change in optical density after chronic
morphine treatment. This change in optical density, corresponding to specific opiate
binding sites after chronic morphine treatment, was seen elsewhere in tissue sections
evaluated subjectively by Dr. Sumner (personal communication) and was not a feature
exclusively of the SON.
From the evidence from this study however, the location of x-receptors in the SON
can only be speculated upon. They might indeed be located on the OT neurones
themselves which would be the most simple scenario in terms of explaining opiate
effects on electrical activity of these neurones. Equally probable however is the
location of opioid receptors presynaptically on the terminals of interneurones in the
SON or upon the terminals of afferents to the SON. These two possibilities are not
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mutually exclusive as the possibility of both presynaptically-located and
postsynaptically-located opioid receptors has been raised elsewhere as a model helpful
in explaining biphasic opiate effects (See Chapter 2). Opioid receptors of the three
subtypes have been found in hypothalamus in a release study in hypothalamic slice.
The release of endogenous opioid peptides was measured in the presence of receptor
subtype-selective antagonists in the presence of tetrodotoxin to prevent axonal
transmission. One conclusion of the study was that the three subtypes of opioid
receptor are present in the hypothalamus and are located upon presynaptic terminals
(Nikolaris et al, 1989). This might be the case in the SON. Finally opioid receptors
might be located on the glia in the SON, the astrocytes. This would parallel what has
been shown in the posterior pituitary where the pituicytes are carriers of functional
opioid receptors (Lightman et al, 1983) which may partly mediate the inhibition of OT
release upon stimulation by appropriate opioid ligands.
The plasticity of opioid receptors in the SON was demonstrated in another aspect of
the present study (Sumner et al, 1990) when chronic morphine treatment was shown to
markedly reduce the density of /x-opioid receptors in the SON. This finding
demonstrates the responsiveness of this system to a chronic stimulus. But this is a
differential responsiveness because as described here the density of K-opioid receptors
is unaffected by chronic morphine treatment, i.e. there is homologous down-
regulation. From my own studies in which the possibility of cross-tolerance between
the /x-agonist morphine, given chronically and the /c-agonist, U50,488H, given acutely,
in terms of electrical activity in oxytocin (OT) neurones of the SON, I was unable to
find evidence of changes in /c-receptor sensitivity whilst demonstrating a marked
reduction in ^-receptor sensitivity (Leng et al, 1990; see also Chapter 2). So these
earlier studies support the implication arising here that although cellular adaptation
clearly occurs in response to chronic morphine exposure, it is restricted to the
population of /x-receptors both in terms of receptor density and function.
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5.4.4. Median preoptic nucleus
Because no attempt was made to identify the subtype(s) of opioid receptor in the
MPN which is subject to adaptive changes after chronic opiate, the result obtained in
SON must colour the interpretation of the down-regulation of opioid receptor clearly
evident here. It seems likely that the subtype affected by chronic morphine is the pc-
receptor but this could be investigated by the use of receptor subtype-selective
displacers in a similar study to unambiguously identify the receptors affected.
I have already alluded to the questions of interpretation which must be considered
when attempting to quantify such data as these. Where such a dramatic change in
receptor density apparently occurs it is worth reflecting on the following points of
controversy. Interpretation of radioligand binding studies often rests on the following
assumptions, 1) all the receptors are accessible to all ligands; 2) the binding properties
of the receptors do not change; 3) the number of receptors is constant 4) ligands are
not altered 4) the concentration of modulators of receptor function do not change;
and 6) the incubation reaches equilibrium' (from Motulsky et al, 1985). Although
these assumptions are acceptable when applied to antagonist ligands, used in isolated
membrane preparations, they do not necessarily hold true for agonist ligands used on
intact cells. Taking the first point, it is possible that incubation with agonist ligands
but not with antagonist ligands can cause a redistribution of cell surface receptors
(clustering) preventing access to the full complement. Secondly, receptor
conformation can be altered after interaction with ligand in a way which changes the
subsequent interactions of the same receptor with fresh ligand, in terms of receptor
binding studies this might mean a decreasing agonist binding affinity with time.
Thirdly, receptor numbers might change during the course of an experiment carried
out at physiological temperatures. The half-life of receptors ranges between hours and
days and thus there may be a significant degree of receptor removal or insertion during
a lengthy incubation protocol. The fifth point in Motulsky's list suggests that where
agonists are present which modulate the availability of GTP, the interaction between
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G-protein and receptor could be modified, consequently affecting the affinity of the
receptor for its ligand. In the present study it might mean that the 100 x excess of
displacers used to look at one particular receptor subtype could produce a change in
intracellular GTP which would affect the affinity of the receptor under study for its
ligand, thus reducing its apparent density. I would answer these points as they apply
to this study by pointing out that although not fixed, the tissue used was first of all
frozen on dry ice and was after sectioning and thaw mounting kept deep frozen for
some time before being incubated at 0-4°C for the SON study and at room
temperature for the MPN study. It was then exposed at 0-4 °C for 9 weeks after which
the autoradiographs were developed. So it seems unlikely that any of the above
processes could occur to any significant degree between the time the brains were taken
and the autoradiographs developed. Because such low temperatures were used
throughout I believe that the density of receptors measured in this study reflects
wholly changes in receptor manufacture/recycling and removal/phosphorylation (see
later for discussion of these mechanisms) and the changes seen in MPN represent a
physiological adaptive process after chronic morphine.
Opioid receptors have been reported in the hypothalamus (Mansour et al, 1986;
Clark et al, 1986; Mansour et al, 1987; Tempel and Zukin, 1987; Mansour et al,
1988; Sharif and Hughes, 1989) but not specifically in MPN which we report for the
first time (Sumner et al, 1990). The amount of [3H]etorphine binding in MPN before
and after chronic morphine treatment was 76.2 ± 9.8 and 17.5 ± 5.2 fmol/mg tissue. A
direct comparison between the present values and those obtained in other quantitative
autoradiographic studies cannot be made as MPN has not previously been probed for
opioid receptors. However, another structure in the AV3V region, the subfornical
organ (SFO) does contain opioid receptors, in order of relative density by receptor
autoradiography, k»^> d (Mansour et al, 1987). A more recent study quantitatively
analysed opioid receptor density in SFO (Sharif and Hughes, 1989) and found /ll-
opioid receptors in the SFO (195 amol/mm2) and x-opioid receptors in the SFO (2.5
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amol/mm2,10/xm sections), but again, MPN was not probed. SFO was probed using 4
anti-idiotypic antibodies for the 5-opioid receptor which was found qualitatively to be
labelled very strongly, both at the level of the cell membranes (although not usually
the synaptic membrane) and in cytoplasmic vesicles (Conrath and Cupo, 1989; see
later discussion on receptor internalisation). This study extends the finding of opioid
receptors in MPN by identifying circumstances under which the manufacture and/or
the removal of these receptors are affected.
Is there a physiological correlate of these data? Are there circumstances under
which endogenous opioids might be chronically elevated sufficiently to reproduce
these changes? The answer is not immediately forthcoming. I had referred in a
previous Chapter to changes in opioid tone possibly occurring during pregnancy in
order to produce a sudden and dramatic rise in OT release to aid expulsion of the
foetuses. Such a model would require a steady increase in opioid tone during
gestation which would be withdrawn precipitously at the time of parturition. In fact
opioid tone is high during parturition as revealed by naloxone, but OT plasma
concentration is still elevated compared to virgin rats (Bicknell et al, 1988b). It is
feasible that a prolonged increase in opioid tone in the MPN, similar to that earlier
suggested to occur in the SON, could result in a down-regulation of receptor numbers
and this could therefore be the physiological correlate of this finding. However, this
hypothesis is not supported by recent evidence obtained from rats at various stages of
pregnancy in which there was found to be no change in receptor density in the MPN at
days 16, 20 and 21 compared to virgin rats (although SON -receptor density is
decreased; personal communication, J.A. Russell/A. Douglas). So, receptor density
changes in MPN do not easily fit with pregnancy as a physiological correlate.
However, it could be that changes in receptor density are much more rapid than the
pregnancy protocols are capable of detecting leaving a question-mark over the
physiological significance of these observations (see later Discussion).
The presence of opioid receptors in the MPN and changes in MPN receptor density
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with chronic morphine agree with earlier electrophysiological results (see Chapter 6)
from which it was concluded that the development of tolerance and expression of
dependence, manifested by the withdrawal response after naloxone, are impaired by
the electrolytic ablation of the AV3V region, which includes MPN. Stimulation of the
AV3V region excites OT neurones (Russell et al, 1988) and its ablation removes a
tonic excitatory drive to OT cells, which are silenced (Russell et al, 1988). The AV3V
region is essential in maintaining the osmotic responsiveness of OT neurones which
are electrically excited by a fall in plasma osmolality and are slowed by a rise in
plasma osmolality but its integrity is not a required for the normal progress of
parturition and for milk-let down with suckling (Russell et al, 1988). So once again it
is difficult to put the observed reduction in opioid receptor density into the context of
the physiological changes that occur leading up to and during parturition. It remains
to be shown however whether there is a measurable change in one subtype of opioid
receptor which is masked by no change in the other subtypes of receptor, should they
be present. It must also be considered that the method of introducing morphine to
neurones of the MPN, adjacent to the 3V, might be somewhat crude in comparison
with likely levels of endogenous opioids in the region even after their elevation by a
physiological stimulus. Exogenous morphine concentration in the MPN might in fact
equate with a more pharmacological than physiological level of agonist at the opioid
receptors present in the MPN and might have induced a pharmacological response in
mechanisms sensitive to endogenous opioids including those controlling receptor
turnover. If this most pessimistic interpretation was true then the observed decrease in
opioid receptor density in the MPN would model morphine tolerance rather than a
physiological control mechanism.
Also intriguing is how receptor down-regulation after chronic morphine treatment
and the observed hyperexcitation of these neurones after acute naloxone requiring a
high degree of functional integrity, might be married with one encompassing
hypothesis. This question has been addressed and based on observations in several
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cell types, excluding SON OT neurones, it has been suggested that tolerance and
dependence might be quite separate phenomena (Wuster and Costa, 1984; Wuster et
al, 1985; Christie et al, 1987). Perhaps the two are in fact separate phenomena: the
decline in receptor density might reflect a mechanism contributing just to tolerance
but not to dependence. Possibly more important for the expression of withdrawal
excitation is the functional state of the receptor or of post-receptor mechanisms which
might be temporarily inactivated by chronic opiate but rapidly reinstated following
naloxone. The system needs to be capable of not only behaving normally, but
supernormally after naloxone, which suggests that the receptor-post-receptor
organisation is not permanently dismantled but is merely temporarily interfered with.
Transient opioid n-receptor desensitisation in locus coeruleus neurones has been
described after 5min application of met-enkephalin (Harris and Williams, 1990) which
is homologous because the a2-adrenoceptor is not substantially affected. The
desensitisation lasts for 15-20min and must therefore involve a modification of tire
receptor which is rapid and probably reversible (see below for a discussion of possible
mechanisms).
There is evidence from a variety of receptors to explain reversible or irreversible
receptor inactivation, although evidence from studies of the opioid receptor
specifically are sparse (Law et al, 1984; Law et al, 1985; Hassan et al, 1989; Conrath
and Cupo, 1989).
5.4.5. Regulation of receptor density by internalisation
Receptors can undergo internalisation by endocytosis within 'coated pits' and can
then either be broken down within lysosmes or preserved (Dickson, 1985).
Endocytosis can be substantial: cells may internalise the equivalent of up to 150% of
the total cell surface per hour (Raffa, 1985). In addition, it seems that some coated
pits only bud off from the cytoplasmic membrane after the creation of a ligand-
receptor complex although others do not require the binding of a receptor-selective
ligand to promote this process. Once internalised, contents of these coated vesicles
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can be enzymatically degraded, secreted after modification or reinserted into the
membrane unchanged (Raffa, 1985). It is easy to speculate on the role of such a
system in opioid receptor down-regulation and desensitisation. Opioid receptors
labelled by an anti-idiotypic antibody directed against the /i/5-opioid receptors appear
to be located not only at the cell membrane of various neurones throughout the rat
brain and of NG108-15 hybrid cells, but also within the cytoplasm, although this can
only be confirmed convincingly by electron-microscopical analysis (Hassan et al,
1989). 5-opioid receptor binding measured using an anti-idiotypic antibody in rat
brain was localised not only to cell membrane but aso intracellularly within vesicles as
confirmed by electron microscopical examination (Conrath and Cupo, 1989). 5-opioid
receptor down-regulation in NG 108-15 hybrid cells after chronic DADLE has been
reported to be accompanied by an increase in the lysosomal compartment of ligand-
receptor complex, where degradation takes place (Law et al, 1984). It was concluded
that because opioid receptor desensitisation requires magnesium and sodium which are
needed for activation of Gi and AC respectively, that the opioid receptor needs to be
coupled to Gi for desensitisation to occur. If internalisation is a significant means of
opioid receptor desensitisation then it might be expected that the opioid receptor
would be internalised together with the coupled Gi protein. However, it has been
shown that the amount of Gi in the membrane does not change after chronic DADLE
and significant opioid receptor internalisation (Law et al, 1985). This is consistent
with homologous desensitisation having occurred in that if Gi was significantly
depleted in the plasma membrane, heterologous desensitisation would be expected
because of the general depletion of available Gi for transduction via other receptors
(see Chapter 3). As post-receptor mechanisms are not shown to be causally involved
in receptor internalisation by the above study, and cell-surface receptor clustering
occurs both with agonists (including morphine) and with naloxone and cannot
therefore be a candidate pre-internalisation marker, the authors of the above study
speculate on the possible role of covalent modification of the opioid receptor upon
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binding of the agonist (ie. phosphorylation) which might deactivate the receptor and
lead to its internalisation (see 5.4.6. for further discussion of receptor
phosphorylation). A recent report raises an interesting corollary to the above findings,
which is the observation that the opioid antagonist, naloxone causes an accumulation
of opioid receptors in the lysosmal fraction of rat brain, albeit a relatively small one,
suggesting that opioid receptor up-regulation might operate by interfering with
receptor internalisation and processing (Simantov et al, 1989).
Recycling of receptors has been reported to occur in as little as 30min (Raffa, 1985)
although there is no figure specifically for opioid receptors. So, the decrease in
density of opioid receptors observed here might be accounted for, should these
processes operate significantly for the opioid receptor, by the reversible internalisation
of receptors which might be preserved internally for later recruitment for example
after exposure of the cells to naloxone. This could provide the basis of a unitary
explanation based primarily upon receptor density for tolerance followed by
supernormal activity after naloxone - dependence in a cell-surface receptor-depleted
preparation. A remaining difficulty however is whether receptors can be recycled into
the membrane sufficiently rapidly to account for the very short latency in the onset of
the withdrawal response seen in electrophysiological studies of these neurones
(approx. 30sec; see Chapter 1). This might be answered if internalised receptors with
their ligand although internalised were accessible to naloxone. Some ligands are
indeed internalised but this scenario seems improbable. Alternatively rapidly
reversible deactivation by another means which renders the receptor less avid for its
selective ligands might make the ligands used in this study blind to cell-surface
receptors which nevertheless are quickly reinstated after a hypothetical conformational
change induced by naloxone. Perhaps receptor phosphorylation operates in this way
as it would not necessarily entail removing the receptor from the membrane as part of
its deactivation, but evidence to support this idea is lacking. An alternative
interpretation is that although the down-regulation of receptors could contribute to
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tolerance possibly by internalisation, a separate mechanism(s) probably accounts for
dependence (Wuster et al, 1984; Wuster et al, 1985; Christie et al, 1987). It is
interesting that after internalisation of the phosphorylated /3-adrenergic receptor the
phosphate residue is removed, presumably by a phosphatase present in the vesicle
(Levitzki, 1986). Thus the functional receptor could be reinserted into the plasma
membrane. The period of receptor internalisation would vary under conditions of
tachyphylaxis (a short internalisation) or tolerance (a longer internalisation). These
experiments have not been performed for opioid receptors so it is not clear whether
these results can be reliably extrapolated.
5.4.6. Regulation of opioid receptor density by phosphorylation
Many modifications can be made to receptor proteins before their transport to the
membrane, possibly to provide resilience to enzymatic attack. However, various
receptors are phosphorylated on serine, threonine and tyrosine residues after ligand
binding (Hanover and Dickson, 1985). For example, insulin induces rapid
phosphorylation of tyrosine residues at its receptor triggering a cascade of such
phosphorylations and ultimately reducing tyrosine kinase activity.
Huganir and Greengard list three classes of receptor, all of which can be
phosphorylated as a means of regulation: chemically-gated ion channels, those linked
to guanine nucleotide binding proteins and receptors for growth factors (Huganir and
Greengard, 1987). An example of the second class of receptor, to which opioid
receptors belong, is the /3-adrenergic receptor. Phosphorylation of the /3-adrenergic
receptor results in desensitisation. The /3-adrenergic receptor undergoes two forms of
desensitisation: homologous and heterologous. That is, desensitisation brought about
by the binding of an appropriate ligand to the /3-adrenergic receptor, or desensitisation
of unrelated receptors after binding of the same ligand again to the /3-adrenergic
receptor. Protein phosphorylation is involved in the development of both forms of
desensitisation. Phosphorylation can be catalysed by cAMP-dependent protein kinase
or protein kinase C, activated by phorbol esters in heterologous desensitisation. In the
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case of homologous desensitisation, a novel protein kinase is involved (/3-adrenergic
receptor protein kinase, /3-ARK), and the degree of phosphorylation correlates well
with the degree of desensitisation in frog erythrocytes. This type of phosphorylation
occurs only when the ligand is bound to the receptor and is therefore, substrate-
activated. Binding of the agonist (but not the antagonist) seems to make the receptor a
better substrate for phosphorylation. /3-ARK promotes functional inactivation of the
receptor and internalisation, whereas protein kinase C marks the receptor for
internalisation at a different site, without functionally inactivating it. Thus it has been
suggested that phosphorylation is a necessary first step in the internalisation of the
receptor (Levitzki, 1986).
Tolerance and dependence in the OT system have not been dissociated by the
protocols described in thid Thesis, where they seem to develop hand in hand. In
systems where tolerance and dependence have been shown to progress at different
rates or to be independent of each other, it has been necessary to explore hypotheses
other than the unitary hypothesis of tolerance and dependence. The present studies do
not provide evidence to exclude either a unitary hypothesis or other proposed
hypotheses in the OT cells of the SON and I leave this question for future clarification.
Decline in receptor density could be one of many adaptive mechanisms which
contribute to tolerance and dependence and it is certainly naive to expect to derive a
convincing hypothesis based on changes in receptor density alone. Indeed, in some
neuronal systems, there is no change or an increase in the density of opioid receptors
after chronic opiate, suggesting that it is not a universally active adaptive mechanism
under conditions of chronic opiate exposure (Geary and Wooten, 1985; Brady et al,
1989).
In conclusion, localisation of x-opioid receptors in the SON gives biochemical
validity to the electrophysiological effects of the /c-selective agonist U50,488H and
other k-receptor agonists in vitro and in vivo (Pumford et al, 1987; Russell et al,
1989b; Inenaga et al, 1990; Leng et al, 1990). That the density of these receptors is
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not influenced by chronic morphine treatment corroborates electrophysiological
findings which suggest no cross-tolerance occurs between the chronically-inactivated
/x-opioid receptor and the acutely activated /c-opioid receptor (see Chapter 2). The
localisation of opioid receptors in the MPN is a novel finding, as is the change in
opioid receptor density evoked by chronic i.c.v. morphine-treatment and is supportive
of the electrophysiological study (see Chapter 6) in which it was found that at least
part of the adaptation that constitutes tolerance/dependence in SON OT neurones
occurs in the AV3V region, of which the MPN is a part (see Chapter 6). Clearly in
vivo, morphine could act to inhibit SON OT neurones partly by an action on the input
from the MPN. These data then are concordant with other studies reported in this
Thesis of the OT neurosecretory system in the SON, as it is regulated by endogenous
and exogenous opioids. Further work might concentrate on identification of tire
peptidergic nature of neurones in the SON carrying subtypes of opioid receptor and
could attempt to clarify the likely physiological relevance of these findings to date.
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CHAPTER 6
MECHANISMS MEDIATING DEPENDENCE UPON MORPHINE IN OXYTOCIN
NEUROSECRETORY NEURONES: WHERE ARE THEY LOCATED?
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6.1. INTRODUCTION
Oxytocin (OT) is released together with vasopressin (AVP) from the posterior
pituitary in the rat in response to osmotic stimuli, such as intraperitoneal injection of
hypertonic saline or chronic dehydration (Brimble et al, 1978) and this is the result of
an increase in the rate of firing of oxytocin neurones (Poulain et al, 1977).
Direct osmosensitivity of oxytocin neurones has been inferred from in vitro studies
(Mason, 1980) and confirmed by in vivo experiments (Leng et al, 1989a) but
complementary to their innate osmosensitivity, these neurones also receive afferents
from regions elsewhere in the brain, which may themselves be osmosensitive sites.
The region anterior and ventral to the third ventricle (AV3V region) includes the
organum vasculosum of the lamina terminalis (OVLT), the median preoptic nucleus
(MPN) and connections between these and the subfornical organ (SFO) (Brody and
Johnson, 1980). Lesions in the AV3V region upset the maintenence of water and
sodium balance (Johnson and Buggy, 1978). AVP and OT release associated with
water deprivation are also inhibited by these lesions (Bealer et al, 1983; Russell et al,
1984) and terminal degeneration is observed in the paraventricular and supraoptic
nuclei (PVN and SON respectively; Carithers et al, 1981), where both the SFO and
the OVLT are known to project to (Miselis, 1981; Renaud et al, 1983).
Stimulation of the AV3V region, most effectively in and around the MPN causes
die release of OT in both lactating and non-lactating rats (Russell et al, 1988). Honda
and coworkers showed that by increasing osmolality discretely in the OVLT by
microinjection, the firing rate of paraventricular neurones was increased (Honda et al,
1987). Although the milk ejection reflex remains intact after electrolytic ablation of
the AV3V region and parturition progresses normally after acute AV3V lesion
(Russell et al, 1988), the osmotically-stimulated increase in plasma OT concentration
is no longer seen (Blackburn et al, 1987). So, the AV3V region selectively influences
the osmoresponsiveness of die magnocellular OT neurones without affecting dieir
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ability to respond to the suckling stimulus with a coordinated increase in firing activity
resulting in the bolus release of OT and milk ejection or to tire passage of a foetus
through the vagina with an increase in oxytocin release.
Stimulation of OT neurones by suckling, angiotensin II and cholinomimetics is
sensitive to the acute inhibitory effects of opiate receptor agonists in a naloxone
reversible way (Haldar and Sawyer, 1978; Clarke et al, 1979; Haldar et al, 1982;
Russell and Spears, 1984). Endogenous opioid peptides may also exert a tonic
inhibitory influence on OT neurones (Bicknell et al, 1984).
Chronic exposure of the OT system to morphine has revealed tire development of
tolerance and dependence to these inhibitory effects (Russell, 1984; see Chapter 1)).
The relative influence of neural inputs to the OT system in the normal state and in tire
opiate tolerant/dependent state could lead to a better understanding of the mechanisms
involved in opiate tolerance and dependence. In addition, if tolerance and dependence
develop to exogenous opioids then the possibility must exist that the same might occur
to endogenous opioids under certain physiological conditions. Thus the influence of
neural inputs in the tolerant state would have a role in the coordination of the system
tolerant to its own endogenous opioids (Lincoln and Russell, 1985)
In this study the contribution of tire AV3V input to the expression of tolerance and
dependence in tire OT system is examined, revealed by precipitated withdrawal with
tire opiate antagonist naloxone, in terms of plasma OT concentration measured by
radioimmunoassay. Specifically, it is hypothesised that if morphine dependence
develops only in the AV3V input to OT neurones, then the AV3V lesion should
prevent withdrawal excitation. From the results, possible mechanisms by which
naloxone affects OT neuronal activity and therefore OT release, in i.c.v. vehicle-
infused and i.c.v. morphine-infused rats, with and without acute electrolytic ablation




Virgin female Sprague-Dawley rats (255.8 ± 21.6g, i.c.v. vehicle-infused group,
n=12; 264.9 ± 6.5g, i.c.v. morphine-infused group, n=12) were used in this study.
They were housed singly with access to food (standard breeder diet) and water ad
libitum in a 12hour light dark cycle (13h/l lh light/dark) at an ambient temperature of
21-23°C.
6.2.2. Intracerebroventricular (i.c.v.) infusion procedure
Rats to be included in the chronic morphine treatment group were taken 5 days
before the experiment and were anaesthetised with ether. Using a stereotactic
apparatus and atlas of the rat brain (Konig and Klippel, 1963), a cannula was
introduced into a lateral cerebral ventricle (3mm posterior, 2mm left lateral to bregma,
4.5mm below the surface of the skull) and an infusion of morphine sulphate BP
(Pharmacy, Royal Infirmary, Edinburgh) at consecutive concentrations of 10, 20 and
50 mg/ml was set up, driven by a subcutaneously implanted osmotic minipump (Alzet
2001, Alza Corp.). Control rats were prepared identically but received an i.c.v.
infusion of sterile pyrogen-free water.
6.2.3. Electrolytic lesioning / sham-lesioning procedure
Rats were anaesthetised with urethane (0.5ml/lOOg of 25% ethyl carbamate i.p.)
and the left femoral artery and vein cannulated for blood sampling and injections
respectively. Body temperature was regulated to 37°C using thermostatically
controlled small animal heating blankets.
Half of each group received an electrolytic lesion in the AV3V area (0.3mm
posterior to bregma and 8.3mm below the surface of the skull with the rat skull level
between bregma and lambda). A lesioning current, 3mA D.C. was passed for 15
seconds from a Stoelting lesion maker (58041, Chicago, IL, U.S.A.; rectal cathode)
using a lesioning electrode (Nichrome; Goodfellow metals, Cambridge; 26 SWG,
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0.5mm diameter insulated to 0.5mm of the tip with Insl-X; Insl-X Products Corp.,
Yonkers, NY, U.S.A.). The remainder received a sham lesion, which involved the
introduction of the lesioning electrode dorsal to the AV3V without the passage of a
lesioning current (0.3mm posterior to bregma and 5.3mm vertically beneath the skull
surface; no current). Pairs of lesioned and sham-lesioned rats were prepared together.
6.2.4. Blood sampling protocol
The blood sampling schedule was as follows,
Blood sample number:
1 Just prior to lesion/sham lesion, rat in frame
Electrolytic lesion / sham-lesion procedure
2 1 minute after making lesion/sham-lesion
3 30 minutes after making lesion/sham-lesion
4 60 minutes after making lesion/sham-lesion
Naloxone (5mg/kg) i.v. 65 minutes after lesion/sham-lesion
5 6 minutes after naloxone
6 20 minutes after naloxone
7 40 minutes after naloxone
8 60 minutes after naloxone
Naloxone (5mg/kg, lOmg/ml solution in 0.9% saline; either a gift from Endo Labs,
or purchased from the Sigma Chemical Co.) was given by intravenous bolus injection
65 minutes after the lesion or sham procedure. Blood samples were 400/d and were
replaced with heparinised blood from a 400g donor rat. They were kept on ice until
the plasma was separated by centrifugation at 0°C and stored frozen at -20°C before
radioimmunoassay for OT by a modified Higuchi method (Higuchi et al, 1985).
Details of the radioimmunoassay procedure are contained in the Methods Section of
Chapter 4 and it was performed by Chris Chapman, AFRC I.A.P.G.R., Cambridge.
After collection of the last blood sample, animals were killed, the brains removed
and fixed in 10% v/v formaldehyde for later examination. The site of the electrolytic
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lesion and the placement of the i.c.v. cannula were confirmed by sectioning the brains
on a freezing microtome (50/xm coronal sections), staining sections with cresyl violet
followed by serial examination under a dissecting microscope and recording of the
spread of the lesion on semi-diagrammatic maps of rat brain derived from tire atlas of
Konig and Klippel (see Figures 6.4.1. and 6.4.2.a and b for a record of the extent of a
typical AV3V lesion and for a composite summary of all lesions made in the control
(a) and the i.c.v. chronic morphine-treated (b) groups). Accurately-placed lesions
were those which crossed tire mid-line and destroyed tissue ventral to the anterior
commisure without involving the magnocellular nuclei directly; data from rats with
mis-placed lesions were not included in subsequent analysis.
6.3.5. Statistical analysis of results
For comparison between groups a non-parametric analysis of variance was initially
performed to locate any differences (Kruskal-Wallis) and once located, further
comparisons were made with the Wilcoxon test for independent samples. For
comparison of paired data (i.e. changes in OT concentration with time in any one
group) the Wilcoxon signed rank test and Student's paired one-tailed or two-tailed t-
test were used where appropriate. Student's t-test was used because of the inadequate
sample size at some time points (where n=5), such that a non-parametric test could not
detect a difference between samples. However, the normality of the data was tested
with the Kolmogorov-Smirnov one sample test in which the control data (pre-lesion
blood sample) was tested against a theoretical normal distribution. In all groups the
data were found to be distributed normally (see Results Section) and parametric tests
were then applied. The one-tailed t-test was the test of choice when a rise in plasma
OT concentration was predicted from earlier published experimental evidence and was
therefore expected. In all cases where this test was applied, plasma oxytocin
concentration did indeed rise (see Results Section). All statistical analyses are
presented in Tables 6.3.1., 6.3.3. and 6.3.4. of the Results Section of this Chapter.
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6.3. RESULTS
Immediately prior to the AV3V lesion/sham lesion procedure plasma OT
concentration did not differ between treatment groups. The plasma samples taken
immediately after and at 30min after the lesion were likewise similar between groups.
However, 60 minutes after the lesion the chronic i.c.v. vehicle-treated/lesioned (V/L)
group had a lower plasma OT concentration than the chronic i.c.v. vehicle-
treated/sham-lesioned (V/S) group (P<0.05, Wilcoxon, see Table 6.3.4. and Figure
6.3.2.) but neither was significantly different from its own pre-lesion control value
(Student's paired, one-tailed t-test). This trend is mirrored hi the chronic i.c.v.
morphine-treated/sham-lesioned (M/S) and chronic i.c.v. morphine-treated/lesioned
(M/L) groups. The pre-naloxone value for M/S was significantly higher than its own
pre-lesion control value (Student's paired, one-tailed t-test, P<0.05). The pre-
naloxone value for the M/L group was similar to its own pre-lesion control value.
Thus whereas plasma OT concentration remained stable after a lesion, it tended to rise
over the 60 min following the sham-lesion in both the i.c.v. vehicle- and i.c.v.
morphine-treated groups.
Naloxone precipitated a massive rise in plasma OT concentration in the M/S group
to a peak of 1839 ± 809 pg/ml, a greater than 80-fold increase on the pre-lesion
control value (P<0.05, Student's paired, one-tailed t-test). This response compares
well with that already observed in previous studies (Bicknell et al, 1988a) in non-
operated morphine dependent rats.
All groups demonstrated a rise in plasma OT concentration after naloxone.
The M/L group showed an attenuated response compared to its sham-lesioned
control (M/S), reaching a peak value of only 326.3 ± 65 pg/ml OT. However,
although the absolute rise on plasma OT was much greater in the M/S group, the
percentage increase in the M/L group after naloxone, compared with the M/S group
was not significantly different (Wilcoxon test for independent samples).
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The V/S group exhibited a significant increase in plasma OT concentration with
naloxone compared with the pre-naloxone value: 67.3 ± 31.2 to 251.1 ± 66.5 pg/ml
respectively, (ca. 4-fold increase; P<0.005, Student's paired, one-tailed t-test).
The V/L group was the least responsive of all to naloxone treatment and showed
only a modest rise in plasma OT concentration from 15.2 ± 7.1 to 47.2 ± 12.4 pg/ml
(ca. 3-fold increase; P<0.05, Student's paired, one-tailed t-test).
Plasma OT concentration was still elevated for 3 of the 4 treatment groups 60 min
after naloxone (see Table 6.3.3.) but in all 4 groups for 40 min after naloxone
(Wilcoxon signed rank test and Student's paired, one-tailed t-test). Only the V/L
group did not vary greatly throughout the protocol in terms of plasma OT
concentration. Comparisons between groups are made using the Kruskal-Wallis test
for analysis of variance and the Wilcoxon test for independent samples. See Table
6.3.1. and Figure 6.3.2. for summaries of these data.
Comparison was made between groups at each time point using the Kruskal-Wallis
test. Only at and after time point 4 (60min after the lesion/sham-lesion procedure)
were there any statistically significant differences in plasma OT concentration. At
time points 4, 5, 6, 7 and 8, P was <0.05, =0.0005, <0.005, <0.01 and <0.05,
respectively. Differences between groups were further tested using the Wilcoxon test
for independent samples where the differences occurred and the results are contained
in Table 6.3.4.. The rank order of the group mean values for plasma OT
concentrations after naloxone (time point 5) were M/S > V/S =M/L > V/L.
All rats included in our study had lesions which crossed the mid-line and fell
beneath the anterior commisure and above the optic chiasm, damaging the ventral
portion of the MPN and the OVLT but leaving both the SON and PVN untouched.
The sham-lesioned rats had tissue damage above the anterior commisure,
corresponding to the track of the lesioning electrode (see Figures 6.4.1. and 6.4.2.).
The intra-assay coefficient of variation for the radioimmunoassay for oxytocin was
8.3%.
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The number in parentheses together with the sample number denotes time in
minutes at which blood samples were taken. (*KW) denotes a statistically significant
difference according to non-parametric analysis of variance by the Kruskal-Wallis test
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at that time point. Plasma OT values are mean ± SE. Naloxone was injected i.v. at 65
min (5mg/kg) and the next blood sample followed 6 min later.
Figure 6.3.2. (overleaf):
a) The groups V/S, V/L, M/S and M/L are as defined in the text. The lesion/sham-
lesion procedure was performed after blood sample 1, as indicated by the asterisk.
Naloxone was injected i.v. between blood samples 4 and 5 as indicated by the bold
arrow. For a full account of where statistically significant differences were detected,
see Tables 6.3.3. and 6.3.4..
b) This histogram was constructed using data from the first four blood samples
only on an expanded y-axis in order to make the differences between groups at these
relatively low plasma oxytocin concentrations more apparent. The asterisk denotes
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Table 6.3.3. Statistical analysis of the change in plasma oxytocin concentration
with time after AV3V-lesion/sham-lesion procedure in morphine-naive and chronic
i.c.v. morphine-infused rats.
Group code Time point vs. pre- vs. pre- Group size
(min after naloxone naloxone
naloxone) value (4); value (4);
Wilcoxon paired, one-
signed rank tailed t-test,
test, P< P<
V/S 5(6) 0.05 0.005 6
6(20) 0.05 0.01 6
7(40) 0.01 5
8(60) 0.05 5
V/L 5(6) 0.05 5
6(20) 0.05 5
7(40) 0.05 5
8(60) >0.05 n.s. 5
M/S 5(6) 0.05 0.05 6
6(20) 0.05 0.005 6
7(40) 0.01 5
8(60) 0.01 5
M/L 5(6) 0.05 0.005 6
6(20) 0.05 0.005 6
7(40) 0.05 0.01 6
8(60) 0.05 0.05 6
Table 6.3.3. Legend
The group codes represent the following groups, V/S, the chronic i.c.v. vehicle-
treated/sham-lesioned group; V/L, the chronic i.c.v. vehicle-treated/AV3V-lesioned
group; M/S, the chronic i.c.v. morphine-treated/sham-lesioned group and M/L, the
chronic i.c.v. morphine-treated/AV3V-lesioned group. The time points (5, 6, 7 and 8)
each correspond to a serial blood sample taken at times given in parentheses. Values
for P are absent ( ) in the Wilcoxon signed rank test column when statistical
significance could not be achieved because the number of pairs was less than 6. These
comparisons were then made using Student's paired, one-tailed t-test. The normality
of the data was tested using the Kolmogorov-Smirnov one sample test. The plasma
OT concentration measured in the pre-lesion control blood sample was compared with
a normal distribution and for all 4 groups tested, the level of significance achieved was
1.00, satisfying the requirement of parametric tests such as1 Student's t-test for the data
to be normally distributed, n.s. denotes that statistical significance was not achieved.
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Table 6.3.4. Statistical analysis of plasma oxytocin concentrations before and after die
AV3V-lesion/sham-lesion procedure in morphine-naive and chronic i.c.v. morphine-
infused rats: comparisons between groups.
Group code
Group code Time point V/L M/S M/L
V/S 4 0.05 >0.05 n.s. >0.05 n.s.
5 =0.005 0.05 >0.05 n.s.
6 0.01 >0.05 n.s. >0.05 n.s.
7 0.05 >0.05 n.s. >0.05 n.s.
8 0.05 >0.05 n.s. >0.05 n.s.
V/L 4 >0.05 n.s. >0.05 n.s.
5 =0.005 =0.005
6 =0.005 =0.005
7 0.01 >0.05 n.s.
8 0.05 0.05






Group codes represent die following groups, V/S, the chronic i.c.v. vehicle-
treated/sham-lesioned group; V/L, the chronic i.c.v. vehicle-treated/AV3V-lesioned
group; M/S, die chronic i.c.v. morphine-treated/sham-lesioned group and M/L, die
chronic i.c.v. morphine-treated/AV3V-lesioned group. The time points each
correspond to a serial blood sample. Blank spaces occur where P values are expressed
elsewhere in the table. Comparison between groups were made with the Wilcoxon test
for independent samples and unless the chosen level of significance (P<=0.05) is not
achieved, values are P< the stated value in the table. Where the value of P exceeds
0.05, this is expressed, n.s. denotes that statistical significance was not achieved.
Group sizes were 5 or 6 rats throughout.
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6.4. Discussion
Photomicrographs of serial tissue sections from one rat (Figure 6.4.1.a-f) show the
extent of a typical AV3V lesion. Figure 6.4.2.a and b are diagramatic composites of
lesions in individual rats in the i.c.v. chronic vehicle-treated group (a) and the i.c.v.
chronic morphine-treated group, showing the area common to all lesions. It is clear
that neither the SON nor the PVN are affected directly by the AV3V lesion and any
impairment of OT secretion in the lesioned groups cannot therefore be accounted for
through destruction of the OT neurones or their axons. As well as the histological
evidence, it would be expected that plasma OT would be reduced shortly after tire
lesion if tire OT neurones themselves were substantially damaged and presumably OT
release could not be stimulated by naloxone, but neither instance arose.
The first observation of note is that before the lesion procedure, plasma OT
concentration was the same in all 4 groups (Kruskal-Wallis). Evidently, the chronic
i.c.v. morphine-treated rats had become tolerant to morphine in terms of OT secretion
since acute morphine inhibits OT secretion (Russell and Spears, 1984; Evans and
Olley, 1988; Grell et al, 1988; Russell et al, 1989a). This agrees with an earlier study
(Bicknell et al, 1988a) and is explained by tolerance to chronic i.c.v. morphine in
terms of the electrical activity of OT neurones in the SON and PVN (see Chapter 1
and Bicknell et al, 1987a; Leng et al, 1989b).
During the post-lesion control period (time points 2-4) blood sampling revealed an
interesting trend. OT output remained stable with time after the lesion procedure in
the lesioned groups (V/L and M/L) but the sham-lesioned groups (V/S and M/S)
showed an upward trend in plasma OT concentration (see Table 6.3.1.). Although this
became maximal after 60 min in both the sham-lesioned groups, it is statistically
significant only in the M/S group (P<0.05, Student's paired, two-tailed t-test). The
pre-naloxone plasma OT concentration in the V/S and V/L groups (at time point 4)
were significantly different from each other (P<0.05, Wilcoxon test for independent
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samples) but no other comparisons achieved statistical significance. The stability of
plasma OT in the lesioned groups suggests that acute ablation of the AV3V region
removes a regulatory mechanism located in or projecting via the AV3V region which
provides a positive drive to OT secretion which is possibly tonically active under the
conditions of the experiment. However, this positive drive to the OT-secreting
neurones in the SON is not essential for the secretion of what appear to be basal levels
of OT by the remainder of the OT neurosecretory system (see Table 6.3.l.and later
Discussion).
The reason for the gradual rise in plasma OT may be related to the consecutive
blood samples taken during the post-lesion period, but these were always replaced
with the same volume of blood from a donor rat, given immediately, to avoid this
potential problem. In addition, there may have been slight blood loss with surgery
which would have the same effect (Poulain et al, 1977). Again, care was always taken
to minimise this problem. Both however, could result in the activation of OT
neurones through the AV3V region, possibly via increased circulating All, with the
observed gradual rise in plasma OT concentration (Nikolaidis et al, 1983; Ferguson
and Renaud, 1986; Gambino and Felix, 1986; Leng et al, 1989a). Fortunately, the
pre-naloxone concentration of OT in these two groups was not sufficiently raised as to





depicted with a dashed line on drawings of serial coronal sections of rat brain (after
Konig and Klippel, 1963). The area common to all lesions in each plane is shaded.
The number at the bottom left of each section is the distance in /xm anterior to the
inter-aural plane.
Abbreviations: AC: anterior commisure; CC: corpus callosum; OC: optic chiasm;




Figure 6.4.2.b Histological description of the anterior-posterior extent of AV3V
lesions in the chronic i.c.v. morphine-infused group (n=6). Lesions in individual rats
are depicted with a dashed line on drawings of serial coronal sections of rat brain
(after Konig and Klippel, 1963). The area common to all lesions in each plane is
shaded.
The number at the bottom left of each section is the distance in /zm anterior to the
inter-aural plane.
Abbreviations: AC: anterior commisure; CC: corpus callosum; OC: optic chiasm;
S: septum; F: fornix; SON: supraoptic nucleus; VL: lateral ventricle and V3: third
ventricle.
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6.4.3. How does naloxone differentiate between the four treatment groups?
Data from the V/S group, can be compared with data previously reported (Bicknell
et al, 1988a) for a control group of rats which were i.c.v. vehicle-infused and blood
sampled immediately before and 6 min after i.v. naloxone (5mg/kg). The rise in
plasma OT measured then was from 42.1 to 125.1 pg/ml, which is similar to that
measured here, 67.3 to 251.1 pg/ml. The slight differences in protocol (i.e. sham-
lesion procedure, number of blood samples) might account for the slightly higher
value for post-naloxone OT concentration here although it is not clear whether the two
values are significantly different anyway. This result points to a tonic opioid restraint
on OT release which is revealed by naloxone. However, because OT neurones
recorded from these control rats are not excited by i.v. naloxone (Bicknell et al, 1988a;
Shibuki et al, 1988), the authors suggest that this rise in plasma OT is explained by
antagonism of the actions of endogenous opioids upon OT release from nerve
terminals located in the posterior pituitary. As discussed in the Introduction, Section
I.2., naloxone antagonises endogenous opioids which appear to tonically inhibit
oxytocin secretion from the neurohypophysis (Bicknell and Leng, 1982; Bicknell et
al, 1988a). There are opioid receptors in the posterior pituitary which are probably
exclusively the k-type (Bunn et al, 1985; Herkenham et al, 1986; Stojilkovic et al,
1987; Sumner et al, 1990). Opioid receptors have been localised to pituicytes
(Lightman et al, 1983b) and K-opioid receptors found on neurosecretosomes (derived
from nerve terminals in the posterior pituitary) are activated by the /c-receptor-
selective agonist, U50,488H (Zhao et al, 1988b). Dynorphin, which is co-localised
with vasopressin in neurosecretory neurones (Watson et al, 1982; Martin et al, 1983)
is probably the endogenous ligand for the /c-receptor (Corbett et al, 1982). So, a part
of the total amount of OT secreted after naloxone in each group is probably derived by
antagonism of tonic endogenous opioid-mediated inhibition of OT secretion. The
neurohypophysis was once proposed as the main site of action of morphine to inhibit
OT secretion (Clarke et al, 1979), but more recent studies show this not to be so
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(Coombes and Russell, 1989) so that even in morphine-dependent rats, naloxone's
actions at the level of the posterior pituitary are likely to be only antagonism of
endogenous opioids to which cross-tolerance does not develop (Bicknell et al, 1985b).
Comparison of the amount of OT liberated after naloxone in the V/S and the V/L
groups highlights a difference brought about by acute AV3V lesion. OT concentration
although elevated after naloxone in the V/L group, is much less so than in the V/S
group (see Table 6.3.1.) in absolute terms (although the proportion by which OT
secretion is raised after naloxone is not significantly different between the V/L and
V/S groups (Wilcoxon test for independent samples)).
The AV3V region maintains a tonic excitatory input to the SON OT neurones
under basal conditions (Russell et al, 1988). Stimulation of the AV3V region excites
OT neurones in the SON (Russell et al, 1988). If the AV3V input is removed by
ablation of the AV3V region, then the overall activity of the nucleus declines
(Blackburn and Leng, 1987; Russell et al, 1988; Leng et al, 1989a) which can be
expected to lead to a fall in the amount of OT secreted basally (see earlier Discussion)
and conceivably after non-osmotic stimulation too because of the reduced excitability
of the neurones. Such a fall in OT release has already been reported after chronic
AV3V lesion (Russell et al, 1984; Gardiner et al, 1985) and acutely there is loss of
responsiveness to osmotic stimulation (Blackburn et al, 1987) but not to suckling or
parturition (Russell et al, 1988).
Perhaps therefore the shortfall in OT output in the V/L group after naloxone is
explained simply by a decrease in electrical activity at the cell bodies of OT neurones
in the SON and PVN which project to the posterior pituitary where consequently they
secrete less OT under basal conditions with or without naloxone antagonism of
endogenous opioid peptides. This idea is discussed further after consideration of the
data from the chronic morphine-treated groups (see later Discussion).
However, it does not follow that all OT neuronal activity is abolished after AV3V
lesion. The dramatic reduction in OT cell electrical activity in the SON after acute
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ablation of the AV3V structures was not matched by an equal fall in OT measured in
the plasma (Leng et al, 1989a). The authors explain this unexpected finding by
suggesting that the magnocellular OT-secreting population of neurones in the PYN are
not so critically involved in the component of osmotic responsiveness which is AV3V-
mediated. This interpretation of results is supported by an early study which reported
a weaker response from PVN OT neurones in terms of OT release after a systemic
osmotic challenge compared to SON OT neurones (Brimble et al, 1978). The
possibility arises therefore that whilst SON OT neurones are substantially affected by
removal of the AV3V tonic drive, PVN OT neurones are not and help to maintain
basal release of OT at the concentration measured in this study which was higher than
would be expected in the virtual absence of electrical activity in the OT
neurosecretory system suggested from studies in SON after AV3V lesion.
Some residual stimulation of OT neurones might exist after AV3V lesion as not all
fibres arising from the SFO course through the AV3V region but travel laterally to
terminate in the SON (Miselis, 1981; Lind et al, 1985; Swanson and Lind, 1986).
The SFO is implicated in body fluid homeostasis (Gross, 1985; Thrasher, 1985) and
may be an osmosensitive site (Buranarugsa and Hubbard, 1988; Sibbald et al, 1988).
The SFO also contains opioid receptors (Mansour et al,1987; Sharif and Hughes,
1989; Conrath and Cupo, 1989) and opioid-sensitive neurones (Buranarugsa and
Hubbard, 1979) and could therefore conceivably contribute to an integrated response
to osmotic challenge, together with the OT and AVP neurones of the magnocellular
nuclei.
Endogenous opioids and their receptors are present in or close to the magnocellular
OT hypothalamic nuclei (Mansour, et al, 1986; Mansour et al, 1987; Tempel and
Zukin, 1987; Sumner et al, 1990; see also General Introduction, Section I.2.).
Application of opioids to OT neurones in vitro and in vivo causes a reduction in their
firing rate (Muhlethaler et al, 1980; Pittman et al, 1980; Wakerley et al, 1983;
Pumford et al, 1987; Bicknell et al, 1988a; Russell et al, 1989b; Leng et al, 1990;
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see Chapters 1 and 2) and it is conceivable that endogenous opioids inhibit OT
perikarya directly. Removal of the excitatory projection from the AV3V region could
hypothetically allow any endogenous opioid inhibition to predominate. Given the
many reports supporting a possible role for endogenous opioids in the regulation of
OT secretion, this would be one scenario to explain the reduction in electrical activity
of OT neurones after an AV3V lesion and the observed fall in plasma OT. A problem
with the situation outlined above is that it infers that naloxone would not only
antagonise opioid inhibition at the neurohypophysis but also at the cell bodies in the
AV3V-lesioned rats, together resulting in a sizeable excitation of the OT system with
an appropriately large increase in OT release but this appears not to be so.
Endogenous opioids play an insignificant role, if any, in tonically inhibiting OT
secretion by regulating central neuronal activity in urethane-anaesthetised virgin rats
as it has been shown that naloxone cannot excite OT neurones in morphine-naive rats
silenced by AV3V ablation (Leng and Russell, personal communication), nor does it
affect OT neurones in intact rats stimulated by hyperosmolarity (Shibuki et al, 1988).
The most striking observation in the present study was the dramatic rise in plasma
OT after naloxone in the M/S group. The rise from 65.3 to 1839.0 pg/ml OT
compares closely with that reported in an earlier study in which a similar protocol,
excepting the sham lesioning procedure, was used (44.7 to 1072.1 pg/ml, Bicknell et
al, 1988a). This increase in OT output is far greater than that seen in the V/S group
after naloxone (proportional increase in OT concentration expressed as time point 5 /
time point 4: 33.7 vs. 5.9, M/S vs. V/S respectively, P=0.02, Wilcoxon test for
independent samples) and the concentration of OT measured after naloxone is also
significantly different between the V/S and M/S groups (P<0.05, Wilcoxon test for
independent samples). This suggests that whilst tolerance has developed to chronic
i.c.v. morphine as inferred by similar plasma OT concentration between groups in the
first blood sample, so too has dependence upon i.c.v. morphine, as revealed after
naloxone which precipitated withdrawal in terms of OT release (Bicknell et al, 1988a).
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The increase in OT secretion is likely to be the result of the combined effects of
increased neuronal firing rate (see Chapter 1) and antagonism of endogenous opioid
peptide action at the posterior pituitary, as discussed above and as shown in the
lactating morphine-dependent rat (Bicknell et al, 1988a).
The M/L group also responded to naloxone with a large rise in OT output from
24.3 to 326.3 pg/ml OT (P<0.005 vs pre-naloxone value, Student's paired one-tailed t-
test). The plasma OT concentration after naloxone was greater than that seen in the
V/L group (P=0.005, Wilcoxon test for independent samples) and the proportional
increase in plasma OT was significantly greater in the M/L group compared with the
V/L group (15.9 vs. 4.7 respectively, P<0.01, Wilcoxon test for independent samples).
So, chronic i.c.v. morphine infusion has resulted in a greater responsiveness of die OT
system to naloxone-evoked OT secretion, even after acute lesion of the AV3V region.
However, the sensitivity of the OT system to naloxone in the M/L group is much
attenuated compared with that of the M/S group. This is unlikely to be the result of
increased potency of naloxone at the level of the posterior pituitary as naloxone does
not stimulate OT release more potently from isolated pituitaries derived from
morphine-dependent rats, compared to control rats (Bicknell et al, 1985b). It seems
therefore to be explained by antagonism of morphine at the level of the perikarya as is
the case in the M/S group. Indeed, some restoration of electrical activity has been
achieved widi naloxone in acutely AV3V-lesioned morphine-dependent rats (Bicknell
et al, 1987b) adding weight to this proposal.
Lesion of the AV3V region therefore diminishes the effectiveness of naloxone, but
does not abolish its potency. So, although the M/L group show a greater
responsiveness to naloxone compared with the V/L group, as discussed above, full
potential sensitivity, as shown in the M/S group has been impaired by AV3V lesion.
This might be because of the relatively low initial firing rate before naloxone in the
M/S group as predicted by electrophysiological studies (Leng et al 1989a; Russell et
al, in press) which even when stimulated would remain lower than the basal firing rate
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of sham-lesioned controls. Given that the relation between firing rate and secretion of
OT is not linear but that as firing rate increases, release is disproportionately increased
(Bicknell, 1988), it is clear that the relative shortfall in firing rate of OT neurones in
the lesioned group will lead to a much exaggerated impairment of OT release. It
seems reasonable to assume that naloxone acted in the same direction on the electrical
activity of OT neurones in both lesioned and unlesioned groups but given the
discussion above, provoked quite different plasma concentrations of OT.
Opioid receptors in the SON have been reported both by ourselves (Sumner et al,
1990; see Chapter 5) and by others (Atweh and Kuhar, 1983; Clark et al, 1986;
Mansour et al, 1986; Mansour et al, 1987; Tempel and Zukin, 1987) and therefore it
follows that the component of opiate withdrawal which is not affected by AV3V
lesion could be within the SON itself.
Another interpretation which does not exclude the former is that part of the
withdrawal hypersecretion of OT is mediated by opioid receptors in the AV3V region
or in areas which project to/through the AV3V region which become dependent upon
morphine. Naloxone methyl bromide - a salt which does not cross the blood-brain
barrier given i.v., elicits withdrawal in terms of OT secretion, albeit incomplete,
suggesting that a site outside of the blood-brain barrier mediates in part, the expression
of withrawal after naloxone (Leng et al, 1989b; the SFO contains opioid receptors,
see above). We have reported //-type opioid receptors in the MPN whose density
decreases after chronic morphine treatment (Sumner et al, 1990; see Chapter 5).
There are opioid receptors in other components of the AV3V region (Mansour et
al,1987; Conrath and Cupo, 1989; Sharif and Hughes, 1989).
In conclusion therefore, naloxone has revealed that the expression of dependence
upon morphine, by its precipitate withdrawal, is mediated partially at the supraoptic
neurones and partially elsewhere in the hypothalamus - possibly in the AV3V region
or in areas which project to or which project via the AV3V region to other critical sites
involved in the centrally-mediated osmotic response . A conclusion cannot be drawn
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from these data about what involvement the AV3V region might have in the
development of tolerance to and dependence upon chronic i.c.v. morphine. This could
be investigated by using rats AV3V-lesioned and implanted with an i.c.v. morphine
infusion assembly simultaneously, 5 days before blood sampling with a protocol
similar to that used here. Hypothetically this might reveal the part played by the
AV3V region in the process of adaptation to chronic morphine, although in practice
compensatory mechanisms would be expected to come into operation during the 5 day
i.c.v. infusion period, possibly confusing the interpretation of these experiments.
Perhaps then, given these results, the appealing model of morphine tolerance and
dependence occurring in a single cell type in isolation and explained in terms of
changes in adenylate cyclase (Sharma et al, 1975a) does not transfer easily into the
fully integrated neural networks of the CNS. In particular it does not model the OT
neurosecretory system fully, which requires the functional integrity of other
hypothalamic structures to fully express morphine dependence evidenced by the
withdrawal syndrome after naloxone. Full withdrawal excitation may result from
amplification of withdrawal within individual neurones by their synaptic connections
with the final neurone (e.g. the oxytocin neurone), in the manner of a cascade.
It is difficult to tie the role of the AV3Y region and the SON OT neurones to a
possible physiological scenario in which tolerance to and dependence upon
endogenous opioids might develop and at some point be withdrawn. I have speculated
elsewhere about a possible build up of endogenous opioid tone before parturition
which might be antagonised at a critical point (i.e. immediately prior to the expulsion
of the first foetus) by an endogenous antagonist resulting in a surge in OT. I have not
found satisfactory evidence in the literature to test such a hypothesis and so the
elucidation of a physiological correlate of morphine dependence in the AV3Y/SON
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ABSTRACT
Oxytocin secretion in the rat is inhibited by kappa-opioid receptor
agonists acting in the posterior pituitary gland and by mu- and kappa-
agonists (morphine and U50,488H) inhibiting the firing rate of oxytocin
neurones in the supraoptic nucleus. U50,488H inhibits firing in the
absence of Ca„ in vitro. After intracerebroventricular infusion of
morphine for 5 days larger doses of intravenous morphine are required to
inhibit oxytocin neurones, indicating tolerance; naloxone-induced
withdrawal stimulates oxytocin hypersecretion as a result of excitation of
the firing of oxytocin neurones via mu receptors, partly outside the
blood-brain-barrier, but partly independent of major excitatory inputs.
The posterior pituitary shows neither tolerance nor dependence.
KEYWORDS
Dependence, morphine, oxytocin, tolerance, U50,488H.
OPIOIDS AND OXYTOCIN NEURONES
Opiates inhibit oxytocin secretion. For example, given to rats that have
begun to give birth morphine dramatically slows parturition by decreasing
oxytocin secretion in a naloxone-reversible fashion (Leng & Russell, 1989).
Oxytocin secretion can be increased by opioid antagonists indicating that
endogenous opioids restrain oxytocin secretion (Bicknell et al., 1988).
Oxytocin is secreted by the posterior pituitary gland from the axon
terminals of magnocellular neurones whose cell-bodies are in the supraoptic
(SON) and paraventricular nuclei in the hypothalamus. All three classes of
opioid peptide and p- and k-subtype opioid receptors are associated with
magnocellular oxytocinergic neurones (see Lincoln & Russell, 1986).
Dynorphin produced by vasopressinergic neurones could act on adjacent
perikarya or axon terminals of oxytocinergic neurones which may themselves
produce met-enkephalin, and enkephalin-containing neurones and B-endorphin-
containing terminals are found close to the magnocellular nuclei.
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Fig. 1 Firing rate of a female rat SON neurone recorded
extracellularly in a 450pm hypothalamic slice. Superfused
with modified Yamamoto's medium containing zero Ca2 and
100pM EGTA, which excites SON neurones. Despite the absence
of Ca2 + U50,488H inhibited firing by ca. 60% (6 indicates
control s.d.). Naloxone reversed the inhibition.
Opioid actions in this system can be investigated by measuring oxytocin
secretion (an integral of the activity of all the oxytocin neurones)
coupled with electrical stimulation of the posterior pituitary in vivo or
in vitro; and by recording the electrical activity of single oxytocin
neurones (characterized by their location and continuous, non-phasic firing
pattern) since this is the major determinant of oxytocin secretion.
Sites of opioid action
Morphine does not act on the posterior pituitary in lactating rats; but the
selective k-agonist U50,488H does inhibit oxytocin secretion evoked by
electrical stimulation of the neurohypophysial stalk with an intravenous
(i.v.) ID50 of ca.500 pg/kg (Coombes & Russell, 1988). Naloxone alone
increases oxytocin secretion in vivo without affecting the firing rate of
oxytocin neurones, and increases electrically-stimulated oxytocin secretion
from the posterior pituitary in vitro (Bicknell et al., 1985, Bicknell et
al., 1988). Thus in the posterior pituitary gland k- and not p- receptors
mediate inhibition of oxytocin secretion, and dynorphin is probably the
endogenous ligand at this site.
Morphine, i.v. or i.e.v., inhibits in a naloxone-reversible fashion the
spontaneous firing of SON oxytocin neurones and it inhibits the spontaneous
or glutamate-stimulated activity of these neurones in hypothalamic slices
(see Pumford et al■, 1987, Leng & Russell, 1989). This explains how
morphine inhibits oxytocin secretion. We have also found that the
k-agonist, U50,488H, inhibits the firing of oxytocin neurones; the same
neurone can be inhibited by both morphine and U50,488H. In the
hypothalamic slice, U50.488H still inhibits, with unaltered potency, SON
neurones excited by superfusion with medium containing zero Ca2+ and
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100pM EGTA (Fig. 1), although k-agonists have been proposed to act on other
neurones via inhibition of Ca2+ influx (see McFadzean, 1988).
Morphine tolerance and dependence
During 5 days of continuous i.e.v. infusion of morphine (up to 50pg/h from
a subcutaneous osmotic minipump), normal function of oxytocin neurones
returns indicating tolerance (Bicknell et al., 1988, Rayner et al., 1988).
Electrically-stimulated oxytocin secretion from the posterior pituitaries
of such rats is still enhanced by naloxone, indicating lack of
cross-tolerance to the k-receptor mechanism in the posterior pituitary
(Bicknell et al., 1985). The median threshold cumulative dose of i.v.
morphine required to inhibit the spontaneous activity of SON oxytocin
neurones was 25-fold greater in 13 chronic morphine-treated rats compared
with 7 controls (p = 0.0035; median dose 60pg/kg in controls). The
maximum effect (100% inhibition) was unaltered. These data are consistent
with a decrease in the number of spare opioid receptors on oxytocin







Fig. 2 Firing rate of a SON putative oxytocin neurone in a
morphine-dependent rat anaesthetized with urethane (1.25g/kg
i.p.). Naloxone methylbromide i.v. (NALX BR) excited the
cell, indicating withdrawal at opioid receptors outside the
blood-brain-barrier. Naloxone HC1 (NALX) was more potent
and increasing doses produced graded effects.
Dependence, revealed by excitation of oxytocin secretion by naloxone to a
level not seen before opioid treatment, is evident in morphine-treated rats
(Bicknell et al., 1988). Naloxone has no greater effect on oxytocin
secretion from the isolated posterior pituitaries of morphine-dependent
rats compared with controls (Bicknell et al., 1985). However, the firing-
rate of SON oxytocin neurones in morphine-dependent, but not control,
urethane-anaesthetized rats is increased by 350% after naloxone(5mg/kg
i.v.) (Fig. 2) and this excitation explains oxytocin hyper-secretion during
withdrawal (Bicknell et al., 1988). The ED50 for naloxone's effect on
firing rate is ca. 50pg/kg. Together with a lower potency of MR2266
(Bicknell et al., 1987) these findings indicate that p-receptors mediate
the withdrawal excitation. Excitation of oxytocin neurones in
morphine-dependent rats by i.v. naloxone methylbromide indicates some
involvement of p-receptors outside the blood-brain barrier, perhaps in a
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circumventricular organ (Fig. 2). However, an acute electrolytic lesion of
the AV3V region, which relays information from the subfornical organ and
organum vasculosum of the lamina terminalis (Russell et al■, 1988) merely
attenuates withdrawal excitation of oxytocin secretion (unpubl.). These
and previous studies (Bicknell et al., 1988) on the role of synaptic input
indicate that a major site of morphine withdrawal is on or close to the
oxytocin neurones themselves.
Morphine tolerance and dependence in the magnocellular oxytocin system
demonstrate potential involvement of endogenous opioids not only in acutely
inhibiting secretion but also in resetting the sensitivity to other inputs.
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Actions of the x-type opioid receptor agonist U50.488H on oxytocin neurones
in the supraoptic nucleus (SON) in normal and morphine-tolerant urethane-
anaesthetized rats
By G. Leng*, K. Pumford and J. A. Russell. Department of Physiology, University
Medical School. Teviot Place, Edinburgh, EH8 9AG and *Department of Neuro-
endocrinology, AFRC Institute of Animal Physiology arid Genetics Research,
Cambridge, CB2 4AT
The terminals of magnocellular oxytocin neurones in the posterior pituitary gland
are inhibited by opioids acting through x-type receptors (Coombes & Russell, 1988).
The firing of action potentials by the cell-bodies of these neurones which is the major
determinant of oxytocin secretion, is inhibited by the //-type opioid receptor agonist,
morphine (Leng & Russell, 1989). But the SON contains /c-type receptors (Mansour
et al. 1988), so we have investigated whether the firing-rate of oxytocin neurones is
affected by the /c-receptor selective agonist U50,488H.
Adult virgin female Sprague-Dawley rats were anaesthetized with urethane (T25 g
kg-1, i.p.) and via a ventral surgical approach a SON was exposed for extracellular
recording (015 m-NaCl-filled glass micro-electrodes, 15 to 50 Mf2) of the spontaneous
activity of continuous, putative oxytocinergic neurones, identified antidromically by
stimulation of the exposed neurohypophysial stalk (Bicknell et al. 1988). Firing-rate
averaged in 30 s bins was analysed over 10 min epochs. Drugs were injected via a
jugular vein. Of eight neurones tested, seven were inhibited by doses of U50,488H
above 1 pg kg-1; the range of threshold cumulative dose to inhibit firing was 1 to
6661 pg kg-1 (n = 7 cells). All neurones tested with morphine sulphate, up to
6661 fig kg-1, were inhibited; the median threshold cumulative dose was 20 pg kg-1,
(n = 8 cells). In rats given intracerebroventricular morphine infusion for 5 days
(Bicknell et al. 1988), the median threshold inhibitory dose for i.v. morphine was
increased to 1660 pg kg-1 (n = 11 cells, P = 0-02 vs. controls, Kolmogorov-Smirnov),
but the threshold inhibitory dose for i.v. U50,488H was unaltered. In both control
and morphine-tolerant rats, low doses of U50,488H (1/rgkg-1) excited 6/18
supraoptic oxytocin neurones: in these cells mean + s.e.m. firing-rate increased from
3-79 + 0-85 Hz to 5-16 + 0-82 Hz (P < 0-005, paired t test 6 cells). Thus both k- and
/f-type opioid receptor agonists can inhibit the firing of oxytocin neurones; after
chronic morphine exposure sensitivity to morphine but not U50,488H is decreased;
at low doses U50,488H is excitatory indicating inhibition of an inhibitory input to
oxytocin neurones.
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OPIOID RECEPTOR SUBTYPES IN THE SUPRAOPTIC
NUCLEUS AND POSTERIOR PITUITARY GLAND OF
MORPHINE-TOLERANT RATS
B. E. H. Sumner,* J. E. Coombes, K. M. Pumford and J. A. Russell
Department of Physiology, University Medical School, Teviot Place, Edinburgh EH8 9AG, U.K.
Abstract—Morphine, given acutely, inhibits oxytocin secretion in adult female rats, but chronic
intracerebroventricular infusion for five to six days induces tolerance and dependence in the mechanisms
regulating oxytocin secretion. One explanation for tolerance could be that there is a loss of opioid
receptors.
To test this hypothesis cryostat sections of selected brain regions and the pituitary, from six control
and six intracerebroventricular morphine-infused rats, were processed for quantitative in vitro receptor
autoradiography. ['HJEtorphine or [3H]( —)-bremazocine were used as ligands, and DAGO, DPDPE and
U50.488H as selective displacers from /(-, 5-, and /c-receptors, respectively. Control incubations had
naloxone determined specificity. The supraoptic nucleus (site of oxytocin-secreting magnocellular
perikarya) contained both /(- and k-receptors in control rats (mean + S.E.M. binding of /(-selective
['H]etorphine was 91.8 + 25.4 fmol/mg of tissue, and of k-selective [3H]( —)-bremazocine was
130.4 + 25.6 fmol/mg). Chronic morphine treatment caused a 83.9% decrease in binding in /(-selective
conditions (P < 0.05), but no significant change in K-selective binding. In the median preoptic nucleus
(which projects to the supraoptic nucleus) mean + S.E.M. binding of [3H]etorphine decreased by 77.0%
(P < 0.01) in chronic morphine-treated rats, from the control value of 76.2 ± 9.8 fmol/mg of tissue. In the
posterior pituitary gland (site of the terminals of the oxytocin-secreting magnocellular perikarya) binding
with [3H]( — )-bremazocine in controls was over 90% lower than in the supraoptic nucleus. No changes
followed chronic morphine treatment.
Thus chronic morphine exposure reduces the numbers of available /(-receptors in the supraoptic
nucleus, and of opioid receptors in the median preoptic nucleus, perhaps accounting for morphine-
tolerance in relation to oxytocin secretion.
The inhibitory effects of opiates on oxytocin secretion
were first demonstrated only a decade ago.18 Since
then inhibitory actions of both exogenous opiates and
endogenous opioids have been shown in a range of
studies on the oxytocin system, mainly in the rat (e.g.
see Refs 20, 48, 50). Morphine acts centrally by
inhibiting the firing rate of continuously firing (puta-
tively oxytocin-secreting) neurons in the supraoptic
nucleus (SON).6-58 Endogenous opioids act also on
oxytocin-releasing nerve terminals in the posterior
pituitary (PP) gland.3,5,6 Opioids can also inhibit
vasopressin secretion in vivo,2 but their effects on
perikaryal electrical activity are inconsistent,58 and
their action on vasopressin release from the PP is less
striking,3~5,17,58 except for a dose-dependent inhibition
by ethylketocyclazocine,55 and U50,488H.60-61
*To whom correspondence should be addressed.
Abbreviations-. AV3V region, region anterior and ventral to
the third ventricle; DAGO, Tyr-D-Ala-Gly-MePhe-
NEI(Ch2)2OH, a /(-type opioid receptor agonist;
DPDPE, [d-Pen2, d-Pen5]-enkephalin, a (5-type opioid
receptor agonist; G;, inhibitory guanine nucleotide-
binding protein; MPN, median preoptic nucleus; PP,
posterior pituitary; SON, supraoptic nucleus; U50, 488H
trans-( + )-3,4-dichloro-A-methyl-A'-(2-[l-pyrrolidinyl]-
cyclohexyl) benzeneacetamide, methane sulphonate salt,
a K'-type opioid receptor agonist.
The actions of opioids in brain are mediated by
three principal opioid receptor subtypes, classified by
agonist selectivity.1,22'63 Mansour et al.34-36 and Tem-
pel and Zukin57 have surveyed the distribution of /(-,
5- and K-type opioid receptors in the rat brain, using
in vitro receptor autoradiography. In the SON, k-
type receptors but not /(- or <5-receptors were found,
yet both /(- and k-opioid receptor agonists inhibit
the electrical activity of SON neurons.49 In the PP,
K-type receptors predominate, with few /(-receptors
and no 5 -receptors;12,25 k -selective, but not /(- or
S -selective, agonists inhibit oxytocin secretion at this
site.7,19
Chronic morphine exposure leads to tolerance (loss
of opiate effect, or a requirement for a larger dose to
achieve the initial effect) and dependence (revealed as
hyperexcitation on withdrawal). Both changes are
seen in the mechanisms regulating oxytocin secretion
in the rat after i.e.v. infusion of morphine for five
days.6,43,54 In contrast, dependence does not develop
in the vasopressin system.6
One possible explanation for opioid tolerance is
that the number of opioid receptors on tolerant
neural elements diminishes. Previous in vitro autora¬
diographic studies on cryostat sections of morphine-
tolerant rat brain found either no change in total
opioid receptor numbers,21 or an up-regulation of
/(-receptors,10 but with no observations on the SON
635
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or PP. Studies on 'H-ligand-binding to other brain
preparations have also yielded conflicting results in
morphine-tolerance.8'27'28'42,45,46'52'56'59 However, most
of these studies did not distinguish between opioid
receptor subtypes, and none focused on the SON and
PP. The aims of the present study were to measure the
densities of p- and k-opioid receptor subtypes in the
SON and PP in normal and morphine-tolerant female
rats, to try to explain morphine-tolerance in relation
to oxytocin neurons.
We also measured opioid receptor density in the
median preoptic nucleus (MPN), which is part of the
region anterior and ventral to the third ventricle
(AV3V region) that projects to the supraoptic




The following were used as probes for opioid receptors
in vitro, (i) [3H]Etorphine (50 Ci/mmol s 1.85 TBq/mmol
Amersham);12'33 (ii) [3H]( —)-bremazocine (21.3 Ci/mmol =
0.79 TBq/mmol, NEN).9'38
The following were used as competitive displacers of the
3H-ligands from individual opioid receptor subtypes, (i)
Tyr-d-Ala-Gly-MePhe-NH(CH,)2 OH, or DAGO (cat. No.
PB2000A, Cambridge Research Biochemicals), for displace¬
ment from p-receptors;34 (ii) [d-Pen2, d-Pen5]-enkephalin, or
DPDPE (cat. No. E-0260, Sigma), for displacement from
<5-receptors;34,40 (iii) trans-( + )-3,4-dichloro-A''-methyl-A''-
(2-[l-pyrrolidinyl]cyclohexyl) benzeneacetamide, methane
sulphonate salt, or U50.488H, (cat No. D-0908, Sigma) for
displacement from k-receptors.16,38 To test specificity, nalox¬
one hydrochloride (cat. No. N-7758, Sigma) was used.
Intracerebroventricular infusion
Adult virgin female albino Sprague-Dawley rats were
implanted stereotaxically under ether anaesthesia with a
cannula in a lateral cerebral ventricle, for continuous infu¬
sion from a subcutaneous osmotic minipump (Alzet, 2001)
of either morphine sulphate (10/rg/h for 40 h increasing to
20 ttg/h, and then 50 pg/h, each for 40 h), or vehicle (sterile,
pyrogen-free distilled water, 1 /rl/h).43 There were six rats in
each group, and the mean + S.E.M. body weights were
274.8 + 5.1 g in the morphine group and 288.8 + 8.7 g in the
vehicle group.
Tissue preparation
After five days of i.c.v. infusion, the rats were decapitated,
their brains removed, and from each a thick coronal slice
was cut extending from approximately 1 mm anterior to the
optic chiasma, to the posterior limit of the mammillary
body. Each slice was frozen onto a pre-cooled layer of
Tissue-Tek II OCT compound (Miles Laboratories) on a
cryostat chuck, in crushed dry ice. The pituitary gland
containing the PP was frozen similarly after orientation for
coronal sectioning.
Cryostat sections were cut at 10 pm, and thaw-mounted
onto acid-cleaned, chrome alum-gelatine-subbed slides.
From each rat for each incubation category there were four
sections containing two SON profiles each, four sections of
the MPN, and four sections of the PP. Mounted sections
were stored at — 20°C for up to three weeks before incu¬
bation.
Detection of opioid receptors
An incubating medium containing a broad-spectrum 3H-
ligand (2 nM), without additional agonists, was used for
total opioid receptors, but for receptor subtypes two unla¬
beled selective agonists were included (2 pM each)57 with
the 3H-ligand, with the intention of competitively displacing
the 3H-ligand from all but the third receptor subtype. In
pilot studies, higher concentrations of displacer (up to
50 /iM) did not reduce 3H-ligand-binding further. The auto¬
radiographic images from different incubation categories
(see Results) suggested that at 2//M the displacers were
effective and selective in the protocol for either 3H-ligand.
[3H]Etorphine (with displacers) was used for p-receptors
in brain, but [3H]( — )-bremazocine (with displacers) was
used for K-receptors, since pilot studies showed more bind¬
ing by [3H]( — )-bremazocine than by [3H]etorphine in brain
sections when DAGO and DPDPE were present. Only
[3H]( —)-bremazocine (with or without displacers) was used
for the pituitary, since we obtained negligible specific la¬
belling with [3H]etorphine, even after long exposure. Neither
3H-ligand gave measurable binding in the presence of
DAGO and U50, 488H at either site, or elsewhere in brain
sections, so quantitative analysis of this category was omit¬
ted. Control sections were incubated with 2 nM 3H-ligand
and 2 /iM naloxone hydrochloride to antagonize all binding
to opioid receptors. In pilot studies, higher concentrations
of naloxone (up to 20 pM) did not further reduce binding.
Further control sections were incubated with 3H-ligand
containing all three displacers to control for possible direct
chemical interaction between naloxone and [3H]etorphine,
and this reduced binding like naloxone; the effects of
naloxone were used to calculate specific binding (see below).
Other control sections were incubated without 3H-ligand to
test for chemography. None of these sections produced
autoradiographic images. The incubation categories and
protocols are shown in Tables 1 and 2. Sections were
brought to room temperature and then preincubated to
detach and wash out endogenous opioid or exogenous
opiate. We used procedures optimized for each 3H-ligand by
others;912 Na+ was not included in the incubating medium
with [3H]etorphine to seek to distinguish high/low affinity
binding to p -receptors.13 The preincubating and incubating
solutions, made up in deionized double-distilled water, were
applied as a 40- or 20-/rl puddle to each brain or pituitary
section, respectively, on slides in moist chambers. After
ice-cold immersion washes, the slides were air-dried, and
stored desiccated at 0^t°C for less than 48 h before auto¬
radiography. All the slides from a pair of control and
morphine-treated rats were processed identically at the same
time.
Autoradiography
Slides at room temperature were apposed to Hyperfilm-
3H (Amersham), keeping similarly incubated slides from
each pair of rats adjacent. A 5-pm section of a tritium
standard (3H-microscales, Amersham) was applied to each
film. The loaded films were clamped between mirror-coated
glass plates with adhesive tape, sealed in light-tight wrap¬
pers, and exposed in the dark at 0-4°C.
The optimum exposure periods (determined empirically
to produce grain densities over tissue that were below
saturation for all positive incubations) were nine weeks for
brain sections and 16 weeks for pituitary sections. The
exposed films were separated from the slides, developed at
18°C in Kodak D19 developer (5 min), rinsed in tap water,
fixed in Ilford Hypam rapid fixer (two changes, 5 min each,
of 1:4 fixer Tap water), washed for 30 min in running water,
then air-dried. The sections were fixed for 10 min in acetic
acid:absolute ethanol:commercial formalin (1:17:2 by
volume), dehydrated, rehydrated, stained for 15 min in
1% aqueous Cresyl Fast Violet, dehydrated, cleared, and
mounted in DPX.
Image analysis
Pieces of film were first cut out and attached to slides.
Subjective assessment. Autoradiographs were matched
with the stained sections in a Wild M3 binocular dissecting
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Table 1. Incubation categories for the detection of opioid receptor subtypes in the different
tissue regions
Intended selectivity for different Tissue region(s)
Incubation category opioid receptor subtypes probed
[3H]Etorphine alone All subtypes SON and MPN
(without displacers) (non-selective)
[3H]Etorphine + DPDPE //-receptor selective SON
+ U50.488H
[3H]Etorphine + naloxone No naloxone-sensitive
opioid receptors detected
SON and MPN
[3H]Etorphine + DAGO No //-, 5-, or k--receptors SON and MPN
+ DPDPE + U50.488H detected
No 3H-ligand, but No receptors of any kind SON and MPN
['Hjetorphine protocol detected
[3H]( — )-Bremazocine alone All subtypes SON and PP
(without displacers) (non-selective)
[3H]( — )-Bremazocine + p -receptor-selective PP
DPDPE + U50.488H
[3H] — )-Bremazocine + k -receptor-selective SON and PP
DAGO + DPDPE
[3H]( — )-Bremazocine + No naloxone-sensitive SON and PP
naloxone opioid receptors detected
[3H]( — )-Bremazocine + DAGO No p, S-, or K-receptors SON and PP
+ DPDPE + U50,488H detected
No 3Fl-ligand, but No receptors of any kind PP
[3FI]( — )-bremazocine protocol detected
microscope (magnification: x 16), to identify appropriate
brain regions.41 Regional silver-grain density was graded on
a subjective scale of 0, +, ++, + + +, and + + + +
(none, weak, moderate, moderately strong, strong).
Quantitative assessment of autoradiographs. The
boundaries of the SON, MPN, and PP profiles were first
scored with a needle-point on the film under the dissecting
microscope. Silver-grain density in these regions was
measured with a Joyce-Loebl //Magiscan image-analysing
computer, receiving video input from a Philips black and
white Video 40 camera (with a Newvicon tube) mounted on
a Vickers M17 microscope.54 Microscope magnification was
x 10 (objective), and xl.6 (intermediate lens); the video
monitor scale factor was 1.1878 pm per pixel. The rectangu¬
lar counting frame (201.63 x 133.04 pm) was set to be
smaller than the average area of the SON, to make measure¬
ments in the dorsal SON, where oxytocin perikarya predom¬
inate.44-54 The same counting frame was used for both MPN,
and for the PP where separate central and peripheral
measurements were made because more opioid receptors
have been found in the oxytocin terminal-rich periphery.9-25
Silver-grain density was calculated from the fraction:
total area of silver deposit
, as justified previously.
total area of counting frame
Grain densities over tissue were corrected by subtraction
of a background count (measured over nearby tissue-free
film). For each rat the mean grain density was determined
for each tissue region (eight, four and four images of SON,
MPN, or PP, respectively) in each incubation category. The
mean grain density representing specific binding to opioid
receptors was obtained by subtraction of the mean grain
density over the corresponding naloxone control sections, if
significantly above background (paired /-test). Then, since
tissue from morphine- and vehicle-treated rats was co-
processed in pairs, the mean grain densities in each incuba¬
tion category were compared by the paired /-test.
For conversion to absolute values, grain densities were
measured similarly, in triplicate, and backgrounds sub¬
tracted, for each step of the standard scale on each sheet of
film. A mean standard curve of grain density against
radioactivity in terms of its brain-gray matter-tissue equiv¬
alent (calibrated by Geary and Wooten for Amersham), was
computed for the SON and MPN analysis (nine weeks
exposure) and for the PP analysis (16 weeks exposure), and
fitted to a power function (y = 0.27 x023 and r = 0.97, for
the SON and MPN standard curve, and y = 0.34 x014 and
r = 0.96, for the PP standard curve). Tissue radioactivity
values (nCi/mg of tissue), were then calculated from the
mean grain densities, and were converted to fmol of 3H-
ligand bound per nig of tissue, by reference to the specific
activity of the 3H-ligand. Specific binding to opioid recep¬
tors was obtained by subtracting binding in the presence of
naloxone.
I.c.v. morphine and control group mean 3H-ligand-
binding values were compared by Student's /-test.
Preincubation tests
To test the efficiency of the preincubation wash procedure
in detaching opioids or opiates from the tissue, brain
sections were preincubated for 0, 1, 10, 15, 30, 45, 60, 75,
or 90min, incubated with [3FI]etorphine (//-selective for
SON; non-selective for MPN), and then processed and
analysed as above.
Blood plasma analysis
Trunk blood was collected from each rat into heparinized
tubes, plasma separated immediately by centrifugation, and
stored at — 20°C. Measurements were made of (i) oxytocin
concentration by radioimmunoassay (Higuchi et al.26) to
assess tolerance; (ii) glucose concentration (using a
Boehringer Kit; Glucosa GOD-Perid) since morphine raises
blood glucose concentration, but tolerance develops;23 (iii)
osmolality and sodium concentration43 to assess hydro-




Subjective assessment. Representative autoradio¬
graphs of the SON in a control rat are shown in
Fig. 1. Using [3FI]etorphine alone the SON was
moderately strongly labelled (+ + +), as was adja-
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cent gray matter in the hypothalamus and thalamus.
White matter gave only a feeble image (0 to +). The
strongest labelling was in patches in the caudate-
putamen, and in the amygdala (+ + + +). Elsewhere
in the caudate-putamen, amygdala, and cerebral
cortex, labelling was moderate (++). The pattern
and intensity of labelling was similar in sections
probed with [3H]etorphine and DPDPE and
U50.488EE Sections probed in the presence of DAGO
and U50,488H gave only weak images (0 to +) in the
SON and elsewhere.
Sections probed with [3H]( — )-bremazocine alone
gave strong images in which the pattern of labelling
resembled that shown by [3H]etorphine, except that
the cerebral cortex and caudate-putamen were more
heavily labelled ( + + to + + +). The SON was
moderately strongly labelled (+ + +). Sections
probed with [3H]( — )-bremazocine and DAGO and
DPDPE gave moderate images in the SON and
elsewhere in the hypothalamic gray matter (++).
The intense patches in the caudate-putamen and the
amygdala, probed with either 3H-ligand alone, or
with [3H]etorphine and DPDPE and U50,488H, were
absent from sections probed with [3H]( —)-brema-
zocine and DAGO and DPDPE.
Specificity control sections, incubated with 3H-
ligand either with naloxone, or with all three
unlabelled displacers, gave extremely faint images.
In morphine-treated rats, the pattern of labelling
was similar to control rats, but there was a decrease
in intensity in sections incubated with [3H]etorphine
and DPDPE and U50,488H.
Quantitative assessment. The results for the SON
are shown in Table 3, and Fig. 2. Specific (naloxone-
displaceable) binding was over 97% of the total
binding in SON sections probed by 3H-ligand alone.
The grain density over the SON incubated with
[3H]etorphine alone was reduced by 26.9% in the
chronic morphine group (P < 0.05; Student's paired
t-test). With [3H]etorphine, DPDPE and U50.488H
the decrease was 46.9% (P < 0.02). There was no
significant difference between morphine- and vehicle-
treated rats for any other incubation category. In the
SON of control and morphine-treated rats the group
mean (+S.E.M.) specific binding of [3H]etorphine
alone was 102.0+ 10.5 and 51.7 + 25.4 fmol per mg
of tissue, respectively (not significant). Over SON
profiles probed by [3H]etorphine and DPDPE
and U50,488H, mean binding was 91.8 + 25.4 and
14.8 + 7.5 fmol per mg of tissue in the control and
morphine groups, respectively (83.9% decrease,
P < 0.05, Student's t-test).
Specific binding of [3H]( — )-bremazocine alone in
the SON was not significantly altered by i.e.v. mor¬
phine treatment. In the control and morphine groups
the means were 125.7 + 35.0 and 70.9 + 24.8 fmol per
mg of tissue, respectively. Similarly, treatment group
means for SON probed with [3H]( —)-bremazocine
and DAGO and DPDPE showed no significant






Fig. 1. (Top row) S is part of a 10-/rm coronal section of rat brain, incubated with [3H]etorphine, apposed to Hyperfilm-3H
for nine weeks, then fixed in acetic acid-ethanol-formalin, and stained with Cresyl Fast Violet. The SON is the small
dark-staining area between the black triangles. The upward-pointing arrow is on the midline. A is the autoradiographic
image corresponding to S, processed on the Hyperfilm-3H after separation of S from the film. The position of the SON
is indicated as in S, and the downward-pointing arrow is on the midline. Magnification x 6. (Second and third rows)
Autoradiographic images of sections incubated with [3H]etorphine alone (Et), or with [3H]etorphine and DPDPE and
U50,488H (Eu), or with [3H]( — )-bremazocine alone (Bt), or with [3H](—)-bremazocine and DAGO and DPDPE (Bk), or
with [3H]( — pbremazocine and naloxone to antagonize all binding to opioid receptors (Bn). In [3H]etorphine alone (Et),
the SON is between the black triangles, and the arrow indicates intense patches of labelling in the caudate-putamen. For
further neuroanatomical details, see Paxinos and Watson.41 Magnification x 4. (Fourth and fifth rows) Autoradiographic
images of sections from an i.e. v. vehicle-infused rat (V), and an i.c.v. morphine-infused rat (M), incubated with [3H]etorphine
and DPDPE and U50.488H following 0, 15, or 90 min preincubation as indicated. Magnification x 4.
640 B. E. H. Sumner el al.
Table 3. Treatment group means (±S.E.M.) of mean grain densities in autoradiographs of the supraoptic nucleus, median
preoptic nucleus and posterior pituitary
Vehicle-treated Morphine-treated Morphine-treated
Tissue Incubation animal group animal group versus vehicle-treated
region category (n =6) (n = 6) (Student's paired t-test)
SON [3H]Etorphine alone 0.38 + 0.01 0.28 + 0.04 P < 0.05
(3H]Etorphine + DPDPE + U50,488H 0.37 + 0.02 0.20 + 0.04 P < 0.02
[3H]( —)-Bremazocine alone 0.32 + 0.02 0.27 + 0.03 n.s.
[3H]( — )-Bremazocine + DAGO + DPDPE 0.32 + 0.01 0.30 + 0.02 n.s.
MPN [3H]Etorphine alone 0.36 + 0.01 0.25 ± 0.02 P < 0.05
PP [3H]( —)-Bremazocine alone 0.18 + 0.04 0.19 + 0.05 n.s.
[3H]( — )-Bremazocine + DAGO + DPDPE 0.13 + 0.05 0.15 + 0.03 n.s.
[3H]( — )-Bremazocine + DPDPE + U50,488H 0.11 +0.05 0.10 + 0.03 n.s.
Data are expressed in /im2 of silver deposit per ^m2 of field; specificity control values subtracted, n.s., not significant.
(means ± S.E.M. were 130.4 + 25.6 and 95.5 +
16.0 fmol per mg of tissue).
Without the preincubation step, the mean binding
of [3H]etorphine with DPDPE and U50,488H in
chronic morphine-treated tissue was not significantly
different from the binding after incubation with
[3H]etorphine and all three selective agonists. With
only 1 min of preincubation, the mean binding in the
presence of DPDPE and U50,488H in morphine-
treated tissue had risen to 15.1% of the value in
vehicle-treated tissue, and thereafter, up to the
longest preincubation time tested (90 min), there
was no further rise. Typical sections are illustrated in
Fig. 1.
Median preoptic nucleus
Subjective assessment. Regional silver-grain distri¬
bution in sections containing the MPN, probed with
pHJetorphine alone, was similar to sections contain¬
ing the SON. Assessed subjectively, in control rats,
the relative intensities were: white matter, 0 to +;
MPN, + + +; patches in the caudate-putamen,
+ + + + ; elsewhere in the caudate-putamen and in
the cerebral cortex, + +. Specificity control sections,
incubated with [3H]etorphine and either naloxone or
all three displacers, gave very weak images.
In i.c.v. morphine-treated rats the pattern of silver-




Fig. 2. Treatment group means (± S.E.M.) of 3H-ligand binding to the SON of i.c.v. vehicle-infused rats
(□) and i.c.v. morphine-infused rats (£2), in each incubation category. The values shown represent specific
binding to opioid receptors since specificity control values have been subtracted. Values are expressed in
fmol of 3H-ligand per mg of tissue. Etorph alone, binding after incubation with [3H]etorphine alone
(without displacers). E + DPDPE + U50, binding after incubation with [3H]etorphine and DPDPE and
U50,488H. Bremaz alone, binding after incubation with [3H]( — )-bremazocine alone (without displacers).
B + DAGO + DPDPE, binding after incubation with [3H]( — )-bremazocine and DAGO and DPDPE.
*P < 0.05 (Student's t-test).
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was similar to the control group, but the silver-grain
density appeared lower in the MPN and elsewhere.
Quantitative assessment. Chronic morphine treat¬
ment significantly decreased grain density over MPN
after incubation in [3H]etorphine (by 29.7%,
P < 0.05; Student's paired t-test, Table 3). Mean
specific [3H]etorphine-binding in the MPN was re¬
duced by 77.0% in morphine-treated rats. In the
control and morphine-treated groups the means
( + S.E.M.) were 76.2 + 9.8 and 17.5 + 5.2 fmol per
mg of tissue, respectively (P <0.01, Student's t-test).
Prolonged preincubation, for 90 min, before incuba¬
tion in [3H]etorphine did not affect the difference
between control and morphine-treated rats.
Posterior pituitary
Subjective assessment. Whole pituitary sections
were apposed to film, but only the PP gave an
autoradiographic image. Typical autoradiographs are
shown in Fig. 3. No consistent differences between
central and peripheral parts of the posterior pituitary
were found in any incubation category. Using
[3H]( — )-bremazocine alone or with DAGO and
DPDPE an intense image was obtained (+ + +).
Inclusion of DPDPE and U50.488H in the incubating
medium gave a less intense image (+ +). Incubation
in the presence of DAGO and U50,488H resulted in
a very weak image (0 to +). Specificity control
sections, incubated with pH]( —)-bremazocine and
naloxone, also gave very weak images (0 to +), and
chemography control sections, incubated without
'H-ligand, gave no images at all.
Images from the posterior pituitaries of morphine-
treated rats were similar to those from vehicle-treated
controls.
Quantitative assessment. Whether the quantitative
results from the posterior pituitary were expressed as
mean grain densities, or as mean binding, no statisti¬
cally significant differences were found between the
centre, and the periphery, of the PP for any incuba¬
tion category so central and peripheral data have
been combined.
In control rats, the mean grain densities were
highest after incubation with pH]( — )-bremazocine
alone (Table 3). Chronic morphine treatment had no
significant effects (Table 3). Results from PP sections
of control rats probed with pH]( — )-bremazocine
alone or with naloxone, showed that specific binding
averaged 79% of the total. Mean ( + S.E.M.) specific
binding after incubation with pH]( —)-bremazocine
without displacers, was 11.6 + 6.30 and 18.0 +
8.46 fmol per mg of tissue in control and i.e.v.
Fig. 3. (Top row) S is a 10-/rm section of rat pituitary, incubated with [3H]( — )-bremazocine, apposed to
Hyperfilm-'H for 16 weeks, then fixed in acetic acid-ethanol-formalin, and stained with Cresyl Fast Violet.
The PP is the pale-staining area. A is the autoradiographic image of S. Note that only the PP has produced
an image. This image shows binding to opioid receptors after incubation in [3H]( — )-bremazocine alone
(without displacers) (Bt). Magnification x 8. (Second row) Autoradiographic images of sections incubated
with [3H]( — )-bremazocine and DAGO and DPDPE (Bk), or with [3H]( — )-bremazocine and DPDPE and
U50.488H (Bu), or with [3H]( — pbremazocine and naloxone to antagonize all binding to opioid receptors
(N). Magnification x 8.
642 B. E. H. Sumner et at.
morphine-infused rats, respectively. In control rats
binding was only 9.2% of that in the SON in the same
incubation category. In the presence of DAGO and
DPDPE the mean ( + S.E.M.) values were 3.25 ± 2.09
and 2.72+ 1.42 fmol of 3H-ligand bound per mg of
tissue in control and morphine groups, respectively.
For control rats, this binding was only 2.5% of the
level in the SON in similar conditions. Mean
( + S.E.M.) specific binding after incubation with
[3H]( — )-bremazocine and DPDPE and U50,488H
was 2.00 ± 1.21 fmol (control group), and
1.07 ± 0.73 fmol (morphine group) per mg of tissue.
There were no significant differences between control
and morphine-treated rats for any incubation cate¬
gory.
Blood plasma analysis
There were no significant differences between the
control and i.e.v. morphine groups for any of the par¬
ameters measured, i.e. trunk blood plasma oxytocin,




Control rats. Unlike some previous studies on male
rats35,36 we found 3H-ligand-binding in the SON of
female rats in conditions designed to be selective for
/(-type opioid receptors. We suggest that this repre¬
sents binding to /(-type opioid receptors, for the
following reasons. Firstly, [3H]etorphine is a broad
spectrum 3H-ligand for opioid receptors, but with a
1000-fold molar excess of the unlabelled agonists,
DPDPE and U50,488H, known to have high relative
affinity for S- and k-type receptors, respectively,16,40
competition for binding sites would be expected to
leave predominantly /(-receptors available for [3H]-
etorphine. Although U50,488H is a stronger dis-
placer at k-type opioid receptors of the guinea-pig
(postulated type 1 k-receptors) than at k-receptors of
the rat (postulated type 2 receptors),62 it nonetheless
blocks in situ [3H]( — )-bremazocine-binding to rat
k-receptors.38,39 Secondly, incubation with DAGO
(which has a high relative affinity for /(-receptors), in
addition to DPDPE and U50.488H, reduced
[3H]etorphine-binding in the SON to a very low level.
Thirdly, elsewhere in the sections containing SON
profiles were intense patches of labelling, present after
incubation in media designed to demonstrate /(-
receptors, but absent after incubation in media de¬
signed to show 3- or k-receptors. Other authors have
claimed these intense clusters in the caudate-putamen
to be /(-receptors.57 Fourthly, the change in the SON
during chronic morphine treatment was confined to
/(-selective binding. This suggests that the subtype
demonstrated by this selective incubation differs from
the others, and that it is uniquely responsive to a
known /(-selective agonist (morphine). Lastly, the
demonstration of /(-type opioid receptors in the SON
is consistent with the inhibitory action of morphine
on the electrical activity of oxytocin neurons when
applied close to their cell bodies.49,58
Specific binding to opioid receptors was also
demonstrated in the SON after incubation with
[3H]( —)-bremazocine in the presence of DAGO and
DPDPE, a procedure designed to be selective for
k-receptors. In the caudate-putamen, this type of
incubation did not show the intense patches of bind¬
ing shown by 3H-ligand alone, or by incubation in
conditions intended to be /(-selective; it seems likely
that DAGO and DPDPE prevented binding to the
receptor subtype(s) at these clustered sites. Addition
of U50.488H, a known k-receptor-selective agonist,16
to the other two unlabelled selective agonists reduced
[3H]( — )-bremazocine-binding to a low level both in
the SON and caudate-putamen, supporting the as¬
sumption that k-receptors were predominantly in¬
volved. Demonstration of k-receptor in the SON is in
agreement with previous reports,35'36 and with electro¬
physiological studies showing inhibitory actions of
U50.488H on oxytocin (and vasopressin) neurons in
the SON.49 Indeed, suppression of electrical activity
by U50.488H, and by morphine, has even been
achieved on the same supraoptic neuron (Russell et
al., unpublished observations).
With the low resolution of the techniques used, we
were unable to determine the distribution of /(- and
k-receptors on or between neurons,24 or indeed
whether they had been internalized.29 It is possible, by
analogy with the PP gland,12,33 that some of the
receptors were on glial cells, especially astrocytes.
Effects of intracerebroventricular morphine infusion.
In the SON, binding of [3H]etorphine in conditions
designed to be /(-selective was reduced by over 80%
by chronic morphine treatment compared with con¬
trol rats. Morphine did not affect k-selective [3H]( —)-
bremazocine-binding.
One possible explanation for decreased binding of
[3H]etorphine to the SON after chronic morphine
treatment could be that morphine still in the tissue
Table 4. Means ( + S.E.M.) of data from blood plasma samples
Oxytocin Glucose Sodium
Treatment concentration concentration concentration Osmolality
group (pg/ml) (mM/1) (mM/1) (mOsmol/kg)
i.c.v. vehicle-infused 13.23 + 5.06 7.82 + 0.43 138.29 + 2.23 270.00 + 5.63
(« = 6)
i.c.v. morphine- 8.67 ± 1.77 7.31 ± 0.24 142.71 ± 1.41 268.29 ± 5.99
infused (n = 6)
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competes with [3H]etorphine. Morphine is remark¬
ably persistent in brain after peripheral adminis¬
tration, [14C]morphine still being detectable three
weeks after a single injection,37 however, morphine
can be washed out in vitro.59 Similarly, altered release
of endogenous opioid in i.e.v. morphine-infused rats
might compete with [3H]etorphine. However, etor-
phine has a high affinity for opioid receptors,22 and
5'-guanylylimidodiphosphate was included in the
preincubating medium to encourage dissociation of
receptor-bound opioids,12 and we showed that pre¬
incubation for much longer than the 15 min used did
not result in any increase in 3H-ligand binding. It
seems reasonable to conclude that in vivo, the number
of n-receptors in the SON is reduced by chronic i.e.v.
infusion of morphine, and that this reduction ex¬
plains the decreased binding of 3H-ligand. However,
a possible wash-resistant blockade by some of the
i.c.v. infused morphine, cannot be ruled out. A
significant reduction in [3H]etorphine-binding was
found also in the MPN, though not resolved to a
particular opioid receptor subtype.
A reduction in number of available /(-receptors
might allow SON oxytocin neurons, and their inputs,
to function normally in morphine-treated rats, as
indicated by similar concentrations of oxytocin in
trunk blood plasma from the i.c.v. morphine- and
vehicle-treated rats in the present study. Normal
functioning has also been inferred in previous
studies.6-43 The consequence of a partial loss or block¬
ade of /(-type receptors would be to decrease the pool
of spare receptors.14-32'53 Thus, even if the affinity of
the receptors for morphine were unaffected, this
would decrease the number of receptors which could
be activated at a given concentration of morphine.
This effect would contribute to tolerance, and the
extent of the loss of binding we have measured might
almost be great enough to explain morphine-toler¬
ance15 in the female rat oxytocin system. We found
no evidence after i.c.v. morphine infusion for changes
in trunk blood plasma glucose or sodium concen¬
trations, or osmolality, that might stimulate the
oxytocin system through osmoreceptor mechan¬
isms,47 and perhaps alter opioid receptor density in
the SON.
Posterior pituitary
Control rats. In common with earlier work,51 we
found a much lower density of opioid receptors in the
PP than in the brain. Longer exposures were required
to produce autoradiographic images. Most binding
was obtained after incubation with [3H]( — )-brema-
zocine alone, or in the presence of DAGO and
DPDPE, which was intended to be selective for
K-receptors. Since addition of U50,488H to DAGO
and DPDPE reduced [3H]( —)-bremazocine-binding
to a low level, it is probable that k-receptors were
indeed responsible for most of this binding. Other
authors have also suggested that opioid receptors in
the PP are predominantly of the k-receptor sub¬
type.9,12'25 In the presence of DPDPE and U50,488H,
which was intended to be /(-selective, there was still
some binding by [3H]( —)-bremazocine, but there was
less binding in pilot studies with [3H]etorphine so the
presence of the /(-receptor subtype in the PP remains
controversial.
We did not find any differences in opioid receptor
density between the central and peripheral zones of
the PP of female rats, unlike the studies of Herken-
ham et al.15 and Brady and Herkenham9 on male
rats.
Effects of intracerebroventricular morphine infusion.
Although i.e.v.-infused morphine reaches the PP,43 we
detected no change in [3H]( — )-bremazocine binding
in any incubating conditions. The lack of effect of
morphine on k -receptors in the PP is consistent with
the persistence of endogenous opioid- (probably
dynorphinj-inhibition of oxytocin secretion in iso¬
lated PPs from i.c.v. morphine-infused rats in vitro?
Thus, chronic morphine treatment neither affects the
number of k-receptors, nor induces cross-tolerance to
the endogenous ligand in the PP. However, the
density of k-receptors in the PP can show plasticity:
during dehydration for five days the number of
x-receptors decreases by about 40% without a
change in affinity."
CONCLUSION
The data we have on the oxytocin and oxytocin
mRNA content of SON neurons, their firing rate, and
the responsiveness of their terminals in the PP to
electrical stimulation, all indicate that the synthesis of
oxytocin and the coupling of electrical activity to
secretion are not altered in morphine-tolerance.3'6'43'54
This leaves opioid-receptor interaction, and early
post-receptor events regulating electrical excitability,
as likely sites for tolerance. We have provided evi¬
dence in this study for a decrease in number of
available /(-receptors in the SON, and of available
opioid receptors in an input pathway, the MPN,
which regulates oxytocin neurons, but we have not
distinguished intracellular forms from surface forms
of the receptor. There may also be reduced effective¬
ness of remaining receptors available for binding to
ligand because of attenuated coupling of receptor to
a Gi/0-like protein, as has been described for mor¬
phine-tolerant locus coeruleus neurons,15 but this has
not been investigated in SON neurons.
Morphine-dependence in the oxytocin system, re¬
vealed by injection of naloxone, is expressed as with¬
drawal excitation of oxytocin hypersecretion result¬
ing from a large increase in the firing rate of oxytocin
neurons.6,30 This phenomenon is mediated through
/(-receptors,31 which the present study has shown to
remain available in the SON at about 20% of the
number in morphine-naive rats. It is difficult to
explain withdrawal excitation of oxytocin neurons in
terms of a reduced number of available /(-receptors.
Adaptive changes in post-receptor mechanisms regu-
644 B. E. H. Sumner et al.
lating ionic fluxes seem more likely. There may also
be compensatory changes in non-opioid pathways.
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